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SUMMARY
The aim of the work described in this thesis was to devise a 
technique for the reduction of body fat by passive or active 
immunisation against the adipocyte. Passive immunisation of rats 
with an antiserum, raised in sheep, against rat adipocyte plasma 
membranes (A/S 83) caused a 50% reduction in parametrial adipocyte 
number which persisted, at least until 24 weeks after treatment. This 
was accompanied by a reduction in parametrial adipocyte size which 
persisted for 8 weeks but had recovered by 24 weeks, resulting in a 
50% reduction in parametrial adipose mass at 24 weeks. Subcutaneous 
and peri-renal adipose depots were, initially, less affected and had 
recovered their total mass by 24 weeks after treatment. Differential 
effects on different adipose depots were found to be due largely to 
the site of injection of the antiserum. Body composition analysis 
showed that total body fat was reduced by 30% 8 weeks after treatment 
and lost fat was replaced by protein and water. Side effects of A/S 
83 were limited to a reduction in food intake on the first day of 
treatment, which gradually recovered to reach normal levels by 4 
days and transient proteinurea with fluctuations in body weight about 
2 weeks after treatment in some rats. The initial effects of A/S 83 
on adipose tissue and food intake were dependent on the presence of 
circulating complement. A doubling of serum free fatty acids and 
triglycerides occurred 6-24 h after treatment, then returned to 
normal levels by 48 h after treatment and was probably evidence of 
adipocyte destruction. Treatment with A/S 83 did not affect the 
ability of rats to undergo a normal pregnancy and lactation.
More recent bleeds of the same sheep did not reproduce the in 
vivo effects of earlier bleeds of A/S 83 and so 2 additional antisera 
were raised against rat adipocyte plasma membranes. These new 
antisera, while reproducing the effects of A/S 83 on adipose tissue, 
had the additional side effects of anaesthetic-like effects 
immediately after administration and the production of gross liver 
abnormalities. The presence or absence of side effects could not be 
correlated with strength of binding to nervous tissue or hepatocyte 
plasma membranes, as determined by ELISA and Western blotting.
An attempt was made to prepare rat adipocyte specific antigens 
by affinity purification of anti-(adipocyte plasma membrane) 
antibodies, adsorption of those antibodies with non-adipose tissues 
and the use of the adipocyte specific antibodies to affinity purify 
antigens from solubilized adipocyte plasma membranes. Six 
polypeptides, with molecular weights of 53-96 kD, were considerably 
enriched in the adipocyte specific antigen preparation. Antisera 
raised against the adipocyte specific antigens showed some binding to 
non-adipose tissues and antisera raised against hepatocyte and 
erythrocyte plasma membranes showed some binding to adipocyte 
specific antigens, which cast doubt on the true adipocyte 
specificity of some of the components of the adipocyte specific 
antigen preparation. However, the anti-(adipocyte specific antigen) 
antiserum showed considerably more adipocyte specificity than 
antisera raised against whole adipocyte plasma membranes, had 
fat-reducing properties in vivo and did not cause liver 
abnormalities. Adsorption of anti-(adipocyte plasma membrane) 
antisera with liver homogenate provided an antiserum that retained 
its effects on adipose tissue but no longer caused liver
abnormalities. It is, therefore, likely that adipocyte specific 
antisera can have fat-reducing properties, but both the 
anti-(adipocyte specific antigen) antiserum and the adsorbed 
antiserum reproduced the anaesthetic-like effects of anti-(adipocyte 
plasma membrane) antisera and caused a reduction in food intake on 
the first day of treatment. Antisera raised against hepatocyte and 
erythrocyte plasma membranes had no effects on adipose tissue.
Attempts were made to reproduce the effects of passive 
immunisation by means of active immunisation against the adipocyte, 
as this might prove a more practical approach for the treatment of 
large species. Rats were immunised with rat adipocyte plasma 
membranes or adipocyte specific antigens conjugated to BSA, or with 
BSA alone in complete Freunds adjuvant. Despite the absence of a 
convincing demonstration of circulating anti-(adipocyte plasma 
membrane) antibodies, adipocyte plasma membrane- and adipocyte 
specific antigen-treated rats showed a 40-50% reduction in adipocyte 
numbers and a compensatory increase in adipocyte size. In only 1 out 
of 3 groups of rats did active immunisation induce a reduction in 
adipose mass and, in this group, body weight was also reduced.
Antisera raised against rat, sheep, pig and chicken adipocyte 
plasma membranes showed some binding to adipocyte plasma membranes of 
other species but the binding was less than 5% of that to homologous 
adipocyte plasma membranes. Sheep and chicken adipocyte specific 
antigens were prepared, in addition to rat adipocyte specific 
antigens and the 3 preparations included some polypeptides of similar 
electrophoretic mobilities. Western blotting of anti-(adipocyte 
plasma membrane) antisera against adipocyte specific antigens of the 
3 species showed some cross-reactivity, particularly between proteins
of molecular weights of 72 and 96 kD, but the binding was always 
weaker than that to the homologous protein of the same molecular 
weight, suggesting that the adipocyte specific antigen preparations 
of the different species did not contain antigenically identical 
proteins.
Active immunisation of lambs with sheep adipocyte plasma 
membranes, conjugated to rabbit serum albumin, in Fruends adjuvant 
did not result in any reduction in body weight or adiposity, compared 
with rabbit serum albumin-immunised controls. In a second 
experiment, lambs were immunised, initially, with sheep adipocyte 
plasma membranes, followed by sheep adipocyte specific antigens, 
conjugated to rabbit serum albumin and were compared with untreated 
controls. Despite the absence of a convincing demonstraton of 
circulating anti-(adipocyte plasma membrane) antibodies, immunised 
lambs showed significantly reduced body weights and fat depot 
weights, compared with untreated controls. Although fat pad weight 
was still reduced in the treated group when expressed as a percentage 
of body weight, this difference was not significant.
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CHAPTER 1 
I N T R O D U C T I O N
1INTRODUCTION
Antisera raised against adipocyte plasma membranes have been 
shown to be cytotoxic to isolated adipocytes in the presence of 
complement (Pillion and Czech, 1978a; Flint, Coggrave, Futter, 
Gardner and Clarke, 1986). This suggests that such an approach might 
prove useful in the reduction of adiposity in vivo.
The reduction of fat deposition is of considerable commercial 
interest. Coronary heart disease is the major cause of death in 
adult men in developed countries, where dietary fat, most of which is 
of animal origin, constitutes 40% of total caloric intake. The 
possible associations between dietary fat intake, serum cholesterol, 
artherosclerosis and coronary heart disease have led to a demand for 
the reduction of the fat content of animal products (Brisson, 1986).
Vast amounts of fat are deposited by all commercially important 
meat-producing animals. There is, therefore, considerable interest 
in techniques that increase the efficiency of meat production by 
repartitioning energy from fat into protein deposition.
A technique for the reduction of fat deposition would also be
of interest to the dairy industry. The nutrient requirements for
milk production are met, in some species, by both increased food 
consumption and lipid mobilisation (Vernon and Flint, 1984). During 
pregnancy and lactation co-ordinated changes occur in the numbers of 
insulin receptors in adipose tissue and the mammary gland. These
changes favour lipid deposition in adipose tissue during pregnancy, 
while restricting lipogenesis in adipose tissue and favouring
lipogenesis in the mammary gland during lactation (Flint, 
Sinnet-Smith, Clegg and Vernon, 1979). In late lactation, as milk
2production declines, lipid deposition in adipose tissue occurs. In 
rats the decline in milk production is also accompanied by an 
increase in the number of insulin receptors per adipocyte but no 
change in the number of insulin receptors of the mammary gland. The
decline in milk production can be delayed by the substitution of 
younger offspring for the original litter and fat deposition in 
adipose tissue is prevented. This raises the question of whether 
competition between adipose and mammary tissue for common precursors 
contributes to the decline in milk yield in late lactation (Flint, 
1986). A reduction in fat deposition in dairy cows might, therefore, 
lead to increases in milk yield during the later stages of lactation.
In addition to commercial applications, an immunological means 
of reducing body fat could be used as a research tool for the
investigation of the control of adipose tissue development. The 
health problems associated with obesity have led to a growing 
interest in factors that control adipocyte hypertrophy and
hyperplasia. Recent work has suggested that adipocyte number is not
'fixed' at an early age but that, given appropriate stimuli, adipose 
tissue of adult animals may proliferate (Faust and Miller, 1981). A 
means whereby adipocyte number or size could be reduced at different 
stages of maturity might yield valuable information about the role 
cellularity plays in the control of adipose tissue development and 
obesity. An important development in this field was the recognition 
of adipocyte precursors (Van and Roncari, 1977). These cells, 
isolated from adult rats, can develop in vitro and in vivo into 
'mature adipocytes' (Roncari and Van, 1978). Antisera raised against 
adipocyte plasma membranes have been used to monitor precursor cell 
differentiation in vitro (Cryer, 1985a).
3An immunological technique for the reduction of body fat would, 
therefore, have many practical applications but the immune response 
must first be shown to cause long-term reduction of adiposity, to be 
devoid of adverse side effects and to be tissue specific.
1.1 ADIPOSE TISSUE DEVELOPMENT
1.1.1 A comparison with non-adipose tissues
At birth rats and pigs contain about 1% fat while ruminants are 
born with 2-4% fat and humans with 16% fat (Leat and Cox, 1984).
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Poultry hatch with very little 1 as the embryo develops as an 
isolated system with no constant supply of maternal glucose and hence 
rates of lipogenesis are very low (Hood, 1984).
Adipose tissue is a 'late-developing' tissue, its growth being 
exceeded by that of bone and muscle in early life. During later 
stages of growth the rate of protein accretion declines and the 
deposition of fat exceeds that of lean (Bergen, 1974). Beyond a 
certain body weight, fat gain becomes a large and constant fraction 
of body-weight gain. In sheep, pigs and cattle fat deposition 
exceeds that of muscle beyond body weights of 30, 50 and 350 kg 
respectively (Searle, Graham and O'Callaghan, 1972). In poultry 
rates of faxcl£pc?stKcv3 increase rapidly on hatching but decline after 
2-3 weeks. In the female fat synthesis increases at sexual maturity, 
in readiness for egg production. In laying hens both protein and fat 
deposition increase up to 32 weeks, thereafter fat deposition 
increases but protein deposition declines (Vogt and Harnisch, 1983). 
Rapid accumulation of fat normally occurs, in human development, 
during 2 periods, perinatally, during the last part of pregnancy and
4the first few months of infancy, and during the adolescent period up 
to adulthood (Hirsch and Batchelor, 1976, Scott, 1981).
1.1.2 The cellular characteristics of adipose tissue development
The assessment of the relative contributions of increases in
cell size and number to increases in mass of adipose tissue has been
hindered by difficulties in measuring the size and number of
adipocytes (Hirsch and Gallian, 1968; Sjostrom, Bjorntorp and Varana, 
1971). Microscopic measurements of histological sections may lead to 
underestimation of cell size due to shrinkage of the tissue. 
Microscopic and automatic measurements on cells liberated by 
collagenase digestion suffer from the problems of breakage of large 
cells and loss of small cells (De Martinis, 1985). Determination of 
DNA content of the intact tissue is an inaccurate estimation of 
adipose cellularity since supporting cells may contribute up to 50% 
of the total amount of DNA., even in mature tissue. Based on the use 
of these techniques, the accepted concepts were that the adult
adipocyte number was 'fixed' very early in life and the full 
complement of mature adipocytes was reached by sexual maturity. 
Subsequent increases in adipose mass could only occur by increases in 
adipocyte size.
However, the techniques used were unable to distinguish between 
the formation of new cells, lipid-filling of preformed cells and 
dedifferentiation of mature adipocytes. To overcome this problem
Greenwood and Hirsch (1974) measured the synthesis of new adipose
\
cells by in vivo tritiated thymidine incorporation and proposed that 
the development of adipose tissue in the rat was divided into 3 
periods. The first was a highly proliferative period to 4 weeks
5after birth, followed by a predominantly lipid-filling period with 
some proliferation until puberty (60-80 days) and a period 
exclusively of lipid-filling during maturity. Roncari and Van (1978) 
isolated adipocyte precursors from adult rats that replicated and 
differentiated completely into adipocytes, both in culture and after 
re-implantation into rats. These authors proposed that, while the 
majority of proliferation occurs early in life, a slow continuous 
rate of adipocyte precursor replication and maturation is balanced by 
dedifferentiation of mature adipocytes in the adult.
Pre-adipocytes have been isolated from adult bovine, ovine, 
avian and human adipose tissue and have been shown to be capable of 
replicating and differentiating into mature adipocytes in culture, 
indicating that, like the rat, there is capacity for the production 
of new adipocytes in the adult in these species (Van, Bayliss and 
Roncari, 1976; Plaas and Cryer, 1980; Broad and Ham, 1983; Hood, 
1986). Growth of extramuscular adipose tissue depots occurs through 
both hypertrophy and hyperplasia in poultry, sheep, pigs and cattle 
up to 14 weeks, 12 months, 5-6 months and 14 months respectively 
(Hood, 1977; Hood, 1982). The cellular development of adipose tissue 
in man is not fully understood. The major period of proliferation 
may range from the thirtieth week of gestation to 9-12 months of age, 
although adipocyte numbers continue to increase after this age, to 
reach adult values at about 15 years (Hirsch and Batchelor, 1976). 
Kirtland and Gurr (1979), however, suggested that the major period of 
adipocyte synthesis is completed by birth.
The times, quoted above, at which hyperplasia is diminished are 
approximate. The precise characteristics of the development of 
adipose tissue depend upon the breed or strain, the sex, the
6nutritional status and the adipose depot of the animal. Apparent 
cell number increases in the rat cease earlier in the epididymal than 
the peri-renal and subcutaneous depots (Bertrand and Masoro, 1978). 
Peri-renal adipose tissue is also an early developing tissue in meat 
species, followed by intermuscular depots, and the subcutaneous depot 
(Leat and Cox, 1984). In the later stages of fattening fat is 
deposited intramuscularly, giving meat a marbled appearance. The 
distribution of fat also varies between species. The ratio of 
subcutaneous to intermuscular fat varies from 0:6 for cattle to 1:2 
in sheep and 2:4 in pigs.
It would appear, therefore, that while the majority of 
proliferation in adipose tissue occurs early in life, there is 
capacity for the production of new adipocytes in the adult. 
Hyperplastic obesity can be of adult onset and is not easily treated 
by dieting, which leads to an abnormally low fat cell size and no 
reduction in adipocyte number (Miller, Faust, Goldberger and Hirsch,
1983). A very low adipocyte size is frequently associated with a 
reduced metabolic rate, a reduced level of thyroid hormone production 
and mental problems. Therefore, a method of reducing adipocyte 
numbers rather than adipocyte size by an immunological approach may 
be of interest in the treatment of certain forms of human obesity.
1.2 THE CONTROL AND MANIPULATION OF ADIPOSE TISSUE DEVELOPMENT
In the preceding section 'normal' adipose tissue development 
has been described, in terms of the contributions made by increases 
in adipocyte number and size. Within a species and within individuals 
there is an enormous capacity for variation in total adipose mass,
7whether due to hypertrophy or hyperplasia. Studies of naturally- 
occurring and experimentally-induced variation have indicated that 
the body composition of an animal is a result of a combination of 
genetic, physiological and nutritional factors. The manipulation of 
these factors has yielded information about the control of adipose 
tissue development and possible means of regulating the body 
composition of commercial species.
Obese strains of laboratory animals have been developed and 
different breeds of birds, pigs, cattle and sheep have widely 
differing propensities to fatten. This indicates the importance of a 
genetic component in the control of adipose tissue development and 
has led to attempts to select for reduced fat
deposition.
Physiological factors affecting degree of adiposity include 
sex, external environment and maturity (Moran, 1986; Webster, 1986). 
Intact males tend to be leaner than castrate males or females. Low 
temperatures tend to reduce growth rate and increase fat deposition. 
The manipulation of photoperiod can influence body composition. 
Extending the day length tends to lead to an increased ratio of 
protein to fat deposition. The fall in day length at the beginning 
of autumn tends to lead to a shift towards fat deposition. Maturity 
is the major non-nutritive determinant of body composition, as 
described in the previous section. The effects of physiological 
factors on adiposity are primarily mediated by hormones and so 
hormone treatment has been used in meat species in an attempt to 
repartition energy from protein into fat deposition.
The effects of nutritional manipulations on fat deposition 
depend, in part, on the age, strain, species and sex of the animal
(Combs, 1976). Manipulation of total energy intake and diet 
composition of laboratory animals and meat species have resulted in 
alterations in growth rate and body composition. These factors are 
discussed in greater detail below.
1.2.1 Genetic selection for reduced fat deposition
Fat deposition is likely to be subject to little natural 
selective pressure because, when a new ecological opportunity is 
exploited, population numbers rapidly reach an equilibrium with the 
amount of food necessary for maintenance, growth and reproduction 
only. Therefore, fat deposition is likely to be heritable.
In contrast, fat secretion in milk for the nurture of the young is 
likely to have been subject to natural selection pressure resulting 
in the arrival at a stable equilibrium of fat content that would best 
support the growth and survival of the offspring. Fat secretion, 
therefore, is likely to have very low heritability (Willham, 1976). 
Domestication has resulted in food consumption exceeding the 
requirements for maintenance, growth and reproduction, resulting in 
the ability to deposit more fat to be expressed.
Vast differences exist between breeds in the rate at which they 
mature and fatten. Within breeds estimations of the heritability of 
fat deposition have been made by comparing relatives and by measuring 
the response to selection for increased or decreased fat deposition. 
Such studies suggest that fat deposition has an average heritability 
of about 50% (Willham, 1976). Selection for reduced fat deposition 
in pigs, for instance, resulted in a 25% reduction in backfat from 
1926-1956 (Croft, 1958). Selection for either milk or meat 
production in cattle has led to differences in fat deposition within
9the species. Dairy cattle breeds tend to have more abdominal fat as 
it has a greater blood supply which can be mobilized more rapidly to 
meet the demands of lactation, while beef breeds have more 
subcutaneous fat (Webster, 1986).
Genetic selection has several disadvantages as a method for 
reducing fat deposition in animals. The effect that can be achieved 
is limited to the available genetic variation and is a long-term 
method that is not able to adapt to rapid changes in requirements. 
Carcass composition must either be measured on the live animal or 
siblings must be used, reducing the selective pressure. In addition, 
undesirable traits have been produced by selection for reduced fat 
deposition, such as Porcine Stress Syndrome and double-muscling in 
cattle (Willham, 1976).
1.2.2 Repartitioning agents
Growth hormone, while stimulating growth in young animals, is 
lipolytic. The daily secretion of growth hormone is positively 
correlated with lean tissue growth and negatively correlated with 
carcass fat in cattle (Bauman, Eisemann and Currie, 1982). Similar 
trends have been found in lambs and pigs. The administration of 
growth hormone to pigs, sheep and cattle has been shown to increase 
weight gain, food conversion efficiency and protein deposition and 
decrease fat deposition (Hart and Johnson, 1986). Recombinant bovine 
growth hormone has similar effects (Muir, Wien, Duquette, Rickes and 
Cordes, 1983). Such studies have shown considerable variation 
depending on species, breed and mode of administration. The 
administration of androgens or oestrogens to cattle can increase 
growth rate, food conversion efficiency and decrease fat deposition
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(Roche and Quirke, 1986). Female cattle and bulls respond best to 
androgens and oestrogens respectively. Similar responses have been 
obtained with sheep but not pigs.
There has been growing interest in recent years in 
pharmacological repartitioning agents, such as clenbuterol and 
cimeratol. These ^-agonists have been demonstrated to increase lean 
tissue accretion and limit fat deposition in rats, broilers, cattle, 
sheep and pigs (Dalrymple, Baker, and Rickes, 1984; Hanrahan, Quirke, 
Bomann and Roche, 1986). Their precise mode of action is unknown but
they bind specifically to ^-adrenergic receptors on the cell
membrane, effecting their responses through the stimulation of cAMP 
production within the cell. ^-agonists inhibit protein degradation 
in muscle, while stimulating lipolysis in adipose tissue and |3 
oxidation and possibly protein synthesis in muscle (Dalrymple et al.,
1984).
The approaches for the improvement of animal performance, 
described above, suffer from several serious limitations, the most 
important of which is the current EEC ban on the use of steroid 
growth promoters in animal production. Hormones and ^-agonists are 
also expensive and frequent administrations are necessary to achieve 
the desired effects on growth promotion and carcass composition. 
These limitations, together with the possibility of adverse effects 
on animal health and behaviour, have led to the search for 
alternative strategies to improve animal performance. Several 
immunological approaches have yielded promising results, including
active immunisation against somatostatin, which inhibits growth 
hormone secretion, resulting in increased growth rates and food 
conversion efficiencies in lambs (Spencer, Garssen and Bergstrom,
11
1983). Anti-idiotypic antibodies, raised against growth hormone 
antibodies, have been shown to resemble growth hormone, both 
structurally and functionally (Morrison, 1986). The use of 
anti-idiotypic antibodies as hormone images may prove useful for a 
number of hormones having growth-promoting effects (Flint, 1987). 
Passive or active immunisation against the adipocyte would share the 
advantages of these methods of giving the option of treatment or no 
treatment, depending on market trends, and of not leaving harmful
residues in the edible tissues. In addition, this approach may not
require continuous or frequent administration of antiserum or 
immunogen and, unlike the methods described above, might reduce the 
number of adipocytes, rather than alter metabolism.
1.2.3 Nutritional manipulations
The effects of nutritonal manipulations on adipose tissue
development partly depend on the age of the animal. Maternal 
undernutrition of rats and man can cause a permanent increase in
of iVu
adiposityA (Ravelli, Stein and Sussex, 1976; Jones and Friedman, 
1982). Food restriction of swine in early pregnancy resulted in a 
reduction in adiposity and total body weight (Pond, Mersmann and 
Jong-Iseng, 1985). Food restriction during the final part of 
pregnancy may cause a permanent reduction in body weight and
adipocyte number, possibly because proliferation of foetal adipose 
tissue has begun (Winnick, 1981).
In the rat underfeeding pre-weaning causes a permanent 
reduction in adipocyte number while underfeedng post-weaning causes a 
reduction in cell size only (Knittle and Hirsch, 1968; Stern and 
Greenwood, 1974). Even severe long-term food deprivation in the
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adult does not cause loss of adipocytes (Miller, Faust, Goldberger 
and Hirsch, 1983). Reduced adipocyte size, produced as a result of 
underfeeding, is recovered, in the adult, upon refeeding. Overfeeding 
pre-weaning may cause a permanent increase in cell number (Knittle 
and Hirsch, 1968). In the adult rat the feeding of a high fat diet 
induces hyperphagia and leads, initially, to an increase in adipocyte 
size. The reaching of a 'critical' cell size appears to trigger an 
increase in adipocyte number (Peckham, Entenman and Carrol, 1962; 
Klyde and Hirsch, 1979; Faust and Miller, 1981). Upon returning to a 
normal diet, adipocyte size returns to a normal level but adipocyte 
number remains elevated, resulting in a permanently elevated fat 
mass.
Evidence for a relationship between adipocyte size and food 
intake has come from studies on the obese Zucker rat, which is 
hyperphagic until 20 weeks of age. This has been correlated with an 
increase in adipocyte size which ceases at 20 weeks and is followed 
by cycles of cellular proliferation followed by increases in 
adipocyte size, coupled with cycles of hyperphagia (Vasselli, 1985). 
A mechanism was proposed whereby the reaching of a critical cell size 
has a depressive effect on food intake. The nature of the signal 
linking adipocyte size with food intake is unknown. Parabiosis 
experiments between obese and normal rats have suggested that 
blood-borne factors are involved with the regulation of food intake 
(Harris and Martin, 1984). Liebel (1977) proposed a biological radar 
system whereby the intensity of a humoral signal, such as insulin or 
the ratio of insulin and glucose, to the CNS varied according to the 
adipose cell surface area. Adipsin is a recently discovered 
candidate for an adipocyte-derived signal that might exert effects on
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food intake (Flier, Cook, Usher and Spiegelman, 1987). Adipsin is a 
serine protease homologue that is synthesized and secreted by 
adipocytes and is found in the circulation. Adipsin secretion is 
decreased during continuous infusion of glucose, which results in an 
increased adipose mass, and is also decreased in genetically obese 
rodents. However, little change in adipsin secretion is found in 
rats that become obese as a result of high-fat feeding.
A number of studies have attempted to increase the growth rates 
of meat-producing animals by increasing dietary energy intake. 
However, an over-consumption of dietary energy tends to lead to 
increased fat deposition (Combs, 1976). The feeding of diets with a 
high protein to energy ratio tends to minimise carcass fat. Unless 
the breed, cross or strain has the genetic potential for a high lean 
to fat ratio, most dietary manipulations have little effect on 
carcass fat.
1.2.4 Lipectomy
Clearly, surgical removal of adipose tissue is not a technique 
to be used in meat species but studies in rats have yielded 
information on the regulation of adipose tissue development. In 
general, lipectomy of internal fat depots in the adult rat is not 
followed by regeneration of lost tissue or compensatory hypertrophy 
of other depots unless the animal is genetically predisposed towards 
obesity or is fed a high fat diet (Faust, Johnson and Hirsch, 1976). 
Lipectomy of internal depots early in life can result in some 
regeneration, (Faust, Johnson and Hirsch, 1977) and subcutaneous 
adipose tissue shows some regenerative capacity (Bailey and Anderson, 
1980). Faust etal. (1977) found that lipectomised animals fed a
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high fat diet had a lower food intake than sham-operated controls, 
providing further evidence that body fat stability in the adult is 
achieved by the regulation of adipocyte size and that such regulation
may operate by influencing food intake.
Surgical removal of adipose tissue in humans has proved
successful only for removing small amounts of fat in areas refractory 
to dieting.
1.3 CHARACTERISATION OF THE ADIPOCYTE PLASMA MEMBRANE AND
ANTI-(ADIPOCYTE PLASMA MEMBRANE) ANTIBODIES
A number of groups have attempted to identify and characterise 
the components of the adipocyte plasma membrane by gel 
electrophoresis with the ultimate aim of studying hormone-plasma 
membrane interactions. Lee, Tume, Cryer and Cryer (1986) have
attempted to characterise the adipocyte plasma membrane using 
adipocyte specific antisera, in order to identify 'differentiation' 
antigens that can be used to identify differentiation of adipocyte 
precursors. Pillion, Grantham and Czech (1979) and Flint et al.
(1986) have raised antisera to adipocyte membranes and studied their 
effects on isolated adipocyte metabolism.
1.3.1. Characterisation of the adipocyte plasma membrane by gel 
electrophoresis
Polyacrylamide gel electrophoresis (PAGE) of rat adipocyte 
plasma membranes has identified between 13 and 20 major peptide 
components with molecular weights ranging from 15 kD to 178 kD (Czech 
and Lynn, 1973 a & b; Trosper and Levy, 1974; Avruch, Leone and
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Martin, 1976; Kawai and Spiro, 1980 and Tume, Lee and Cryer, 1985). 
These groups have also identified 2 prominent glycopeptides with 
molecular weights of 88-108 kD and 77-81 kD. Czech and Lynn (1973a) 
found that the 2 glycoproteins represented about 50% of the total 
membrane protein and constituted almost all of the protein on the 
exterior of the adipocyte surface, as determined by iodination of 
intact cells.
Two reports comparing the polypeptide composition of adipocyte 
plasma membranes of rats with those of other species, have yielded 
conflicting results. Both groups found differences in polypeptide 
and glycoprotein composition between plasma membranes of different 
species. However, while Kawai and Spiro (1980) concluded that 
rabbit, rat and bovine plasma membranes were alike in containing a 
major glycoprotein component with a molecular weight of 74-79 kD, 
Tume et al. (1985) reported that mouse, ox, chick, rabbit and rat 
adipocyte plasma membranes differed in the number and electrophoretic 
mobility of all major glycopeptides. These authors also found 
differences in the polypeptide composition of adipocyte plasma 
membranes from rats of different strains.
1.3.2 Characterisation of the adipocyte plasma membrane using 
anti-(adipocyte plasma membrane) antisera
Thompson and Abraham (1979) raised antisera to mouse mammary 
adipose cells that could be used to distinguish mammary adipose cells 
from mammary epithelial cells and fibroblasts. Lee et al. (1986) 
raised antisera to mouse, rat, bovine and chicken adipocyte plasma 
membrane antigens. Each antiserum showed some reactivity towards 
erythrocyte, liver and heart membranes but this could be removed by
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absorption without affecting reactivity against adipocytes (Cryer, 
1985; Plaas, Woodhead and Cryer, 1981). The antisera showed low 
levels of reactivity against adipocytes from different species with 
the exception of anti-mouse and anti-(rat adipocyte plasma membrane) 
antisera, which showed 30% cross-reactivity with rat and mouse 
adipocyte membranes respectively.
Lee et al. (1986) have attempted to identify adipocyte
differentiation-related antigens by reacting solubilized plasma 
membranes with adipocyte specific antisera and analysing the 
resulting immunoprecipitates by gel electrophoresis. The components 
immunoprecipitated were distinguishable when antisera and plasma 
membranes from different species were used. Three components were 
isolated from rat adipocyte plasma membranes with molecular weights 
of 124, 90 and 60 kD, one component was obtained from bovine
adipocyte plasma membranes with a molecular weight of 87.5 kD and 3 
components were prepared from chicken adipocyte plasma membranes, 
with molecular weights of 37, 47 and 57 kD. These antigens were not 
identified on freshly confluent adipocyte precursors and their 
appearance could be used as a marker of adipocyte differentiation 
before the development of enzymic markers of differentiation.
1.3.3 In vitro effects of anti-(adipocyte plasma membrane) 
antisera on isolated adipocytes
Pillion and Czech (1978b) raised antisera, in rabbits, to rat 
adipocyte intrinsic plasma membrane proteins, prepared by the 
treatment of plasma membranes with dimethylmaleic anhydride. This 
fraction consisted of 2 major glycoproteins of molecular weights of 
94 kD and 78 kD and has been shown to exhibit D-glucose transport
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activity when incorporated into liposomes (Shanahan and Czech, 1977). 
The anti-(adipocyte plasma membrane) antiserum caused cytolysis of 
isolated adipocytes. This effect could be abolished by heat 
inactivation of the antiserum to destroy complement. The 
heat-inactivated antiserum stimulated glucose uptake and carbon 
dioxide production from glucose by isolated adipocytes, comparable to 
effects seen with maximal doses of insulin, while catecholamine 
stimulated lipolysis was reduced (Pillion and Czech, 1978a). Similar 
effects have been produced by antibodies raised against rat insulin 
receptors and by human autoantibodies to the insulin receptor 
isolated from the sera of patients suffering from insulin-resistant 
diabetes (Jacobs, Chang and Cuatrecasas, 1978; Kahn, Baird, Flier and 
Jarrett, 1977).
Insulin binding to the adipocyte plasma membrane was not 
affected by the anti-(adipocyte plasma membrane) antiserum of Pillion 
and Czech (1978a) which led to the suggestion that the antiserum 
reacted directly with the hexose transport system. Studies with fab 
fragments of the anti-(membrane) antibodies showed that multivalency 
was required for activity (Pillion, Grantham and Czech, 1979). The 
authors proposed a mechanism of action for the antibodies involving 
aggregation of membrane components, similar to the model proposed for 
the mechanism of action of anti-(insulin receptor) antibodies (Kahn, 
Kasuga, King and Grunfeld, 1982). Immunofluorescence studies with 
anti-adipocyte plasma membrane) antibodies showed capping on the cell 
surface (Pillion and Campbell, 1984). There was no correlation 
between the extent of capping and antibody concentration or between 
capping and glucose oxidation, but there was a clear relationship 
between glucose oxidation and antibody concentration. Adipocytes
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fixed in paraformaldehyde before exposure to anti-(plasma membrane) 
antibodies showed a similar number of caps to unfixed cells. These 
studies suggest that adipocytes have areas on their cell surfaces 
where antigenic components are clustered into groups. Anti-(membrane) 
antibodies do not appear to mimic insulin action in isolated 
adipocytes by causing aggregation of antigenic sites on the cell 
surface.
The work of Pillion and Czech has been supported by that of 
Flint et al. (1986), where an antiserum was raised against whole rat 
adipocyte plasma membranes in sheep. The antiserum was shown to have 
insulin-like effects on adipocytes at low concentrations, stimulating 
glucose transport and glucose incorporation into lipid, while, at 
higher concentrations, an inhibitory effect on glucose incorporation 
was observed. This effect was found to be due to complement- 
mediated cytotoxicity since, under such conditions, large amounts of 
the intracellular enzyme, lactate dehydrogenase, were released and 
the effect could be abolished by heat-inactivation of the antiserum. 
This antiserum appeared to interact directly with the glucose 
transport system by a mechanism not involving the insulin receptor 
since antibodies were able to stimulate glucose transport in cells 
from which the insulin receptors had been removed by trypsinisation 
and the antiserum was unable to immunoprecipitate solubilized insulin 
receptors.
The adipocyte plasma membrane, therefore, has a number of 
antigenic components some of which are tissue and species specific. 
The fact that antisera raised against adipocyte plasma membranes are 
cytotoxic to isolated adipocytes in vitro suggests that such antisera 
might have fat-reducing properties in vivo.
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1.4 MECHANISMS OF IMMUNE TISSUE DAMAGE
The immune system serves as a defence against viral, bacterial, 
fungal and parasitic infections. Under normal circumstances an 
individual does not mount a destructive immune response against its 
own tissues but virally-infected or tumour cells can elicit a 
cytotoxic immune response against host cells. Both passive and 
active immunisation have been used to augment the effective immune 
response against infectious agents and tumour cells. Passive 
immunisation involves the administration of preformed antibody in the 
hope that it will activate the recipient's antibody-dependent immune 
effector mechanisms. By active immunisation antigen-specific 
antibodies and/or antigen specific T cell-mediated immune responses 
to the injected antigen may be induced. The cytotoxic mechanisms 
used by an organism in defence against infection or in response to 
immunisation vary according to the nature of the infection or 
immunogen, and several factors are usually involved.
1.4.1 Complement-mediated cytolysis
Complement consists of a complex series of proteins tbe
c{ v>Y\\CY'
primary functionsAare chemotaxis and activation of polymorphonuclear 
leucocytes ( and macrophages, cytolysis of target cells and 
opsonisation. Complement may be activated via the classical pathway, 
in which case the primary stimulus is binding of antibody to antigen, 
or via the alternative pathway, which occurs independently of 
antibody and is often initiated by carbohydrate components of 
microbial cell walls.
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1.4.1.1 Complement activation
The biochemistry of complement has been reviewed by Porter and 
Reid (1978). The sequential activation of the complement cascade by 
the classical pathway is shown in Fig. 1.1. Binding of certain 
subclasses of IgG and IgM to the Clq component of the Cl complement 
protein complex activates Clr and Cls in turn. Cls cleaves C4 into a 
small peptide C4a and a larger peptide C4b. Cls is highly 
proteolytic for C2 when complexed to C4b. A small C2a fragment is 
lost and the larger C2b fragment joins with C4b to form the C3 
convertase C4bC2b. The C3 convertase activates C3 by splitting off 
the anaphylatoxin C3a, revealing a nascent thio-ester-reactive 
binding site on the larger fragment C3b. C3b cleaves C5 into C5b and 
the anaphylatoxin C5a. C5b, when fixed to biological membranes, is 
followed by the sequential addition of C6, Cl, C8 and C9 to form the 
membrane attack complex.
The chemistry of the alternative pathway of complement has been 
reviewed by Miiller-Eberhard and Schreiber (1980). The C3 convertase 
of the alternative pathway is formed by an association between C3b 
and factor B (Fig. 1.2). C3b is thought to be continuously formed 
in small amounts. Factor H competes with factor B for binding of C3b 
and which is preferably bound depends on the nature of the substrate 
to which C3b is attached. Certain polysaccharides on microbial cell 
walls favour the uptake of factor B onto C3b. C3bB is susceptible to 
enzymatic cleavage by factor D. The small Ba fragment is lost and 
C3bBb forms the C3 convertase, thus forming a positive feedback loop. 
C3bBb has a half life of approximately 5 minutes unless it is bound 
to properdin, forming C3bBbP. This complex has a half life of 30 
minutes. When factor H is bound to C3b, factor I cleaves C3b into 
C3c and C3d which are inactive.
Fig. 1.1. Complement activation via the classical pathway
The binding of immune complexes to Clq causes the activation of Clr 
and Cls in turn. Cls cleaves CU into Cka. and CVb. When C2 is hound 
to C4b, Cls cleaves C2 into C2a and C2b. C2b joins with C^b to form 
the C3 convertase CVbC2b. The C3 convertase cleaves C3 into the 
anaphylatoxin, C3a and C3b. C3b cleaves C5 into C5b and the 
anaphylatoxin, C5a. C5b, when fixed to biological membranes, is 
followed by the sequential addition of C6, C7, C8 and C9 to form 
the membrane attack complex.
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Fig. 1.2 Complement activation via the alternative pathway
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The C3 convertase is formed by an association between C3b and factor 
B. Factor H competes with factor B for binding of C3b but certain 
polysaccharides on microbial cell walls favour the uptake of factor 
B onto C3B.
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Animals can be depleted of complement by activation of the 
alternative pathway with cobra venom factor (Cochrane, 
Miiller-Eberhard and Aikin, 1970). A complex is formed between cobra 
C3b and host Bb which is resistant to factors H and I and has a half 
life of 37 hours. This results in massive conversion of C3 to C3b, 
discharging the feedback loop to exhaustion.
1.4.1.2 Cytolysis
Much of the available information on complement-induced lysis 
comes from studies on the destruction of erythrocytes, although lysis 
of nucleated cells appears to proceed similarly (Humphrey and 
Dourmashkin, 1969). Ultrastructural studies have suggested that C9 
mediates the fusion of two C5-9 complexes to form a tubule traversing 
the membrane, which is highly amphiphilic, 1700 kD molecular weight, 
15 nm long and 10 nm in diameter (Podach, Essex, Biesecker and 
Miiller-Eberhard, 1980). Such a complex would allow the free exchange 
of electrolytes and water across the plasma membrane. The net influx 
of sodium ions and water would lead to cytolysis.
Different classes and subclasses of antibody vary in their 
ability to activate complement. For the lysis of sheep red blood 
cells by anti-Forssman antibody, the relative effectiveness of 
IgM:IgG molecules has been calculated as 800:1 (Humphrey and 
Dourmashkin, 1969).
One of the commonest examples of complement-mediated cytolysis 
is the transfusion reaction caused by the transfusion of blood into a 
recipient who has antibodies to the transferred cells. Haemolytic 
disease can also occur in newborn infants where the mother has 
circulating antibodies to blood group antigens on the infant's red
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blood cells, the most commonly involved antigen being the Rhesus D 
antigen (Wintrobe, 1956).
In vitro studies have demonstrated a relative inefficiency of 
complement to lyse cells from homologous species (Shin, Hausch, Hu 
and Nicholson-Weller, 1986). A 'decay-accelerating factor' (DAF) has 
been isolated from erythrocyte membranes which is believed to be 
involved in the regulation of C3/C5 deposition on the surface of 
homologous erythrocytes (Nicholson-Weller, Burge and Austen, 1981). 
Patients with Paroxysmal Nocturnal Haemoglobinuria produce red blood 
cells that are deficient in DAF and are abnormally sensitive to 
complement-mediated lysis (Nicholson-Weller, March, Rosenfield and 
Austen, 1983). The existence of an additional homologous restriction 
factor that regulates C9 insertion has also been demonstrated (Shin 
et al., 1986).
Antibody has also been shown to cause complement-mediated 
cytolysis of virally infected human cell lines. Here the alternative 
pathway is required to amplify the triggering of the lytic sequence 
by the classical pathway, which is not, by itself, sufficient to 
cause damage (Sissons and Oldstone, 1980).
Antibodies have been detected in the sera of patients with 
Burkitt's lymphoma, malignant myeloma and sarcomas which show 
complement-mediated cytotoxicity to tumour cells in vitro. Their in 
vivo significance, however, is not clear (Herberman, 1977).
There are, therefore, several examples of cytotoxicity caused 
by the formation of the complement membrane attack complex. However, 
in some responses to infections and in some auto-immune conditions, 
where complement is activated, tissue damage may occur as a result of 
cell-mediated reactions.
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1.4.2 Cell-mediated cytolysis
1.4.2.1 Polymorphonuclear leukocytes and macrophages
Neutrophils and macrophages possess Fc receptors and so may 
bind to Fc-coated cells and be to of the cell types responsible for 
antibody-dependent cell-mediated cytotoxicity. C5a, generated by 
complement activation, is chemotactic for and activates 
polymorphonuclear leukocytes. Neutrophils are phagocytic, but if 
unable to phagocytose their target, their lysosomal contents may be 
released, damaging the underlying tissue. The main role of 
complement in immune complex-induced kidney injury has long been 
thought to be C5a attraction of neutrophils to the site of immune 
deposits, and the subsequent release of toxic products of neutrophil 
activation adjacent to the glomerular basement membrane (Couser, 
1985; Ulich, Bannister and Wilson, 1987). Neutrophils have also been 
found to exert toxic effects on tumour cells. The administration of 
a streptococcal preparation to patients with malignant ascites 
increased the numbers of neutrophils with cytotoxic activity against 
tumour cells, probably due to C5a generated via the alternative 
pathway (Fujimura and Torisu, 1987).
Antigen-activated T and B lymphocytes release lymp< hokines that 
may activate macrophages in an antigen non-specific manner. T cell 
lymphokines are the most well defined but have been identified by 
their activity and so it is not always clear whether an activity is 
due to one factor or several or whether there is an overlap between 
lymphokines. Lymphokines that modulate the action of macrophages 
include migration inhibition factor, macrophage activation factor and 
the interferons (Rocklin, Bendtzen and Greineder, 1980). Lymphokines
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activate macrophages by inducing the formation of more Fc and C3
receptors and by stimulating the production of various enzymes and
other factors, including toxic oxygen metabolites (Nathan, Karnovsky 
and David, 1971; Klimetzek and Sorg, 1977). T cell activated 
macrophages have been shown to have enhanced phagocytic activity 
(Nathan et al., 1971), tumoricidal capacity (Piessons, Churchill and 
David, 1975) and bacteriocidal activity (Godal, Rees and Lamvik, 
1971).
1.4.2.2 K cells
The cells involved in antibody-dependent cell-mediated 
cytotoxicity (ADCC) are poorly defined. Classical K cells are 
lymphoid cells that do not consistently carry the surface markers of 
either T or B cells but possess Fc receptors (van Boxel, Stobo, Paul 
and Green, 1972). ADCC has been demonstrated in vitro, using 
antibodies to tumour or MHC-associated antigenic determinants, to 
haptens conjugated to cell membranes, or to membranes of nucleated 
erythrocytes (Sanderson, Clark and Taylor, 1975; Korec, Herberman,
Dean and Canon, 1980). The in vivo significance of ADCC is open to 
question but K cells may kill virus-infected cells by binding to 
specific antibody via surface Fc receptors (Kohl and Loo, 1982). The 
antibody requirements for ADCC appear to be different to those 
required for complement-mediated cytotoxicity. All classes of
immunoglobulins are capable of mediating ADCC although IgG 
predominates. A very much smaller number of antibodies is required 
to coat the cell than for complement-mediated cytotoxicity and a 
single effector cell appears to be able to cause lysis (Perlmann, 
Perlmann and Wigzell, 1972).
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1.4.2.3 Natural killer cells
Natural killer cells are a heterogeneous population of cells, 
both with respect to surface markers and the target cells that they 
recognise. They have Fc receptors but killing is not achieved 
through Fc receptor binding and is not antigen-specific.
1.4.2.4 Cytotoxic T lymphocytes
Cytotoxic T lymphocytes (CTLs) recognise antigen in association 
with self MHC products, predominantly class I MHC products on the 
surface of antigen-presenting cells (Marrack and Kappler, 1986). A 
single cytotoxic T lymphocyte is able to lyse an antigen-bearing 
target cell (Kranz, Pasternack and Eisen, 1987). The precise 
mechanism whereby cytolysis is achieved is not clear but, in the 
process, a novel serine esterase and a C9-like protein, perforin, are 
released from the cytolytic granules of the CTL which has led to the 
suggestion that CTLs and complement have similar cytolytic
mechanisms. However, the resistance of some CTLs to lysis by other
CTLs but not to lysis by antibody-activated complement suggests that 
there are differences between the two cytolytic mechanisms (Kranz et 
al., 1987).
One of the major physiological functions of CTLs is the 
elimination of virally-infected cells, where the CTL recognises
foreign viral antigens on the host cell surface in conjunction with 
self MHC class I antigens (Zinkernagal and Doherty, 1974). Some 
cancer patients exhibit peripheral blood cytotoxicity against 
autologous tumour cells. Here, the CTL recognises neoantigens on the 
tumour cell in conjunction with MHC I antigens (Henney, 1977). CTL 
may also play a role in graft rejection. One theory is that T helper
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cells recognise foreign MHC II antigens on the graft cell and
stimulate host CTLs to destroy the graft cell. The CTLs may
recognise the graft via foreign class I MHC antigens (Roitt, 1986).
1.4.3 Phagocytosis
C3b coating of target cells and particles is probably the major 
biological effect of complement. Neutrophils, eosinophils, monocytes 
and macrophages bear C3b receptors. C3b coating facilitates
adherence of foreign particles to phagocytic cells and facilitates
the ingestion of foreign particles by macrophages.
1.4.4 Cytolysis enhanced by immunotoxins
The use of antibodies to target toxins and drugs to cells has 
received a lot of attention in recent years, particularly as agents 
of tumour destruction (Vitetta, Krolick, Miyama-Inaba, Cushley and 
Uhr, 1983). Plant and bacterial toxins show structural homology.
Ricin, one of the best characterised, is composed of a polypeptide B
chain, which is a galactose-specific lectin and hence binds to
virtually all eukaryotic cells, and an A chain which displays 
enzymatic activity (Vitetta and Uhr, 1985). Entry of toxins into the 
cell is achieved by receptor-mediated endocytosis and, after cleaving 
of the disulphide bonds linking the A and B chains, the A chain may 
be translocated into the cytoplasm. The entry of a single ricin A 
chain into the cytoplasm is sufficient for cell killing. The A  chain 
catalytically inactivates ribosomal subunits by binding at or near 
the Elongation Factor 2 binding site and thereby inhibits protein 
synthesis.
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Most immunotoxins are composed of antibodies conjugated to 
ricin A chains only, since the B chain confers excessive non-specific 
toxicity. Immunotoxins have been assessed for their ability to 
facilitate bone marrow transplantation for the treatment of cancer 
(Krolick, Uhr and Vitetta, 1982). In a mouse model, bone marrow from 
tumour-bearing animals was treated with a specific anti-tumour A 
chain toxin. After supra-lethal irradiation mice were reconstituted 
with immunotoxin-treated bone marrow and 75% of such treated animals 
remained disease-free. The prevention of graft versus host disease 
in allogeneic bone transplants by eliminating T lymphocytes with 
immunotoxins has been successful in mice and man (Vitetta and Uhr,
1985).
Potential problems for the use of immunotoxins in vivo include 
non-specific cytotoxicity of immunotoxins, particularly to the 
reticulo-endothelial system, specific cytotoxicity to non-target 
cells that bear cross-reacting antigens with target cells and the 
host immune response to the immunotoxin. Successful treatment of 
tumour-bearing mice with immunotoxins has been reported, where 95% of 
the tumour burden had already been removed by other methods (Krolick, 
Uhr, Slavin and Vitetta, 1982).
The most important requirement for the use of immunotoxins in 
vivo is probably for specific antibodies to antigens that show no 
cross-reactivity with other tissues. The work of Lee et al. (1986) 
suggests that such antigens may exist on adipose tissue.
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1.5 SELF TOLERANCE AND AUTOIMMUNITY
At the beginning of the century Ehrlich proposed that the body 
does not have lymphocyte receptors directed against self molecules, a 
phenomenon he termed "horror autotoxicus" (Ehrlich and Morgenroth, 
1900). This was based on the fact that he failed to induce animals 
to generate antibodies to their own tissues. The idea that all 
self-reactive lymphocytes were deleted early in life persisted for 
many years until several lines of evidence demonstrated the existence 
of self-reactive lymphocytes in normal adult individuals. Immune 
responses have been induced in experimental animals to many self 
tissues including the liver (Watanabe, Kawakami, Kawamoto, Ikemoto, 
Masuda, Takzaki, Nakanishi, Kajiyama and Takeno, 1987), kidney 
(Germuth, Senterfit and Pollock, 1967; Vnanue and Dixon, 1967), the 
CNS (Kallen and Nilsson, 1986) and the thyroid (Clagett and Weigle, 
1974) by immunising with either autologous or heterologous antigens 
in complete Freunds Adjuvant. B and T lymphocytes have been 
identified in normal individuals binding many self antigens, 
including thyroglobulin (Roberts, Whittingham and Mackay, 1973), DNA 
(Pisetsky, Caster and Steinberg, 1983), various common serum proteins 
(Guilbert, Dighiero and Avrameas, 1982), antigens of the CNS (Silberg 
and Swanborg, 1986) and immunoglobulin (Defranco, Raveche, Asorfsky 
and Paul, 1982). It is now generally accepted that self-reactive 
lymphocytes and self-antigens must be able to make contact in normal 
individuals although, under normal circumstances, controlling 
mechanisms must exist which prevent the triggering of an autoimmune 
reaction.
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1.5.1 Iimnunoregulation
The immune response to any antigen is under complex regulatory 
control mediated by antibody and cellular circuits of helper and 
suppressor cell interactions and lymphocyte products (Roitt, 1986). An 
outline of a minimal model for immunoregulation is given here in 
order to facilitate discussion of the control of autoimmunity.
Before a B lymphocyte can respond to an antigen, the antigen 
must be processed and presented by an antigen-presenting cell, 
frequently a macrophage. Most B lymphocytes also require T cell 
help. T helper cells recognise different antigenic determinants to 
those recognised by B cells in conjunction with MHC class II antigens 
on the antigen-presenting cell. Both B and T cells are subject to T 
cell suppression. The nature of interactions between lymphocytes are 
not clearly defined. Soluble antigen-specific and MHC restricted 
factors are produced by T cells in vitro but their in vivo 
significance is not clear.
The variable region of an antibody molecule, the idiotype, may 
act as an antigenic determinant, inducing the formation of anti- 
idiotypic antibodies. Such antibodies may recognise the antigen- 
combining site of the idiotypic antibody and, hence, will compete 
with the antigen for binding of the idiotypic antibody. In the early 
1970s Jerne (1974) proposed a network hypothesis, whereby idiotypes 
and anti-idiotypes function in the maintenance of immunological 
homeostasis by forming a network with multitudinous connections. He 
proposed that any antibody made in response to an antigen will induce 
the formation of an anti-idiotypic antibody which will regulate 
production of the idiotypic antibody. The anti-idiotypic antibody 
will, in turn, induce the formation of an anti-anti-idiotypic
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antibody and so on. T and B cells also bear idiotypes. Jerne's 
hypothesis envisages idiotype-bearing cells interacting with 
anti-idiotype bearing cells to suppress or stimulate them.
In vitro studies have suggested that circuits of helper and 
suppressor cells may exist, possibly including inducer, transducer 
and contrasuppressor cells (Flood, Chue and Green, 1986). The 
balance betwen stimulation and suppression by T helper cells, T 
suppressor cells and idiotype-anti-idiotype interactions determines 
whether a state of immunity or tolerance is induced by an antigen.
1.5.2 Mechanisms of self tolerance
Theories of how immune responses against self tissues are 
avoided in the normal individual centre around lack of T cell help, T 
cell suppression and suppression by the idiotype network. Since T 
cells bear idiotypes and anti-idiotypes, these theories are not 
mutually exclusive.
Autoimmune responses to some self antigens may be induced by 
immunising animals with heterologous antigen or antigens modified by 
linkage to a drug or hapten (Allison, Denman and Barnes, 1971). 
Clagett and Weigle (1974) found that immunisation with heterologous 
thryoglobulin induced an autoimmune response against self 
thyroglobulin as long as T cells were present. This work suggested 
that some autoantigens are recognised by B cells but not T helper 
cells. If T helper cells are presented with foreign antigenic 
determinants on a heterologous antigen or a hapten linked to a self 
determinant, they may provide T cell help to self-reactive B cells.
There is substantial evidence for an important role of T cell 
suppression in the prevention of autoimmunity. Romball and Wiegle
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(1987) transferred autoimmunity to thyroglobulin from autoimmune mice 
into irradiated syngeneic mice but could not transfer autoimmunity 
into normal mice. They suggested that autoimmunity could be 
transferred into irradiated mice due to abrogation of suppressor 
function. Autoimmune diseases, such as thyroiditis and gastritis, 
can be induced in some strains of mice by thymectomy at a critical 
stage, without further treatment (Taguchi and Nishizuka, 1987). This 
led to the proposal that autoantigen-reactive suppressor cells are 
continuously generated by stimulation from self antigens and inhibit 
the activation of potentially autoreactive cells. Neonatal 
thymectomy increases the frequency of autoimmune disease because, at 
this stage, suppressor T cells have not been peripheralized while 
cytotoxic T cells have. Support was given to this hypothesis by the 
prevention of autoimmune disease in thymectomised animals given 
injections of spleen cells from syngeneic adults 24 hours after 
thyme c tony.
Theories of how the idiotype network might be involved in the 
prevention of autoimmunity are controversial. The evidence is mostly 
indirect and is derived from studies where autoimmunity has been 
induced in experimental animals by manipulation of the idiotype 
network. Mice immunised with insulin produced anti-(insulin) 
antibodies which stimulated the production of anti-idiotypic 
antibodies which behaved like antigen images, binding to the insulin
receptor and mimicking the action of the hormone (Shechter, Maron,
a
Elias and Cohen, 1982). Cross-reacting idiotypes are of widesprqd 
occurrence on human and animal autoantibodies, suggesting that they 
may have arisen as the result of a perturbation of the idiotype 
network (Zanetti, 1986). Bigazzi (1986) found that established
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autoimmune responses in a rat model of autoimmune thyroiditis could 
be inhibited by the administration of the corresponding 
anti-idiotypic antibodies. Immunisation against the idiotype
resulted in more vigorous and protracted autoimmune responses, 
possibly through the production of anti-anti-idiotypic antibodies. 
Anti-idiotypic antibodies binding to anti-acetylcholine receptor and 
anti-thyroglobulin antibodies have been identified in serum of
patients suffering from Myasthenia gravis and Hashimotofs Thyroiditis 
respectively (Dwyer, Bradley, Oh and Kearney, 1984; Sikorska, 1986). 
In some cases the presence of anti-idiotypes is associated with a 
recession of the disease. It is, therefore, possible to induce 
autoimmune responses by deliberate perturbation of the idiotype 
network and there is evidence of disturbances of the network in 
established autoimmunity.
1.5.3 Autoimmune diseases
In the normal individual a variety of complex mechanisms 
maintain a delicate immunological balance, preventing pathological 
autoimmune responses. This balance can be disturbed experimentally, 
but can also breakdown naturally. A number of diseases are now 
recognised that are associated with the production of autoantibodies 
and autoreactive T cells. Autoimmune diseases range from the highly 
organ-specific, such as Hashimoto's thyroiditis, where antibodies to 
thyroglobulin are produced, to non-organ specific, such as Systemic 
Lupus Erythematosus, where antibodies to a wide range of tissues are 
produced.
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1.5.3.1 The pathogenesis of autoimmune disease
In some autoimmune diseases, while autoantibodies are present, 
they may not be responsible for the pathogenesis of the disease. 
Cell-mediated immune responses may be more important or the 
autoimmunity may be a consequence rather than a cause of the disease.
The most convincing evidence for the cause of disease by 
autoimmune processes is the production of lesions characteristic of 
the disease by deliberate induction of autoimmunity. Immunisation of 
animals against thyroglobulin produces infiltration of the thyroid 
gland with mononuclear cells and lesions resembling those seen in 
Hashimoto's thyroiditis (Clagett and Weigle, 1974). Immunisation 
against myelin basic protein induces lymphocyte infiltration of 
nervous tissue and demyelination, resembling lesions seen in Multiple 
Sclerosis (Kallen and Nilsson, 1986). While in these models 
autoantibodies against thyroglobulin and myelin basic protein are 
present, they may not be responsible for the production of the 
lesions characteristic of the diseases. Antigen-specific 
autoreactive T cells, rather than antibody, also appear to be 
responsible for the induction of Experimental Allergic 
Encephalomyelitis and Experimental Autoimmune Synovitis, which is 
induced by intra-articular immunisation against IgG (Goldberg, Lance 
and David, 1974).
In other models of autoimmune diseases, a role for antibody in 
the pathogenesis of the disease has been indicated. In the Obese 
Strain chicken, in which thyroid autoantibodies and thyroiditis occur 
spontaneously, the severity of the thyroiditis is greatly diminished 
by removing the site of B cell synthesis, the bursa of Fabricius, 
soon after hatching (Wick, Boyd, Hala, de Canalho, Kofler, Muller and
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Cole, 1981). Removal of the thymus at birth increases the severity 
of the disease, indicating a role for T cell suppression controlling 
the normal outcome of the disease. Transient thyroiditis occurs in 
guinea pigs upon passive immunisation with anti-(guinea pig 
thyroglobulin) antiserum (Kareson, 1970). Symptoms of Myasthenia 
Gravis can be reproduced by passive immunisation with 
anti-(acetylcholine receptor) antibodies (Newson-Davies, 1981). The 
mechanism of action of antibodies in the production of autoimmune 
lesions is not clear. Complement-mediated membrane attack, blocking 
of receptors and induction of an increased rate of receptor loss from 
the post-synaptic membrane by anti-(acetylcholine receptor) 
antibodies may contribute towards the pathogenesis of Myasthenia 
Gravis. Antibody-dependent cell-mediated cytotoxicity may play a role 
in Type I insulin independent diabetes (Pozilli, DiMario and 
Andreani, 1982).
It is likely that, in many autoimmune diseases, a combination 
of T cell-mediated and antibody-mediated responses is responsible 
for the pathogenesis of the disease.
1.5.3.2 The aetiology of autoimmune diseases
The mechanisms by which autoimmune diseases arise are not 
clear. There is evidence of suppressor cell defects in patients with 
SLE, Graves disease, insulin dependent diabetes mellitis and 
autoimmune chronic active hepatitis (Topliss, How, Lewis, Row and 
Kolpe, 1983; Vento, Hegarty, Bottazzo, Macchia, Williams and 
Eddlestone, 1984).
Thyroid cells can be induced to express class II MHC molecules 
upon stimulation with phytohaemmaglutinin. Lymphokines, such as
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X-interferon and interleukin I, released during viral infections, can 
also induce class II MHC antigens on cells on which they are not
normally expressed (Cooke, Rayner and Lydyard, 1986). Such
inappropriate expression of MHC antigens may lead to activation of 
helper T cells reactive against self antigens expressed on that 
tissue and induce the production of autoantibodies or cytotoxic T
cells (Zanetti, 1986).
Hansen (1986) suggested a means whereby viral infections might 
disturb the idiotype network and induce autoimmunity. Antibodies
raised in the normal immune response to the virus might recognise the
part of the virus that binds to the host cell surface receptor.
Anti-idiotypic antibodies might then bind to the cell surface
receptor and would, therefore, be autoantibodies. Any infectious 
agent that can cause a disturbance in the idiotype network may lead 
to autoimmune disease.
It is likely that multiple factors are responsible for the 
production of autoimmunity. Several genetic loci, particularly those 
of the MHC, appear to be associated with susceptibility to autoimmune 
diseases. In addition, there is an age-dependent increase in
autoantibody production, which is possibly due to the relaxation of
hormonal control of the regulation of the idiotype network (Hansen, 
1986).
1.6 IMMUNOLOGICAL ADJUVANTS
In order to raise an antiserum against a heterologous or 
homologous antigen, the immunogen is frequently administered in the 
presence of an adjuvant. An adjuvant can be defined as an agent that
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acts non-specifically to augment an immune response to a specific 
antigen. An enormous number of compounds have been found to modulate 
the immune response which vary in the type of immune response they 
stimulate and their mode of action.
1.6.1 Bacterial adjuvants
Freunds complete adjuvant, an emulsion of mineral oil, Arlacel 
A, and mycobacterium, is one of the most potent adjuvants known for 
stimulating both humoral and cellular immunity (Warren, Vogel and 
Chedid, 1986). Water in oil emulsions form a depot from which 
antigen is slowly released • This prolongs the time of interaction 
between the antigen and antigen-presenting cells. The mycobacterial 
component attracts lymphocytes to the site of injection where they 
accumulate and release lymphokines. This leads to the aggregation 
and proliferation of macrophages. Granulomas, thus formed, serve to 
expose antigen-presenting cells and lymphocytes to high 
concentrations of antigen. The toxicity of Freunds complete adjuvant 
(CFA), mainly because it contains non-metabolizable mineral oil and 
because the mycobacterial elements elicit granulomatous reactions, 
has led to attempts to purify the adjuvant-active components. The 
smallest structure that will replace the mycobacterium in CFA is 
muramyl-dipeptide (MDP). MDP enhances T helper function and is 
mitogenic for T and B lymphocytes. MDP is also chemotactic for and 
activates macrophages. MDP, administered in saline, stimulates 
humoral immune responses and, in mineral oil, stimulates both humoral 
and cell-mediated immunity (Audibert, Chedid, Lefrancier and Choay, 
1976). Derivatives of MDP have now been isolated that are devoid of 
pyrogenicity but retain adjuvant activity (Chedid, Parant, Audibert, 
Riveau, Lederer, Choay and Lefrancier, 1982).
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Lipopolysaccharide (LPS), a component of bacterial cell walls, 
is another potent stimulator of both humoral and cell-mediated 
immunity (Warren et al., 1986). It appears to act directly on 
macrophages, stimulating the production and release of lymphokines 
and increasing expression of la molecules, thus improving the 
efficiency of antigen presentaton. LPS is also a polyclonal B cell 
mitogen and, hence, may stimulate antibody responses by bypassing the 
requirement for T cell help. LPS is highly toxic but the lipid A 
portion of the molecule, while retaining adjuvanticity, is less 
toxic. Relatively non-toxic synthetic analogues of lipid A have now 
been produced.
Whole cell Bordetella pertussis vaccine has 2 adjuvant 
components, LPS and pertussis toxin. Pertussis toxin is a protein 
exotoxin that has been linked to the harmful effects and long-lasting 
immunity to whooping cough. Pertussis toxin potentiates 
cell-mediated immunity through its ability to alter the recirculation 
of T lymphocytes (Allison, 1979).
Bacterial adjuvants, though widely used in experimental 
animals, are toxic and are most effective when administered in 
water-in-oil emulsions which are non-metabolizable and induce 
granuloma formation, rendering their use unacceptable in humans. 
Consequently, efforts have been made to develop non-bacterial, 
metabolizable immunological adjuvants.
1.6.2 Non-bacterial adjuvants
Rluminium compounds have been used 
since the 1920s as adjuvants. They appear to act by slowing the 
excretion of antigen and by the attraction of immunocompetent cells
38
to the area of injection. They may also direct antigens to T-cell- 
containing areas of the lymph node. However, aluminium compounds 
have little effect on cell-mediated immunity and are not as potent as 
CFA in stimulating antibody responses (Warren et al., 1986).
Studies using synthetic polymer adjuvants show that the 
induction of antibody responses can be dissociated from the induction 
of inflammation and granuloma formation. Large insoluble polymers 
with hydrophilic moieties flanking hydrophobic moieties stimulate 
chemotaxis, complement activation and antibody formation. Smaller 
polymers induce inflammation rather than adjuvant effects while 
polymers with hydrophobic moieties flanking hydrophilic moieties 
induce granuloma formation (Warren et al., 1986; Kohm, Niemi, Albert, 
Murphy, Langer and Fox, 1986). Such polymers are thought to act by 
directing antigens to highly efficient antigen presenting cells in 
the lymph nodes. They are in an early stage of development and their 
in vivo metabolism and toxicity need to be further evaluated.
Liposomes have been shown to confer adjuvant activity (Heath, 
Edwards and Ryman, 1976). They can elicit both humoral and cellular 
immunity, the adjuventicity being determined by their charge, 
composition and method of preparation. They appear to act as a depot 
for antigen, prolonging its release. The presentation of antigen in a 
hydrophobic environment may cause increased uptake of antigen by 
antigen presenting cells. Liposomes themselves may act as antigen 
presenting cells if MHC class II molecules are present on their 
surface. The potency of liposomes as immunological adjuvants may be 
increased by the inclusion of LPS, lipid A or MDP within the vesicles 
(Alving and Richards, 1983).
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Despite the development of apparently non-toxic vehicles 
showing immunostimulatory effects, none have been shown to have 
consistent effects equivalent to those of CFA and further 
characterisation of their toxicity and effects on the immune system 
is required.
1.7 A SUMMARY OF THE AIMS AND POSSIBLE PROBLEMS OF PASSIVE AND
ACTIVE IMMUNISATION AGAINST THE ADIPOCYTE
The cost of excess fat deposition in farm animals and the 
demand for leaner meat have led to a search for methods of reducing 
fat deposition and increasing protein deposition. Existing 
approaches include genetic selection for reduced fat deposition, 
nutritional manipulations and the administration of hormonal 
repartitioning agents. Cost, lack of flexibility, possible adverse 
effects on animals and consumers and the EEC ban on the use of 
steroid hormones to improve animal performance, are likely to limit 
the practical use of many of these approaches. The immunological 
reduction of body fat using passive or active immunisation against 
adipocytes is an attractive approach as harmful residues would not be 
left in the edible tissues, the option to treat or not to treat could 
be used, according to demand, and the repeated administration of 
antiserum or immunogen may not be necessary.
Initial attempts to reduce body fat by an immunological 
approach were made by passive immunisation with antisera raised 
against whole adipocyte plasma membranes. Passive immunisation has a 
number of advantages when compared with active immunisation. High 
titre antisera against heterologous adipocyte plasma membranes could
40
be easily raised and have been shown to be cytotoxic to isolated 
adipocytes in vitro. With active immunisation it is necessary to 
overcome the individual's immunoregulatory mechanisms that normally 
prevent pathological immune response against self tissues. 
Self-reactive lymphocytes are present in normal individuals and, 
given the appropriate immunisation protocols, can be induced to mount 
autoimmune responses resulting in tissue lesions resembling those 
seen in autoimmune diseases. Since autoimmune responses have been 
induced against a wide variety of tissues by immunisation with 
homologous or heterologous self antigens in the presence of 
adjuvants, it is likely that an autoimmune response against adipose 
tissue could be induced. However, while passive immunisation 
involves the administration of antisera of defined specificity and 
titre, the results of active immunisation are inevitably subject to 
the variability of the individual's own immune response. Passive 
immunisation also allows the conjugation of immunopotentiators to 
antibody to enhance efficacy, as has been attempted in tumour 
immunothe rapy.
For passive immunisation against the adipocyte to be a useful 
approach for the commercial reduction of fat deposition, any effects 
on body fat must be long-lasting. Recent evidence suggests that, 
while the majority of proliferation in adipose tissue occurs early in 
life, there is capacity for new adipocyte production in the adult. 
Regeneration of lost tissue is a potential limitation of the use of 
passive immunisation for the reduction of body fat since, if 
heterologous antiserum were used, repeated treatments would not be 
effective unless animals were tolerized to the antibody administered. 
Active immunisation against the adipocyte may have the advantage of
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inducing a longer-lasting immune response which may not allow
regeneration of lost tissue. Active immunisation also requires the 
administration of minute amounts of antigen and so may prove a more 
practical approach for the treatment of farm animals on a commercial 
scale.
Theoretically, active immunisation allows the recruitment of a 
wider range of mediators of immune tissue damage than passive 
immunisation. The injection of preformed antibody allows the 
activation of complement which may result in complement-induced 
cytolysis or the attraction and activation of phagocytic cells. In 
addition to these mechanisms, active immunisation, using an 
appropriate adjuvant, may induce the formation of antigen-specific 
cytotoxic T cells, which may be responsible for the pathogenesis of 
several autoimmune diseases.
In order to determine whether either passive or active 
immunisation against the adipocyte could cause a reduction in body 
fat deposition, initial experiments were performed using immunisation 
against whole adipocyte plasma membranes. After the demonstration of 
initial effects, efforts were made to increase the adipocyte 
specificity of antisera by the preparation of adipocyte specific 
antigens as immunogens for both passive and active immunisation.
The majority of the work described in this thesis was performed 
using the rat. An antiserum against adipocyte cell membranes was 
already available and so the effects of passive immunisation in the 
rat could be characterised as far as possible before attempts were 
made to extend the approach to other species. Preliminary 
experiments in sheep, pigs and chickens were aimed at raising 
antisera against whole adipocyte plasma membranes of these species
42
and comparing any adipocyte specific components with those of the 
rat. The main aim of experments involving active immunisation in rats 
and sheep was to devise an immunisation protocol that induced an 
immune response able to cause a reduction in fat deposition. It was 
not possible to fully characterise the nature of that immune response 
or to develop adjuvants suitable for use in commercial species.
CHAPTER 2
M A T E R I A L S  A N D  M E T H O D S
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MATERIALS AND METHODS
2.1 CHEMICALS
All chemicals were obtained from Sigma Chemical Co., Poole, 
Dorset, Boehringer Corp. Ltd., Lewes, East Sussex or BDH Chemicals 
Ltd., Poole, Dorset, unless otherwise stated.
2.2 ANIMALS
2.2.1 Rats
Female and male Wistar rats and female Sprague-Dawley rats from 
A. Tuck and Son (Rayleigh, Essex) were givefla Labsure (Poole, Dorset) 
irradiated diet composed of 57% carbohydrate, 19% crude protein, 2.4% 
crude oil and 3.6% crude fibre and water ad libitum, unless otherwise 
stated. Rats were maintained on a 12 h light-dark cycle (light phase 
from 08.00-20.00 h).
2.2.2 Sheep and goats
Sheep used as antiserum donors at the Hannah Research Institute 
were either Clun or Finn x Dorset Horn cross-bred ewes, whilst those 
provided by S. Kestin from the Institute of Food Research (Bristol 
Laboratory) were either Welsh Mountain, Dorset Down crosses or 
Scottish half breeds. The goat used as an antiserum donor at the 
Hannah Research Institute was a British Saanen goat. Experiments 
involving the active immunisation of lambs were performed in 
collaboration with Dr. S. Rhind at Hill Farming Research
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Organisation (Penicuik, Midlothian) where the animals were kept.
Twin Scottish Blackface lambs were housed with their dams and fed a 
complete ration ad libitum until weaning, at about 16 weeks of age. 
Thereafter the lambs were fed the same complete diet ad libitum.
2.3 PLASMA MEMBRANE PREPARATION
2.3.1 Adipocyte plasma membrane preparation
Rat adipose tissue was obtained from female Wistar rats at the 
Hannah Research Institute. Pig and sheep adipose tissue was obtained 
from Landrace and Scottish Blackface crosses respectively from the 
local abattoir. Fresh chicken adipose tissue was obtained from Ross 
Fl hybrid chickens at the West of Scotland Agricultural College (Ayr, 
Strathclyde). Frozen chicken adipose tissue from Ross F Hybrids was 
obtained from S. Kestin, Institute of Food Research (Bristol 
Laboratory).
Membranes for immunisation and for screening antisera were 
prepared from isolated adipocytes (unless otherwise stated), in order 
to obtain a preparation as free from contaminating connective tissue 
and red and white blood cells as possible. Membranes for antigen 
purification were prepared by homogenisation of whole tissue, in 
order to obtain large quantities of membrane protein.
2.3.1.1 Preparation of adipocyte plasma membranes from isolated 
adipocytes
c 'of pf'-'d u'VV, tf. i^jC (-T 
Approximately 5 g of fresh adipose tissue was A and
incubated in 10 ml of Krebs Ringer Phosphate containing 3% BSA
(essentially fatty acid free), 0.1% collagenase (Type II, Sigma
Chemical Co., Poole, Dorset) and 0.02% dispase (Grade II, Boehringer
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Mannheim, Lewes, East Sussex) at 37° C for pig, rat and chicken
tissue and 42° C for sheep tissue, for 45 minutes, under constant
agitation. The suspension was filtered through a nylon sieve to 
remove undigested material and washed 3 times by flotation in Krebs 
Ringer Phosphate, containing 1% BSA. Adipocytes were suspended in at 
least twice their volume of extraction medium, containing 0.25 M 
sucrose, 0.05 M Tris-HCl pH 7.4, 2 mM EGTA and 2 mM PMSF. After
vortexing for 60 seconds, adipocytes were centrifuged at 2,500 g, at
37° C for rat, pig and chicken cells and 42° C for sheep cells, for 
5 minutes. The infranatant and pellet were collected onto ice and 
the remaining unbroken cells were resuspended in extraction medium 
and vortexed and centrifuged once more. The pooled pellets and 
infranatants were centrifuged at 40,000 g at 4° C for 30 minutes. 
The pellet was resuspended in 0.05 M Tris-HCl pH 7.4, containing 
2 mM EGTA and 40% w/w sucrose, and homogenised using a ground glass 
homogeniser. A similar solution, but containing 32% w/w sucrose, was 
layered onto the 40% sucrose solution. 0.05 M Tris-HCl, containing 
2 mM EGTA, was layered onto the sucrose solution and the
discontinuous gradient was centrifuged at 75,000 g at 4° C for 1 h. 
The material lying on the top of the 32% sucrose layer (plasma 
membranes) was removed, diluted at least 10-fold with 0.05 M 
Tris-HCl, containing 2 mM EGTA, and centrifuged at 75,000 g for 1 
hour. The pellet was resuspended and homogenised in 0.05 M Tris-HCl, 
containing 2 mM EGTA, snap frozen in liquid nitrogen and stored at 
-20° C.
2.3.1.2 Preparation of adipocyte plasma membranes by homogenisation 
of whole adipose tissue 
One part of adipose tissue was homogenised in at least 2 parts 
of extraction medium, containing 10 mM phosphate pH 7.4, 0.25 M
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sucrose, 1 mg/ml bacitracin and 2 mM PMSF, at 37° C for rat, pig and 
chicken tissue and 42° C for sheep, in a Waring blender for 30 
seconds. The homogenate was spun at 2,500 g for 5 minutes at 22° C 
for rat, pig and chicken tissue and 42° C for sheep tissue. The
pellet and infranatant were centrifuged at 50,000 g for 1 h. The
resulting pellet was purified as described in the previous
section but using 10 mM phosphate in place of 0.05 M Tris-HCl.
2.3.2 Hepatocyte, erythrocyte, kidney and brain plasma membrane 
preparation
Liver, kidney or brain tissue was homogenised in extraction 
buffer as described for adipose tissue in Section 2.5.1.2, except 
that the temperature was maintained as close to 4° C as possible. 
Erythrocytes were washed 3 times with ice cold Krebs Ringer Phosphate 
by centrifugation at 1,000 g for 5 minutes. The cell pellet was 
suspended in 0.87% ammonium chloride for 5 minutes and homogenised in 
a Waring blender for 60 seconds. All homogenates, where plasma
membranes were to be used for affinity purification of antigens, were 
purified as described for adipose tissue in Section 2.3.1.2. Plasma 
membranes for screening of antisera by ELISA were purified by 
centrifugation at 40,000 g for 30 minutes. The pellet was discarded 
and the supernatant was centrifuged at 75,000 g for 1 h at 4° C. The 
resulting pellet (microsomal fraction) was homogenised in 10 mM 
phosphate, 2 mM EGTA, snap frozen in liquid nitrogen and stored at 
-20° C.
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2.4 PREPARATION OF ANTI SERA FROM SHEEP AND GOATS
200 //g of antigen protein in 1 part of aqueous phase was 
emulsified in 2 parts of Freunds complete adjuvant for the first
immunisation. Subsequent immunisations were given in incomplete
Pi VlAl'A r("
Freunds adjuvant. x 2 ml of emulsion were injected subcutaneously at 3 
different sites. Sheep were bled from the jugular vein 10-18 days 
after the second and subsequent boosts. The blood was allowed to 
clot for 16 h at 4° C and the serum was decanted and spun at 2,500 g 
for 15 minutes. The clear serum was then snap frozen in liquid 
nitrogen and stored at -20° C.
2.5 PREPARATION OF IgG FRACTION FROM SERUM
90% (w/v) saturated ammonium sulphate solution was added to
serum to a final concentration of ammonium sulphate of 40%. The 
suspension was incubated for 30 minutes stirring and then
centrifuged at 2,500 g for 30 minutes at 4° C. The pellet was 
resuspended in 10 mM phosphate pH 7.4, and dialysed for 16 h at 4° C 
against 10 mM phosphate. The IgG fraction was snap frozen in liquid 
nitrogen and stored at -20° C.
2.6 ENZYME-LINKED IMMUNOASSAY (ELISA)
2.6.1 Coating of antigen to microtitre plates
Insoluble antigens were sonicated using a Kontes 
micro-ultrasonic cell disrupter (Burkard Scientific, Uxbridge, 
Middlesex) on setting 2 for 60 seconds before coating to plates.
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Antigens available in the absence of detergent were coated to plates 
by adding 100 //I of protein (10 //g/ml) in phosphate buffered saline 
(PBS) pH 7.4 and incubating for 16 h at 4° C. Plates were washed 3 
times with PBS-Tween (containing 0.05% Tween 20, Sigma Chemical Co., 
Poole, Dorset) using a Titertek microplate washer 120 (Flow
Laboratories, Rickmansworth, Herts.) and incubated for 2 h at room 
temperature in PBS Tween to block non-specific binding sites on the 
plate.
Purified antigens, prepared in the presence of Triton X-100, 
could not be adsorbed onto the plate by the method described above 
because of the presence of detergent, so plates were first coated 
with 0.0005% (w/v) poly-l-lysine in PBS for 30 minutes at room
temperature. Plates were then aspirated but not washed. Antigen was 
diluted to a concentration of 2.5 //g/ml which had previously been
shown to be the concentration that resulted in maximum binding to the
plate. 100 /j1 of antigen solution was added to each well and
incubated for 16 h at 4° C. 100 pi of 0.25% glutaraldehyde in PBS 
was then added to each well and incubated at 22° C for 15 minutes. 
Plates were washed 3 times with PBS Tween and incubated for 1 h in 
100 mM glycine in PBS (to block any remaining glutaraldehyde), 
containing 10% normal serum of the species in which the 
enzyme-conjugated second antibody was raised (to reduce non-specific 
binding of the conjugate) or 1 mg/ml casein, to block non-specific 
binding sites on the plate as described in Results. If the plate was 
not to be used immediately, wells were filled with PBS Tween and 
stored at -20° C.
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2.6.2 Antibody binding assay
100 /j1 of test serum or non-immune serum, diluted in PBS 
Tween, was added to each well and incubated for 2 h at room 
temperature. Plates were washed 4 times with PBS Tween and 100 yl 
alkaline phosphatase-conjugated second antibody raised against 
immunoglobulin of the species of the first antibody (Sigma Chemical 
Co, Poole, Dorset), diluted 1:600 in PBS Tween, was added to each 
well. Plates were incubated for 2 h at 22° C, were then washed 4
times with PBS Tween and 200 yl of 0.1% 4-nitrophenyl phosphate
(Boehringer Mannheim, Lewes, East Sussex) in 0.1 M glycine, pH 10.4, 
containing 1 mM zinc chloride and 1 mM magnesium chloride, was added 
to each well. Plates were incubated in the dark at 22° C until wells 
with the greatest colour development had an absorbance of 
approximately 1.2 at 405 nm. The reaction was stopped by the 
addition of 50 /j1 of 0.5 M sodium hydroxide and the absorbance at 
405 nm was read using a Titertek Multiskan (Flow Laboratories, 
Rickmansworth, Herts.).
2.6.3 Quantitation of results from ELISA
Unless otherwise stated, serial dilutions of antisera were made 
with the aim of covering the range of antiserum concentrations from a 
negative result to a plateau, where antigen had become limiting. In
practice this was not always achieved as the range of antiserum
concentrations occasionally exceeded 4 log10 dilutions. Equivalent 
dilutions of non-immune serum were always tested in parallel and the 
absorbances subtracted from those achieved with antisera so that the 
dose response curves for antisera represented specific binding only.
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Difficulties in quantitation of results arose because 
dose-response curves for antisera were not always parallel and 
cross-overs, presumably due to differences in affinity, were 
observed. In an attempt to overcome this problem, one anti serum or 
pool of anti sera was selected as a standard and, for each test
antiserum, 2 values relative to the standard were determined,
relative antibody binding and relative antigen abundance. Fig. 2.1a 
represents the ideal situation where the curves are parallel. The 
relative antigen abundance (A) measures the relative abundance of the 
particular epitopes within the complex antigenic mixture on the ELISA 
plate to which the antisera bind. Thus, in this example, the test 
antiserum recognises 50% of the epitopes recognised by the standard. 
The relative antibody binding (B) measures the relative amounts of 
antisera required to produce the same absorbance at a point where the 
curves are as parallel as possible. Thus, in this example, the test 
antiserum shows 10% of the binding to the antigen of the standard
when antigen is in excess. This may be due to a lower affinity, or 
lower titre or a combination of both. Fig. 2.1b represents a
situation where the test antiserum has a lower antibody titre or 
affinity but recognises a larger number of epitopes than the 
reference antiserum. Thus, while the relative antibody binding (A) 
is 10%, the relative antigen abundance (B) is >200%.
Despite the problem of lack of parallellism of curves, 
quantitation of results in this way has advantages over titration 
methods, where the highest dilution that produces a positive result 
is determined. In addition to giving an indication of the relative 
numbers of epitopes bound by an antiserum, relative binding is 
measured at the linear part of the sigmoidal curve where sensitivity
Fig. 2.1. The quantitation of results from ELISA
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The above is a schematic diagram showing how relative antigen 
abundance (A) and relative antibody binding (B) are calculated. 
The standards are represented by unbroken lines and the test samples 
are represented by broken lines.
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is maximal. This overcomes the problems of distinction between 
positive and negative values at the flattening part of the curve.
In active immunisation experiments, where differences between 
groups of antisera were investigated, dose-response curves with 
standard errors of absorbances are presented. The statistical 
significance of differences in absorbance at each antiserum dilution 
can then be determined. Absorbances for pooled normal sera 
(non-specific binding) were subtracted from antiserum values.
2.7 CYTOTOXICITY ASSAYS
2.7.1 Cytotoxicity against erythrocytes
Erythrocytes were washed as described in 2.3.2 and resuspended 
in Krebs Ringer Phosphate containing 1% BSA and 0.1% glucose. This 
buffer was also used for the dilution of antisera and complement. 
Antisera and non-immune sera were heat-inactivated at 56° C for 30 
minutes to inactivate complement. Guinea pig complement was obtained 
from Wellcome diagnostics (Dartford, Kent), while rat and sheep 
complement were prepared by allowing blood to clot for 3 h at 4° C 
and spinning at 11,000 g for 5 minutes at 4° C. If not to be used 
immediately, the serum was frozen in liquid nitrogen and stored at 
-20° C. In the standard assay procedure 50 //I of erythrocytes (2.5% 
haematocrit), 50 /vl of 10% complement and 50 /ul of serial dilutions
of non-immune serum or antiserum were incubated in v-shaped 
microtitre plates for 1 h at 37° C. Wells were also included that 
contained erythrocytes and 100 jjl of 2% Triton X-100 in distilled 
water to obtain a measure of total lysis. Additional wells contained 
erythrocytes, complement and buffer to obtain a measure of
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spontaneous lysis. In typical assays spontaneous lysis and lysis in 
the presence of non-immune serum represented less than 10% of total 
lysis. After 1 h plates were centrifuged at 1,000 g for 5 minutes. 
75 /vl of supernatant was removed into a flat-bottomed well microtitre 
plate and the absorbances were read at 405 nm (optimal for
haemoglobin). Specific cytotoxicity was measured by subtraction of 
spontaneous lysis from both lysis in the presence of antiserum and 
total lysis. Corrected lysis in the presence of antiserum was
divided by corrected total lysis to obtain specific cytotoxicity as a
percentage of the maximum.
Lysis by anti serum - lysis by non-immune serum - 
Lysis by Triton X-100 - lysis by non immune serum
2.7.2 Cytotoxicity against adipocytes
Isolated adipocytes were prepared as described in Section
2.3.1.1 but the tissue was allowed to digest for only 30 minutes in 
order to maximise the viability of the isolated cells. The assay was 
performed in the same way as for erythrocyte cytotoxicity except that 
50 /vl of approximately 50% packed adipocytes (approximately 5 x 104 
cells) were used. After a 1 h incubation at 37° C the assay was 
stopped by layering both cells and medium onto dinonylpthalate oil in 
400 /vl microfuge tubes. Tubes were spun for 2 minutes at 11,000 g to 
separate the medium from the cells. The tubes were cut and the
medium was assayed for lactate dehydrogenase (LDH) content. Wells 
containing cells, complement and buffer were stopped before 
incubation at 37° C to assess initial LDH content. LDH was assayed 
by incubating 40 /vl of medium with 200 /vl of 0.25M triethanolammonium 
chloride pH 7.4, containing 0.05% NADH until the absorbance at 340 nm
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was constant. 25 /j 1 of 10 mM sodium pyruvate was added and the rate 
of change in absorbance at 340 nm was measured. LDH in the medium at 
time 0 varied from 15-30% of total release. Spontaneous release and 
release in the presence of non-immune serum varied from 25-50% of 
total release. Specific cytotoxicity (expressed as a percentage of 
total release) was measured as described in the previous section for 
erythrocytes.
2.8 ANALYSES OF ADIPOSE TISSUE
2.8.1 Determination of adipocyte size and number
Adipocyte size and number were determined by the method of 
Vernon (1977), except that after digestion cells were spun at 200 g 
for 30 seconds and measured without washing, in order to minimise the 
loss of small cells. The diameter of 100 cells for each tissue was 
measured at a magnification of X145 using a haemocytometer placed 
under a projecting microscope and, from this, the mean adipocyte
volume was calculated.
The dry weight of the cells or tissue was determined and,
assuming a specific gravity of 0.91 for lipid, the cell number could
be calculated using the following formula:
_ ,, , Dry weiqht of tissue (g) x 0.91 x 10
Cell number = — 1 r,■,----- n ----i— — ?— t ~\-------Mean cell volume (pi)
2.8.2 U—14C—glucose incorporation into total lipid in isolated
adipocytes
Isolated adipocytes were prepared as described in 2.3.1.1. The 
medium used for diluting cells, hormone and glucose was Krebs Ringer
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Phosphate containing 1% BSA and 0.01% glucose. 100 /vl of adipocytes 
were incubated with increasing concentrations of insulin from 0 to 
100 ng/ml and 0.025 yi/Ci of U-14C-glucose (Amersham International, 
Amersham, Bucks.) in flat-bottomed wells of 96-well plates, with a 
total incubation volume of 300 jj 1. Blank wells were included that 
contained no U-14C-glucose during incubation but to which 
U-14C-glucose was added immediately before stopping. After 
incubation for 2 h at 37° C, cells and medium were removed into 
toluene scintillation fluid (Packard Instruments, Caversham, Berks.).
1 4
The incorporation of U- C-glucose into lipid was measured using a 
Packard (Tri-Carb 2405, Packard Instruments, Caversham, Berks.). 
U-14C-glucose was added to emulsifier scintillant 299 (Packard 
Instruments, Caversham, Berks.) to measure total counts. The number 
of adipocytes per well was determined as described in Section 2.8.1 
so that results could be expressed as nmol U-14C-glucose incorporated 
by 106 cells. (OfW'Av.y aw-A
2.8.3 Glycerol release from isolated adipocytes
The assay was performed as for glucose incorporation into lipid 
but U-14 C-glucose was excluded and the insulin was replaced by 
noradrenalin concentrations of 0-200 ng/ml. After incubation for 2 h 
at 37° C, medium was removed from beneath the adipocytes and assayed 
for glycerol.
Glycerol was assayed by incubating 50 //I of sample with 200 /j1 
of assay buffer containing 0.25 M triethanolammonium chloride pH 7.5, 
0.6% (w/v) Triton X-100, 2.5% NAD, 6.25% ATP, 12.5 mM MgCl2, 0.5% a
glycerophosphate dehydrogenase, 0.25% diaphorase and 4% MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetazolium bromide,
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thiazolyl blue). When absorbance at 600 nm had become constant, 
50 /vl of 2% glycerokinase was added and the change in absorbance at 
600 nm with time was measured. The standard used was 1 mM glycerol.
2.9 PREPARATION OF ADIPOCYTE SPECIFIC ANTIGENS
An outline of the method used for the preparation of adipocyte 
specific antigens is shown in Fig. 2.2. The y-globulin fraction of 
an antiserum raised against whole adipocyte plasma membranes was 
passed down an affinity column bearing solubilized adipocyte plasma 
membranes. Unbound material, which contained irrelevant antibodies, 
was washed through the column and the bound antibodies were eluted by 
washing with glycine buffer at pH 2.5. The glycine wash was then 
passed down an affinity column bearing hepatocyte, kidney and 
erythrocyte plasma membranes to remove anti-(adipocyte plasma 
membrane) antibodies that cross-reacted with these tissues. The 
unbound material, containing adipocyte specific antibodies, was
used to prepare a third affinity column. Solubilized adipocyte 
plasma membranes were passed down the third column. Unbound
material, which contained antigens that cross-reacted with other 
tissues or to which antibodies had not been raised, was washed 
through the column and bound material, which contained adipocyte
specific antigens, was eluted with glycine buffer at pH 2.5.
2.9.1 Preparation and use of affinity columns
Plasma membranes were prepared by homogenisation of whole 
adipose tissue and purification, as described in Section
2.3.1.2. Membrane pellets were resuspended in 0.1 M sodium
Fig. 2.2. An outline of the method 
for the preparation of adipocyte specific antigens
The anti-(APM) antiserum vas passed down an affinity column of whole 
APM which hound antibodies recognising adipocyte specific antigens 
( A ) and antigens shared with non-adipose tissues (H,E,K)- Bound 
antibody was eluted with glycine buffer pH 2.5 and passed down a 
column of HFM, EPM and KPM which bound antibodies recognising antigens 
shared between adipocytes and hepatocytes ( H ), erythrocytes 
( E ) and kidney ( K ) - Unbound antibodies were used to prepare 
a 3rd affinity column down which were passed solubilised APM. This 
column bound antigens that were not present on HPM, EPM and KPM.
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bicarbonate buffer pH 8.0 and sonicated as described in Section 
2.6.1.
Purified Triton X-100Awas then added to a final concentration 
of 2% and the suspension was sonicated as above. After stirring for 
1 h, the membrane solution was centrifuged at 75,000 g for 1 h at 4°C 
to remove insoluble material.
Freeze-dried activated CH-sepharose 4B (Pharmacia Fine 
Chemicals, Milton Keynes, Bucks) was swollen for 15 minutes in 1 mM 
ice-cold HCl and washed on a sintered glass filter with the same 
solution, using 200 ml per g of freeze-dried powder. The plasma 
membranes were incubated overnight at 4° C with the swollen gel in an 
end-over-end mixer. Two parts of membrane solution to 1 part of gel 
were used. The protein concentration found to give the most 
efficient binding to the column was 5 mg/ml of gel which resulted in 
a binding efficiency of 50-70%. 10-15 ml plasma membrane columns and
5-10 ml specific antibody columns were prepared, depending upon the 
amount of ligand available.
After coupling, excess ligand was washed away with coupling 
buffer and any remaining active groups were blocked by treatment with 
1 M ethanolamine pH 9.0, containing 0.1% Triton X-100, for 1 h at 
22° C. The column was then washed alternately with borate buffer, 
containing 0.1 M disodium tetraborate pH 8.0, 0.5 M NaCl and 0.1% 
Triton X-100, and glycine buffer, containing 0.1 M glycine pH 2.5, 
and 0.1% Triton X-100. The protein concentration of all washes was 
measured by Bradford assay so that the amount of protein bound to the 
column could be determined.
Antibody was coupled to CH-sepharose 4b in the same way as used 
for solubilised plasma membranes, except that detergent was absent.
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Where columns of less than 5 ml of swollen gel were prepared, 
0.8 x 4 cm Bio-Rad Poly-Prep chromatography columns (Bio-Rad, 
Watford, Herts) and flow rates of 0.5 ml/minute for all washes and 
elutions were used. Where columns of more than 5 ml of gel were 
prepared, 60 ml plastic syringes with a 0.25 /mi filter and flow rates 
of 1.5 ml/minute for all washes and elutions were used. When not in 
use, affinity columns were stored in borate buffer, containing 0.02% 
thi&mersal, and 0.1% Triton X-100 where appropriate.
When antisera were to be passed down plasma membrane columns, 
y-globulin preparations containing 0.1% Triton X-100 were used. Where 
plasma membranes were to be passed down antibody columns, membranes 
were dissolved in borate buffer containing 2% Triton X-100 as 
described above. Approximately 500 //I of anti-(APM) y globulin 
(100 mg/ml) was added per ml of APM column. Approximately 500 //I of 
anti-(APM) antibody (2 mg/ml), purified from the APM column, was 
added per ml of HPM, EPM and KPM column. Approximately 500 //I of 
solubilized APM (2 mg/ml) was added per ml of specific antibody 
column. Antibody or membrane solutions were run into affinity 
columns and incubated for 4-16 h at 4° C. Unbound material was 
washed from the column using 10 column volumes of borate buffer 
containing 0.1% Triton X-100. Fractions of appropriate volume were 
collected and assayed for protein to ensure that all unbound material 
had been eluted. The column was then incubated in glycine buffer, 
containing 0.1% Triton X-100 at pH 2.5 for 20 minutes. The column 
was then washed with 10 column volumes of the same glycine buffer. 
Fractions collected were neutralised immediately with 2 M Tris and 
assayed for protein. Fractions of borate and glycine washes that 
contained the bulk of the protein were frozen in liquid nitrogen and 
stored at -20° C.
The performance of membrane affinity columns was monitored by 
measuring antibody activity in the borate and glycine washes. The 
borate and glycine washes from adipocyte plasma membrane columns were 
adjusted to the same protein concentration and tested, by ELISA, 
against adipocyte plasma membranes. The borate and glycine washes 
from the hepatocyte, kidney and erythrocyte plasma membrane columns 
were tested, by ELISA, against adipocyte, hepatocyte, kidney and 
erythrocyte membranes. For the preparation of chicken and rat 
antigens, sheep antisera raised against whole chicken and rat 
adipocyte plasma membranes respectively were used. For the
preparation of sheep antigens, a goat antiserum, raised against whole 
sheep adipocyte plasma membranes, was used. The antigens prepared 
were characterised by SDS polyacrylamide gel electrophoresis and 
Western blotting.
2.10 SDS POLYACRYLAMIDE GEL ELECTROPHORESIS
SDS polyacrylamide gel electrophoresis was performed using a 
Bio-Rad Mini Protean II electrophoresis system (Bio-Rad, Watford, 
Herts), using the buffer systems of Laemmli (1970). Samples for 
electrophoresis were boiled in 62.5 mM Tris-HCl pH 6.8, containing 2% 
SDS, 5% 2-mercaptoethanol, 0.001% bromophenol blue and 10% glycerol. 
The 12% running gel was composed of 375 mM Tris-HCl pH 6.8, 
containing 12% acrylamide, 0.07% methylene-bis-acrylamide, 0.1% SDS, 
0.034% tetramethylethylenediamine (Temed) and 0.01% ammonium 
persulphate. The stacking gel was composed of 125 mM Tris pH 6.8, 
containing 5% acrylamide, 0.15% methylene-bis-acrylamide, 0.1% SDS, 
0.05% Temed and 002% ammonium persulphate. The upper running buffer
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was composed of 25 mM Tris-HCl pH 8.3, containing 192 mM glycine and 
0.1% SDS. The lower running buffer had the same composition, except 
that glycine was excluded. Gels were run for 45-75 minutes at 
150 mV. Gels to be stained for protein were fixed in 45% (v/v)
methanol and 9% acetic acid for 15 minutes. They were stained for 30 
minutes in the same fixative containing 0.1% (w/v) Coomassie blue. 
Gels were destained in 7% (w/v) acetic acid, 5% (w/v) methanol.
2.11 WESTERN BLOTTING
Transfer of proteins onto nitrocellulose was performed using a 
semi-dry electroblotter (Sartorius, Belmont, Surrey). The graphite 
plates of the electroblotter were rinsed with distilled water. Filter 
paper, nitrocellulose membrane and dialysis membranes were trimmed to 
the size of the gel. Two layers of filter paper soaked in anode 
buffer no. 1 (300 mM Tris-HCl pH 10.4, containing 20% methanol) were 
placed on the anodic graphite plate. A 'trans-unit' was then 
assembled, composed of 1 layer of filter paper soaked in anode buffer 
no. 2 (25 mM Tris-HCl pH 10.4, containing 20% methanol), on top of 
which was placed a nitrocellulose membrane soaked in distilled water. 
Next was placed the polyacrylamide gel soaked in anode buffer no. 2. 
An additional layer of filter paper soaked in cathode buffer (25 mM 
Tris-HCl pH 9.3, containing 40 mM 6-amino-n-hexanoic acid and 20% 
methanol) was placed on the gel. Finally, a dialysis membrane, 
soaked in distilled water was placed on top of the trans-unit. 
Several trans-units could be stacked on top of each other. The stack 
was covered with 2 layers of filter paper soaked in cathode buffer 
Electroblotting was carried out for 1 h at 0.8 mA/cm2 of gel. After
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electroblotting the gel was stained with Coomassie blue, as described 
in Section 2.10, to ensure that all the protein had transferred onto 
the nitrocellulose membrane. The nitrocellulose was washed twice in 
transblot saline (50 mM Tris-HCl pH 10.3, containing 150 mM NaCl). 
Free binding sites were blocked with transblot saline containing 0.5% 
Tween 20 for h at 22° C. The nitrocellulose was then washed 5 
times with transblot saline and incubated with the first antibody, 
which was raised in sheep, diluted 250-500 times in transblot 
saline, containing 0.5% Tween, for 16 h at room temperature. After 
washing 5 times with transblot saline, a hundred-fold dilution of
donkey anti-(sheep IgG) serum in transblot saline containing 0.5%
Tween was added. After incubation at 37° C for 1% h, the 
nitrocellulose was washed 5 times with transblot saline. A 
hundred-fold dilution of peroxidase-anti-peroxidase complex, raised 
in sheep, was then added and incubated for 1% h at room temperature. 
The membrane was washed 5 times with transblot saline and twice with 
50 mM Tris-HCl pH 7.6. The membrane was then incubated in 50 mM 
Tris-HCl pH 7.6, containing 0.05 (w/v) 4-chloro-naphthol and 0.011%
H202 , until colour development was considered optimal. The reaction 
was stopped by rinsing in distilled water and membranes were dried 
between filter paper and stored in the dark.
2.12 SERUM ASSAYS
2.12.1 Complement
Rat serum complement levels were measured by assessing the 
ability of the test sera to support complement-mediated lysis of 
sensitized chicken red blood cells. 50 fjl of 0.5% sheep anti-chicken
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erythrocyte) antiserum was incubated with 50/vl of chicken 
erythrocytes (2.5% haematocrit) and 50 //I of 1-10% test rat serum to 
serve as a source of complement. Dose-response curves were performed 
for normal and test sera and the relative concentration of serum 
required to support the same degree of lysis as the control was 
determined.
2.12.2 Glucose
Serum glucose was measured using a glucose analyser, Analox
GM-6 (Analox Instruments, London) according to the manufacturer's 
instructions.
2.12.3 Insulin
Rat serum insulin was measured by radioimmunoassay. The buffer 
used for all dilutions was 50 mM Na2HP04 pH 7.4, containing 0.15 M 
NaCl, 15 mM NaN3 , 0.5% BSA (RIA grade, fraction v, Sigma Chemical 
Co., Poole, Dorest). 25 pi of test serum was incubated with 100/ul of
0.01% anti-(insulin) serum (raised to bovine insulin in guinea pigs
by Dr. D. J. Flint) at 4° C for 20 h in a total volume of 300^
Approximately 20,000 cpm (0.1 ng) 125I-labelled insulin was then 
added in a volume of 100/yl and the incubations were continued at 
4° C. Porcine insulin (Sigma Chemical Co., Poole, Dorset) was 
iodinated using the lactoperoxidase method (see Morrison & Bayse, 
1970). After 20 h 300 pi of second antibody, containing 12pl of 
anti-(guinea-pig) precipitating serum, 150 pi 16% polyethylene 
glycol, 14 mg EDTA, 1 pi normal guinea-pig serum and 150 pi of 
buffer. The samples were incubated at 22° C for 5 h and then 
centrifuged at 2,500 g for 30 minutes. The supernatant was removed
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and the pellet was counted in a gamma counter (Rackgamma 11, LKB 
Instruments Ltd., Selsdon, Surrey). The insulin content of the 
pellet was determined using a standard curve which was obtained by 
performing the assay as described above but with a range of
concentrations of porcine insulin (0-10 ng/ml) replacing the serum 
sample.
2.12.4 Triglycerides and free fatty acids
Serum triglycerides and non-esterified free fatty acids were 
measured using Wako kits (Alpha Laboratories Ltd., Eastleigh,
Hampshire) according to the manufacturer's instructions.
2.12.5 Urea
Serum urea nitrogen was measured using kit no. 640 (Sigma 
Chemical Co., Poole, Dorset), according to the manufacturer's 
instructions.
2.13 PROTEIN ASSAY
Protein was assayed using the Bio-Rad protein assay reagent. 
200 /yl of 20% (v/v) Bio-Rad reagent in distilled water was added to
50 /jl of protein solution and the absorbance was measured at 600 nm
after a 15 minute incubation at 22° C. When membrane or antibody 
protein solutions were measured, sheep IgG was used as a standard. 
When protein concentrations of urine were to be measured BSA was used 
as a standard. Where the concentrations of detergent-solubilized 
proteins were measured a maximum of 50 /jl of 0.02% Triton could be 
used without interfering with colour development.
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2.14 BODY COMPOSITION ANALYSIS
2.14.1 Neutron activation analysis
Neutron activation analysis of live rats was performed 
according to the method of Preston, Reeds, East and Holmes (1985) at 
the Scottish Universities Research and Reactor Centre, East Kilbride. 
This provided a measure of body nitrogen, phosphorus, chlorine, 
sodium, calcium, potassium and oxygen. The body nitrogen value was 
multiplied by 6.25 to obtain an estimation of total body protein.
i I •'\ , ..t/ O.sT'cX. V-V\\cVP v 1 ~'j
2.14.2 Estimation of total body water by tritiated water dilution 
Rats were injected i.p. with 20 yCi. of tritiated water
(Amersham International, Amersham, Bucks.). Rats were bled from the 
tail under ether anaesthesia at 1, 2, 3 and 6 days after injection. 
Serum protein was precipitated by the addition of an equal volume of 
6% perchloric acid. After 10 minutes, 300 fjl aliquots of 
protein-free serum were added to emulsifier scintillant and counted 
on a Packard counter (Tricarb 240S, Packard Instruments, Caversham, 
Berks.). A blank was included containing equal volumes of 6% 
perchloric acid and distilled water. By plotting the logarithm of 
counts per minute per ml (cpm/ml) against time, the cpm/ml at time 0 
could be calculated by extrapolation. The dilution factor, i.e. 
total body water, could be determined from the cpm/ml of the original 
injected solution.
2.14.3 Rat carcass analysis
After dissection of the major fat depots and removal of the 
stomach and intestines, rats were freeze-dried in a centrifugal
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freeze drier, Model 30 T12/796 (Edwards High Vacuum Ltd., Sussex), 
for 5-7 days until the weight of the dried carcass no longer changed. 
Dry weights of the dissected depots were determined by heating at 
70° C for 2-4 days. 0.4 times the wet weight of the stomach and 
intestines had previously been shown to approximate to the wet weight 
of the stomach and intestinal wall, 30% of which was assumed to be 
dry matter. Subtraction of the dry weight of the carcass, gut wall 
and adipose depots from the wet weight of the same provided an 
estimation of their water content.
The lipid content of the carcass was determined by ether 
extraction in a Soxhlet apparatus at Western General Hospital, 
Edinburgh by Mr. D. Shirling.
Total body nitrogen was determined by the Kjeldahl method and 
was multiplied by 6.25 to obtain total body protein. Body minerals 
were estimated by difference.
2.14.4 Lamb carcass analysis
Carcass dissection of lambs was performed at the Macaulay Land 
Use Research Institute (Penicuik, Midothian) according to the Meat 
and Livestock Commission's standard.
CHAPTER 3 
PASSIVE IMMUNISATION OF RATS 
WITH AN ANTI -(ADIPOCYTE PLASMA MEMBRANE)
ANTISERUM (A/S 83)
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PASSIVE IMMUNISATION OF RATS 
WITH AN ANTI-(ADIPOCYTE PLASMA MEMBRANE) ANTISERUM (A/S 83)
3.1 INTRODUCTION
The administration of an anti-(adipocyte plasma membrane) 
antiserum (A/S 83) to 6-week old rats caused a 50% reduction in mass 
of parametrial adipose tissue 8 days after treatment (Flint et al., 
1986). The inital aim of the work described in this chapter was to 
determine whether lost adipose tissue could be regenerated. This was 
difficult to predict since studies of the effects of surgical removal 
of adipose tissue have reported no regeneration (Krai, 1976), partial 
regeneration (Bailey and Anderson, 1980), total regeneration of lost 
tissue (Taylor and McBean-Hopkins, 1971) or compensatory hypertrophy 
of remaining depots (Larson and Anderson, 1978; Bailey and Anderson, 
1980). Treatment with A/S 83 could, therefore, result in the recovery 
of lost adipose tissue mass. Alternatively a permanent reduction in 
mass of adipose tissue and, consequently, a decrease in total body 
mass, could occur. The final possibility was that energy released 
from adipose tissue and possibly excess energy intake could be used 
by other tissues, including possible 'repartitioning' into protein 
deposition, resulting in improved protein:fat ratios in the carcass. 
In order to investigate these possibilities, body mass, food intake 
and body composition of A/S 83-treated rats were examined.
Before the development of antibiotics, diseases, such as 
diptheria, were treated by the administration of large quantities of 
antiserum, usually raised in the horse. Serum sickness sometimes 
occurred, caused by the patient's immune response to the injected
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foreign protein. Since A/S 83 was raised in a sheep, the rat immune 
response to sheep y globulin was examined and kidney function was 
monitored.
Intraperitoneal injection of A/S 83 caused a greater reduction 
in mass of parametrial than of peri—renal or subcutaneous adipose 
tissue. This was despite the absence of differences in specificity 
of A/S 83 for adipocyte plasma membranes of different depots (Flint 
et al., 1986). The importance of the site of injection on the 
relative effects of A/S 83 on different adipose depots was, 
therefore, determined. The effects of different durations of 
treatment with A/S 83 were also examined.
The administration of A/S 83, but not non-immune sheep y 
globulin, resulted in a reduction in food intake that was most 
dramatic during the 24 h after the first treatment (Flint et al., 
1986). A role for serum glucose, free fatty acids, triglycerides and 
insulin in the control of food intake has been suggested (Harris and 
Martin, 1984). The short-term effects of A/S 83 on these metabolites 
and hormones were, therefore, investigated.
While the work of Flint et al. (1986) demonstrated 
complement-mediated cytotoxicity of A/S 83 against adipocytes in 
vitro, the in vivo importance of complement in mediating the effects 
of A/S 83 was not demonstrated. Therefore the in vivo effects of A/S 
83 administration on circulating complement levels and the effect of 
complement-depletion on A/S 83-mediated effects were investigated in 
vivo.
Gross abnormalities of parametrial adipose tissue were observed 
8 days after treatment with A/S 83 (Flint et al., 1986). In order to 
determine whether this resulted in damage to the underlying uteri or
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ovaries, the ability of A/S 83-treated animals to mate and undergo a 
normal pregnancy was examined.
3.2 AN ASSESSMENT OF THE LONG-TERM EFFECTS OF PASSIVE
IMMUNISATION OF RATS WITH A/S 83
3.2.1 Experimental
Female Wistar rats, weighing 120-140 g, were injected intra- 
peritoneally, between 09.00 h and 11.00 h on 4 consecutive days, with 
the equivalent of 2 ml of A/S 83 y globulin. These rats were killed 
1, 3, 8 and 24 weeks after the first injection. An equivalent group 
of rats were pair fed with the treated group for 5 days after the 
first injection. These rats were killed at 1, 3 and 8 weeks after 
treatment. A second group of control rats were injected 
intraperitoneally, on 4 consecutive days, with the equivalent of 2 ml 
of non-immune sheep y globulin. These animals were pair fed with the 
treated group for 4 days after the first injection and were killed 24 
weeks after the first injection. Non-immune sheep y globulin had 
previously been shown to have no effects on body weight gain, food 
intake or adiposity, but was included in the second group of controls 
in order to study the rat immune response to sheep y globulin.
Blood samples were taken from the tail, under ether 
anaesthesia, at 1, 2, 3, 5, 10 and 24 weeks after treatment. Serum 
glucose, non-esterified free fatty acids, triglycerides, insulin and 
urea and urine protein concentrations were measured as described in 
sections 2.12 and 2.13. Anti-(sheep y globulin) responses were 
measured by ELISA. Body weight gain and food intakes were determined 
daily, for the first 3 weeks after treatment and weekly thereafter.
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Five weeks after treatment 6 A/S 83-treated rats and 6 untreated 
controls were subjected to neutron activation analysis to obtain 
estimations of total body protein and minerals, according to the 
method of Preston et al (1984). Body water was measured by tritiated 
water dilution (see Section 2.14.2) enabling body fat to be
calculated by difference.
Rats were killed 1, 3, 8 and 24 weeks after treatment by
cervical dislocation and the dry weights, mean adipocyte volumes and 
adipocyte numbers of inguinal subcutaneous, parametrial and 
peri-renal fat depots were determined. The wet weights of the liver, 
kidneys, spleen, gut and adrenals were also determined. Carcass 
analysis was performed on rats killed 8 weeks after treatment, as 
described in Section 2.14.3.
3.2.2 Results
The dry weight of the parametrial fat pad was significantly 
reduced in A/S 83-treated rats, compared with controls, 1,3, 8 and 24 
weeks after treatment (Fig. 3.1). This reduction was due to reduced 
adipocyte numbers and adipocyte volume 3 and 8 weeks after treatment 
and to reduced adipocyte numbers alone 24 weeks after treatment 
(Fig.s 3.2, 3.3). The dry weight of the parametrial fat pad showed a 
71% and 49% reduction in treated animals after 8 and 24 weeks, 
respectively. In contrast, the dry weights of peri-renal and 
subcutaneous fat pads 8 weeks after treatment showed reductions of 
only 32 and 26% respectively (Fig. 3.1). This was due, primarily, to 
a reduction in mean adipocyte volume, although this was not 
significant. Twenty four weeks after treatment the dry weights, mean 
adipocyte volumes and adipocyte numbers of peri-renal and 
subcutaneous adipose depots had completely recovered.
Fig. 3.1. The effects of A/S 83 on the dry weight
of fat pads 1, 3, 8 and 2k weeks after treatment
Rats were injected intraperitoneally with the equivalent of 2 ml 
of A/S 83 y globulin for 4 consecutive days (filled symbols). 
Control rats were pairfed with the treated group for 5 days and then 
allowed to feed ad libitum (open symbols). Dry weights of the 
parametrial (circles), peri-renal (triangles) and inguinal 
subcutaneous (squares) fat pads were determined. Results are mean 
_+ SEM of 3~8 observations. *P<0.01, ***P<0.001, compared with
controls (Student’s unpaired t test).
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Fig, 3-2. The effects of A/S 83 on mean adipocyte volume
1, 3, 8 and 2k weeks after treatment
Treatment and symbols as for Fig. 3.1. Mean adipocyte volumes were 
determined by collagenase digestion of the tissue and the measurement 
of the diameters of 100 adipocytes. Results are mean SEM of 3- 
8 observations. ***P<0.001, compared with controls (Student* s 
unpaired t test).
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Fig- 3-3- The effects of A/S 83 on adipocyte numbers
1, 3a 8 and 2h weeks after treatment
Treatment and symbols as for Fig. 3.1. Adipocyte numbers were 
calculated from the dry fat pad weights and mean adipocyte volumes. 
Results are mean _+^ SEM of 3_8 observations- *P<0.015 **P<0.05,
***p<0.ooi, compared with controls (Student’s unpaired t test).
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Between 1 and 8 weeks the parametrial adipose depots of 
A/S-treated rats accumulated about 33% of the lipid accumulated by 
controls while, between 8 and 24 weeks, the same depot in A/S-treated 
rats accumulated 86% of that of controls (Table 3.1). Lipid 
accumulation in peri-renal and subcutaneous fat pads was slightly 
reduced in A/S-treated rats between 1 and 8 weeks but was nearly 
twice that of controls between 8 and 24 weeks after treatment (Table 
3.1).
Adipocytes isolated from parametrial adipose tissue 3 and 8 
weeks after treatment showed no significant differences in basal and 
insulin-stimulated glucose incorporation into lipid or in basal or 
noradrenalin-stimulated glycerol release (Figs 3.4, 3.5).
The relative antibody binding of A/S 83 to hepatocyte, kidney 
and erythrocyte plasma membranes were, respectively, 32, 25 and 7% of 
that to adipocyte plasma membranes. Relative antigen abundances 
against hepatocyte, kidney and erythrocyte plasma membranes were, 
respectively, 100, 66 and 37% of that against adipocyte plasma
membranes (Fig. 3.6). Western blotting of A/S 83 against adipocyte 
and hepatocyte plasma membranes showed that A/S 83 bound to at least 
19 major polypeptides of the adipocyte plasma membrane and at least 7 
of the hepatocyte plasma membrane (Fig. 3.7). No significant 
differences in the wet weights of liver, kidney or spleen were 
observed between control and A/S 83-treated rats 1 , 3 , 8  and 24 weeks 
after treatment, except the spleen weight, which was elevated in 
A/S-treated rats after 1 week (Table 3.2).
A/S-treated rats showed an 8-10 g drop in body weight, 
accompanied by a 75% fall in food intake, on the first day of 
treatment (Fig. 3.8). The rats showed no signs of distress. Some
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Fig. 3.U. The stlmulation of glucose incorporation 
into lipid by insulin in parametrial adipocytes 
isolated from A/S 83~treated and control rats
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Adipocytes isolated from A/S 83-treated (filled symbols) and control 
(open symbols) rats 3 weeks (circles) and 8 weeks (squares) after 
treatment were incubated in Krebs Ringer phosphate pH J.h, containing 
1% BSA, 0.1 % glucose, p- ^ C-glucose and insulin for 2 h at 37° C. 
Results are mean + SEM of 3~5 observations.
Fig. 3.5. The stimulation of glycerol release by noradrenalin
in parametrial adipocytes 
isolated from A/S 83-treated and control rats
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Symbols as for Fig. 3.h. Adipocytes were incubated in Krebs Ringer 
phosphate pH 7.U, containing 1% BSA, 0.1% glucose and noradrenalin 
for 2 h at 37° C. Results are mean + SEM of 3~5 observations.
Fig. 3.6. The binding of A/S 83 to adipocyte, hepatocyte, 
erythrocyte and kidney plasma membranes 
as determined by ELISA
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Binding of A/S 83 to rat adipocyte (filled circles), hepatocyte (open 
squares),erythrocyte (open circles) and kidney (open triangles) plasma 
membranes was measured by ELISA. Samples were assayed in duplicate 
and results have been corrected for non-specific binding, using values 
obtained with non—immune sheep Y globulin.
Fig. 3-7. The binding of A/S 83 to adipocyte 
and hepatocyte plasma membranes 
as determined by Western blotting
APM HPM
Adipocyte plasma membranes (APM) and hepatocyte plasma membranes 
(HPM) were separated by SDS PAGE and transferred to nitrocellulose 
and binding of A/S 83 to transferred proteins was detected, as 
described in Section 2.11.
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rats showed slightly abnormal postures for the first 2 h after 
treatment but showed no signs of pain in the area of injection. Food 
intake and body weight gain returned to normal levels by the fourth 
day of treatment. During the first 2 weeks after treatment the A/S 
83-treated rats that were killed 24 weeks after treatment showed 2% 
more weight gain but 7% less food intake than controls (Table 3.3). 
A/S-treated rats gained 23% more weight and ate 12% more food than 
controls between 2 and 6 weeks after treatment. These differences 
resulted in a 9% increase in food conversion efficiency (FCE), 
calculated as food intake divided by body weight gain, in 
A/S-treated rats, compared with controls, during the first 6 weeks 
after treatment. From weeks 6 to 20, FCEs of the 2 groups were equal 
because A/S-treated rats gained 7% more weight but ate 7% more food 
than controls. The differences in body weight gain were not 
statistically significiant. Food intake was measured on groups of 
rats, rather than individuals, and so statistical significance of 
differences in food intake and efficiency could not be determined.
Control rats, pairfed with A/S 83-treated rats, showed a 
voluntary reduction in water intake of the same magnitude as the 
enforced reduction in food intake. A/S 83-treated rats, however, 
showed no reduction in water intake (Fig. 3.8). Subsequently, there 
was no difference in water intake between control and treated rats 
(results not shown).
Neutron activation analysis 5 weeks after treatment showed a 
38% reduction in total body fat in A/S-treated rats, compared with 
controls, which was balanced by an increase in total body water and 
protein (Table 3.4). Carcass analysis after 8 weeks showed a 29% 
reduction in body fat and incceuiscPS' in body water and body protein 
(Table 3.4).
Table 3.3. The long-term effects of A/S on body weight gain
food intake and food conversion efficiency
Treatment Number of 
observations
Weeks
0-2
after
2-6
treatment
6-20
Body weight 
gain (g/rat)
NS 
A/S 83
8
5
67
±3
69
±5
68
±6
84
±4
72
±5
78
±12
Food intake N/S
8 301 646 1997
(g/rat) A/S 83 5 279 724 2133
Intake N/S 8
4.5 9.5 27.6
Gain
A/S 83 5 4.1 8.7 25.5
Rats were injected intraperitoneally with the equivalent of either 
2 ml of A/S 83 y globulin or 2 ml of non-immune sheep y globulin 
(N/S) for 4 consecutive days. N/S-treated rats were pairfed with the 
iys-treated group for the first 5 days and then allowed to feed ad 
libitum.
Fig. 3.8. The short-term effects of A/S 83
on body weight gain, food intake and water intake
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Rats received the equivalent of 2 ml of A/S 83 Y globulin 
intraperitoneally for U consecutive days (filled circles). Control 
rats were pair fed with the treated group for 5 days and were then 
allowed to feed ad libitum (open circles). All rats were allowed 
free access to water throughout. Body weight gains are means SEM 
of 10 observations.
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No significant differences between serum glucose, triglyceride, 
n o n — esterified free fatty acids or insulin were found between control 
and A/S 83-treated rats (Fig. 3.9, 3.10). A/S 83-treated rats showed 
a greater anti-( sheep IgG) response than non-immune sheep y globulin- 
treated rats (Fig. 3.11). The response in both groups was first 
measurable 2 weeks after treatment and reached a peak 5 weeks after 
treatment, before gradually declining. Some A/S 83- and non-immune 
sheep y globulin treated rats showed a transient proteinurea and 
fluctuations in body weight gain between 1 and 3 weeks after 
treatment (Fig. 3.12).
3.2.3 Discussion
3.2.3.1 The effects of A/S 83 on parametrial adipocyte number
The most dramatic effects of A/S 83 were observed on 
parametrial adipose tissue. This depot was reduced by 75% at 3 and 8 
weeks after treatment and by 50% at 24 weeks after treatment (Fig.
3.1). At 3 and 8 weeks this was due to reduced adipocyte numbers
only (Figs. 3.2, 3.3). Apparent adipocyte numbers of both treated 
and control rats at 24 weeks were less than those at 8 weeks. Since 
adipocyte numbers cannot be reduced in normal adult rats, even after 
severe food restriction (Miller et al., 1983), cell numbers were
probably underestimated at 24 weeks, due to overestimation of 
adipocyte volume. The presence of very large adipocytes in rats
killed after 24 weeks may have obscured a proportion of the very 
small adipocytes, leading to an inaccurate estimation of mean
adipocyte volume. However, parametrial adipose tissue of treated 
animals had half the number of adipocytes, compared with controls, at 
all time points measured, indicating that the relative adipocyte
Fig. 3-9* The effects of A/S 83 on serum triglycerides
and non-ester if ied free fatty acids
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Rats received the equivalent of 2 ml of A/S 83 Y globulin (filled 
circles) or 2 ml of non-immune sheep y globulin (open circles) for 
^ consecutive days. Blood samples were taken from the tail under 
ether anaesthesia. Serum triglycerides and free fatty acids were 
measured as described in Section 2.12. Results are means +_ SEM of 
5~8 observations.
Fig. 3.10. The effects of A/S 83 on serum glucose
and insulin concentrations
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Treatments and symbols as for Fig. 3-9- Sernm glucose and Insulin 
were measured as described in Section 2.12. Results are means +_
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Fig. 3.11. The anti-(sheep IgG) response of A/S 83-treated
and non-immune sheep y globulin-treated rats
Treatments and symbols as for Fig. 3-9- The anti-(sheep IgG) response 
was measured by ELISA and urinary protein was measured as described 
in Section 2.13. Results are means of 5“8 observations.
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Fig. 3.12. The effects of A/S 83 on body weight gain
and urinary protein 1-3 weeks after treatment
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numbs^s are probably valid and that lost parametrial adipocytes were 
not replaced in A/S-treated rats.
Studies of the regenerative capacity of adipose tissue in rats 
have been performed exclusively on males and so no information is 
available on the effects of lipectomy on parametrial adipose tissue. 
Schemmel (1971), Faust et al. (1976), Krai (1976) and Bailey and 
Anderson (1980) found no recovery of adipocyte numbers of epididymal 
adipose tissue following lipectomy. Since the degree of adiposity is 
more variable in the female than the male, particularly during 
pregnancy and lactation, it is possible that adipose tissue
regeneration may occur more readily in the female than the male.
Pre-adipocytes have been isolated from adult rats, capable of 
proliferating and differentiating into 'mature adipocytes' in vitro 
and in vivo (Roncari and Van, 1978). There is, therefore, capacity 
for the production of new adipocytes in the adult rat. The work of 
Faust, Johnson, Stern and Hirsch (1978) showed that prolonged feeding 
of rats with a high-fat diet initially caused an increase in
adipocyte size, which was followed by increases in adipocyte number. 
The authors suggested that the reaching of a 'critical cell size'
acts as a trigger for the production of new adipocytes. In A/S
83-treated rats increases in parametrial adipocyte size were 
inhibited, at least until 8 weeks after treatment. One explanation 
for the long-term reduction of adipocyte numbers caused by A/S 83 is, 
therefore, that a 'critical adipocyte size' was not attained and so 
proliferation was not triggered.
An alternative explanation for the permanent reduction in 
adipocyte numbers of A/S 83-treated rats is that the pre-adipocyte 
population was reduced. Preliminary experiments suggested that A/S
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83 was cytotoxic to cells isolated from the stromal vascular fraction 
of adult rat adipose tissue (results not shown). However, the 
precise nature of the target cells used in these experiments was not 
determined, as time did not allow the setting up of a culture system 
capable of supporting adipocyte precursor proliferation and 
differentiation. Antisera, raised in rabbits, to rat adipocyte
plasma membranes showed low level binding to freshly isolated 
adipocyte precursors but a sharp increase in binding was observed 
upon the reaching of confluence (Cryer, Gray and Woodhead, 1984). 
The authors suggested that the low but significant binding to
preconfluent precursors might indicate that these cells were already
partially determined and derived from pluripotent stem cells, only 
present during embryogenesis. It is likely, therefore, that mature
adipocytes bear surface antigens specific to the mature cell and 
antigens that are also present on adipocyte precursors in adult 
adipose tissue. It is possible that adipocyte precursor numbers, in 
addition to mature adipocyte numbers, were reduced in A/S 83-treated 
rats, thus reducing the regenerative potential of the tissue.
3.2.3.2 The effects of A/S 83 on parametrial adipocyte volume
The reduction in dry weight of parametrial adipose tissue 24 
weeks after treatment was 50%, compared with 75% at 8 weeks (Fig.
3.1). This partial recovery of lost adipose mass was due to a
complete recovery of mean adipocyte volume. Table 3.1 shows the 
amounts of lipid accumulated by each adipose depot during different 
times after treatment. The measurements at different time points
were made on different animals so statistical significance cannot be 
determined. However, the results indicate that between 1 and 8 weeks
the parametrial depot of A/S-treated rats accumulated about 33% of
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the lipid accumulated by that of control rats. Between 8 and 24 
weeks the parametrial depot of A/S-treated rats accumulated 86% of 
the lipid accumulated by that of control rats. Since A/S-treated 
rats had 50% fewer parametrial adipocytes throughout the experiment, 
lipid accumulation per adipocyte must have been reduced in treated 
animals betwen 1 and 8 weeks and increased between 8 and 24 weeks, 
compared with controls.
The causes of the reduction in the ability of parametrial 
adipocytes to accumulate lipid for about 8 weeks, followed by 
recovery, is not clear. The massive infiltration of adipose tissue 
by lymphocytes and polymorphonuclear leucocytes seen one week after 
treatment (Flint et al., 1986) may cause damage to supporting 
tissues, reducing the blood and/or nervous supply to adipocytes. A 
reduction in supply of nutrients, hormones or other stimuli might 
lead to a reduction in the rate of lipid accumulation by the tissue. 
Recovery after 8 weeks may have been the result of regeneration of 
supporting tissues.
Alternatively, adipocytes of A/S-treated rats, while apparently 
intact, may have suffered damage, causing a reduction in their 
intrinsic ability to accumulate lipid. This may have been due, for 
example, to a reduction in uptake of glucose or fatty acids. Such a 
reduction could operate through the modification of hormone 
sensitivity, membrane transporters or lipoprotein lipase (LPL) 
activity. LPL activity was not measured in A/S-treated animals. 
Adipocytes isolated from parametrial adipose tissue of A/S-treated 
and control rats showed no differences in basal or insulin-stimulated 
glucose incorporation into lipid or in basal or
noradrenalin—stimulated glycerol release (Figs. 3.4, 3.5). These
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results suggest that, in addition to there being no differences in 
nutrient uptake, there were no direct effects on lipogenesis or 
lipolysis in adipocytes. However, the adipocytes of A/S-treated 
animals were smaller than those of controls and smaller adipocytes 
show higher rates of glucose incorporation and are more 
insulin-sensitive than larger adipocytes (Salans, Knittle and Hirsch, 
1968). Differences between adipocytes of A/S-treated and control 
rats may, therefore, have been obscured by differences in cell size. 
The in vitro studies were performed on cells isolated from whole 
adipose tissue by collagenase digestion. Cells suffering from 
A/S-induced membrane damage may have been less able to survive the 
effects of collagenase digestion than undamaged cells.
The recovery of mean adipocyte volume of A/S-treated rats by 24 
weeks may have been the result of a slow rate of turnover of 
adipocytes, suggested to occur in the adult rat (Roncari and Van, 
1978). In this way, damaged adipocytes may have been gradually, 
randomly or preferentially lost from the population to be replaced by 
newly-formed cells.
3.2.3.3 Differential effects of A/S 83 on parametrial, peri-renal 
and subcutaneous adipose depots
In contrast to the long-term reduction of parametrial adipocyte 
numbers caused by A/S 83, adipocyte numbers of peri-renal and 
inguinal adipose depots, while showing a 30% reduction one week after 
treatment, approached normal levels by 3 weeks (Fig. 3.3). Mean 
adipocyte volumes of both depots were still reduced 8 weeks after 
treatment, but not significantly so (Fig. 3.2). Between 1 and 8 
weeks after treatment lipid accumulation in subcutaneous and 
peri-renal adipose depots of A/S-treated rats was 75-80% of controls
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(Table 3.1). During this period, there was a gradual recovery of 
lost adipocyte numbers in both depots and so any inhibition of lipid 
accumulation in remaining adipocytes in these depots was probably 
very short-lived.
There was no difference in the specificity of A/S 83 for 
adipocyte plasma membranes prepared from parametrial, peri-renal or 
inguinal subcutaneous adipose depots (Flint et al., 1986). 
Differences in the pattern of development of adipose depots and their 
capacity for regeneration in rats have been reported although this 
work has been performed predominantly with males. Bertrand and 
Masoro (1978) measured adipocyte number increases in rat peri-renal 
adipose tissue up to 18 months of age, while increases in cell number 
of epididymal adipose tissue ceased before 6 months of age. 
Subcutaneous adipose tissue has a greater capacity for regeneration 
after lipectomy than internal fat depots (Larson and Anderson, 1978; 
Faust, 1979). Differential effects of A/S 83 on different adipose 
depots may, therefore, have been due to differences in the ability of 
different depots to regenerate or the result of the site of 
injection.
Twenty four weeks after treatment fat pad weights and adipocyte 
volumes of peri-renal and subcutaneous adipocytes were larger in 
A/S-treated rats than in controls. These results, though not 
significant, suggest that a limited amount of compensatory 
hypertrophy of other depots, to compensate for the loss of 
parametrial adipose tissue, had occurred. A number of studies have 
been undertaken to test the theory, proposed by Kennedy (1966), that 
total body fat mass is maintained, in the adult, at a constant level 
through the control of food intake. Such studies have yielded
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conflicting results. Bailey and Anderson (1980) reported that 
lipectomy of epididymal fat depots resulted in compensatory 
hypertrophy of peri-renal, omental and subcutaneous depots until 
total fat mass was the same as controls. Similarly, Larson and 
Anderson (1978) reported that surgical removal of inguinal and 
epididymal adipose tissue resulted in enlargement of other depots 
such that total body fat was not reduced 13 weeks after surgery. 
Internal fat depots of lipectomised animals responded by increases in 
cell number. In contrast, Krai (1976) found that the removal of 
various adipose depots did not result in compensatory growth of 
remaining depots. He suggested that body fat stability in the adult 
is achieved by regulation of adipocyte size, rather than total 
adipose mass. He proposed that, after a period of food restriction, 
missing fat is replaced because adipocyte size is reduced, but, 
after lipectomy, missing fat is not replaced because adipocyte size 
is unchanged and only adipocyte numbers are reduced. A/S 83-treated 
rats showed some compensatory hypertrophy of peri-renal and inguinal 
adipose depots, which may have been stimulated by the reduced total 
body fat mass or by the reduced adipocyte size of the parametrial 
depot. However, compensation was not total, possibly because the 
remaining reduction in adiposity was due to reduced adipocyte 
numbers, rather than size.
3.2.3.4 Cross-reaction of A/S 83 with non-adipose tissues
There were no significant differences in wet weights of 
kidneys, spleen or liver between A/S-treated and control rats 1, 3, 8 
and 24 weeks after treatment, with the exception of the spleen weight 
which was elevated in A/S-treated rats 1 week after treatment (Table 
3.2). The elevated spleen weight may have been due to an immune
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response against the immunising antiserum or to the recruitment of 
lymphoid cells to the site of antiserum deposition. A/S 83 appeared, 
at least in gross terms, to be tissue-specific in vivo, despite 
clear cross-reactions with kidney, hepatocyte and erythrocyte plasma 
membranes in vitro (Fig. 3.6). Discrepancies between apparent in 
vitro and in vivo specificity of A/S 83 may be due to differences in 
affinity of antibodies for different tissues. Cross-reactivity of 
antibodies may be based on the binding of structurally different 
determinants by the same antibody, known as polyfunctional 
antibodies. The covalent bonds responsible for binding of antibody 
to antigen are critically dependent on the distance between reacting 
groups. The higher the degree of complementarity between the 
antigenic determinant and the antibody combining site, the higher is 
the affinity of the antibody for the antigen. Hence, an antibody 
raised against an adipocyte plasma membrane determinant would be 
expected to have high complementarity with and so high affinity for 
that antigenic determinant. If the same antibody bound to a 
different determinant on, for instance, hepatocyte plasma membranes, 
the degree of complementarity and hence the affinity of the antibody 
for the liver antigen would be less than that for the adipocyte 
antigen. Low affinity antibodies tend to bind antigen more 
effectively at low temperatures. Therefore ELISAs, performed at 
22° C, may measure low affinity antibodies that are not of 
physiological importance in vivo.
In addition to antibodies binding to structurally unrelated 
determinants, cross-reactivity may involve the existence of common 
epitopes on different antigens, in which case there would be no 
difference in the affinity of antibodies for the antigen.
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A/S 83 is a polyclonal antiserum composed of antibodies raised 
against numerous antigens. The overall specificity of the antiserum 
is, therefore, the result of a combination of the affinity and titre 
of a range of different antibodies raised against a variety of 
different antigenic determinants. Western blotting showed that A/S 
83 binds to at least 7 major polypeptides of hepatocyte plasma 
membranes compared with at least 19 polypeptides of adipocyte plasma 
membranes (Fig. 3.7), indicating that the antiserum recognises some
adipocyte plasma membrane antigens that are not shared with 
hepatocyte plasma membranes.
The site of injection may confer extra specificity on the
antiserum in vivo. As only tissue weight rather than function was 
measured, direct effects of A/S 83 on tissues other than adipose
cannot be discounted but the most dramatic effects certainly occurred 
in adipose.
3.2.3.5 The effects of A/S 83 on food intake, body composition and 
food conversion efficiency
The administration of A/S 83 caused an 8-10 g drop in body 
weight, accompanied by a 75% decrease in food intake on the first day 
of treatment (Fig. 3.8). Slightly abnormal postures were sometimes 
adopted for about 2 h after treatment. Non-immune sheep y globulin 
treatment caused none of these effects. It is possible that the
antiserum cross-reacted with a component of the nervous system, 
affecting muscle co-ordination, near the site of injection. 
Cross-reactivity of A/S 83 with nervous tissue was investigated and 
is described in Chapter 4. Control rats, pairfed with A/S 83-treated 
rats, showed an equal fall in body weight on the first day of 
treatment. Therefore, the reduction in body weight, seen in
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A/S-treated rats, can be entirely attributed to a reduction in food 
intake and this reduction in food intake could be due to the rise in 
serum metabolites, such as triglycerides, released from adipose 
tissue.
The fate of lipids, released from adipose tissue in A/S-treated 
rats, is unclear. Body composition analysis at 5 and 8 weeks showed 
that protein deposition was increased in A/S-treated animals (Table 
3.4). Eight weeks after treatment in A/S-treated rats, a reduction 
of about 50 g/kg of fat was balanced by increases of 10 and 40 g/kg 
of protein and water respectively. While fat is deposited without or 
with the partial replacement of water, protein deposition is 
accompanied by the deposition of water. Muscle has a protein:water 
ratio of 1:3-4 (van Es, 1977) so the ratio of protein increase to 
water increase, described above, is as would be expected.
The increase in protein deposition at 5% and 8 weeks could not 
be entirely due to the incorporation into protein of substrates 
released from adipose tissue as a result of immune attack. Between 1 
and 8 weeks A/S 83-treated rats showed an elevated food intake and 
reduced fat deposition. There must, therefore, have been a 
repartitioning of energy intake from fat into protein deposition. 
Alterations in nutrient partitioning in A/S-treated rats could occur 
by a modification of hormone levels, by direct differential effects 
on adipose tissue, muscle and liver or by direct effects on adipose 
tissue which indirectly affect nutrient uptake by muscle or the 
liver.
A/S 83 may cross-react in vivo with any of the numerous 
endocrine organs which influence growth and carcass composition, such 
as the pituitary, pancreas and adrenal. The only hormone measured
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was insulin which was reduced at 2 weeks and elevated at 5, 10 and 24 
weeks in A/S-treated rats, although these differences were not 
significant. Insulin concentrations are generally correlated with 
degree of fatness, as the anabolic effects of insulin tend to be 
greater on fat than on muscle. Elevated serum insulin concentrations 
may have contributed towards the elevated fat accumulation, seen in 
peri-renal and subcutaneous depots between 8 and 24 weeks (Table
3.1). Growth hormone has anabolic effects on muscle, probably 
mediated by somatomedins, and is lipolytic. The administration of 
exogenous growth hormone frequently results in the repartitioning of 
nutrients from fat to protein deposition (Hart and Johnsson, 1986). 
Elevated growth hormone levels are frequently correlated with 
decreased insulin levels, so it would be of interest to measure 
growth hormone levels 2 weeks after treatment with A/S 83 when 
insulin levels, in some rats, were reduced. The pulsatile release of 
growth hormone and its response to stress make meaningful 
measurements of growth hormone levels difficult to obtain, without 
the use of chronically cannulated animals. The repartitioning 
effects of the synthetic £ agonists, clenbuterol and cimeratol, are 
believed to involve their known |3 adrenergic stimulation of lipolysis 
in adipocytes, coupled with their known limiting effects on muscle 
protein degradation (Dalrymple et al., 1984). Direct effects of A/S
83 on muscle have not been investigated, so stimulatory effects of 
A/S 83 on nutrient uptake and protein deposition by muscle cannot be 
excluded.
Alternatively, repartioning of nutrients in A/S 83-treated rats 
may occur simply as a result of competition between adipose tissue 
and muscle for common precursors, such as glucose. Reduced uptake of
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nutrients by adipose tissue may have led to compensatory increases in 
uptake by other tissues.
Table 3.3 shows the effects of A/S 83 on body weight gain, food 
intake and food conversion efficiency (FCE). FCE is expressed as 
food intake divided by weight gain, making no adjustment for 
maintenance requirements. As A/S 83-treated rats were heavier than 
controls, any differences in efficiency would be accentuated by 
subtracting maintenance requirements from food intakes, as larger 
animals have greater maintenance requirements. FCE was increased in 
A/S-treated rats, particularly between 2 and 7 weeks. During this 
period A/S-treated animals deposited more protein and less fat than 
controls. It should be noted, however, that measurements of FCE and 
body composition were made on different animals and the animals whose 
body composition was measured showed no increase in body weight gain 
(results not shown). A number of studies have attempted to estimate 
the energy cost of fat and protein deposition in rats (McCracken and 
Weatherup, 1973). Such studies have yielded varied results, partly 
because both maintenance requirements and energy partitioning are 
influenced by maturity and so are not independent variables. However, 
more recent experiments have been designed to overcome this problem 
by using fat and lean Zucker rats, between which energy partitioning 
into fat and protein varies independently of maturity (Pullar and 
Webster, 1974, 1977). Such work has indicated that the amount of
energy required to deposit 1 KJ of fat and protein are 1.36 and 2.25 
KJ, respectively. The energetic efficiency of net protein synthesis 
is, therefore, lower than that of net fat synthesis. Assuming 
energy contents of 39 and 24 KJ per gram of protein and fat 
respectively, the energy requirements of the deposition of 1 g of
83
protein and 1 g of fat become almost identical (about 53 KJ). As the 
deposition of 1 g of protein is accompanied by the deposition of 2-3 
g of water, a shift from fat deposition to protein deposition results 
in a reduction in the amount of energy required for a given amount of 
weight gain. The increase in FCE in A/S-treated rats could,
therefore, have been due to decreased fat deposition and increased 
protein deposition. Body composition was not measured at 24 weeks, 
but fat deposition, in the depots measured, was greater between 8 
and 24 weeks in A/S-treated than in control rats. A repartitioning 
of nutrients, favouring fat rather than protein deposition, may
account for the reduction in the difference in FCE between
A/S-treated and control rats between 7 and 24 weeks.
3.2.3.6 The rat immune response to injected sheep immunoglobulin
The administration of 2 ml of A/S 83 to a rat resulted in the 
injection of about 100 mg of foreign protein, mainly y globulin. The 
rat immune response to sheep igG was, therefore, investigated. Fig. 
3.11 shows that A/S 83-treated rats produced a much greater immune 
response to sheep IgG than non-immune sheep IgG-treated rats. This 
was probably because, in A/S-treated rats, where the antibodies had a 
target, antigen-presenting cells were attracted to the site of 
antibody deposition, possibly by complement activation. This would 
lead to improved antigen presentation and, thereby, antibody 
production. Immune clearance of xenogeneic serum is normally rapid, 
but A/S 83 bound to tissues may have provided an antigenic stimulus 
for a longer period than non-immune sheep IgG. A suitably assay for 
the detection of sheep IgG in rat serum was not available.
Body weight gain of both A/S 83- and non-immune sheep 
IgG-treated rats fluctuated at about 2 weeks after treatment. This
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was accompanied by transient proteinurea which tended to be more 
severe in A/S-treated rats (Fig. 3.12). Proteinurea is indicative of 
abnormal kidney function, which may be caused by antibodies directed 
against renal antigens or by the deposition of circulating immune 
complexes in the glomerulus.
A/S 83 binds to renal antigens (Fig. 3.6) so antibodies may 
have localized in the kidneys of A/S-treated rats, in the absence of 
immune complex formation. Passive nephrotoxic nephritis has been 
induced, in rats, by the injection of a foreign antiserum raised 
against rat renal antigens (Unanue and Dixon, 1967). The progress of 
the disease occurs in 2 phases. The first is a heterologous phase, 
characterised by the reaction of nephrotoxic antibodies with 
glomerular antigen. If sufficient amounts of nephrotoxic antibodies 
are administered, this phase is immediate and proteinurea can be
detected within a few hours. In the few instances where it was 
possible to obtain urine samples a few hours after treatment with A/S 
83, proteinurea was not detected and there were no changes in serum 
urea concentrations during the first week after treatment (results 
not shown). The second phase of the disease is the autologous phase, 
which occurs after a week, and results from the immunological
response of the host to heterologous immunoglobulin. As nephritis 
progresses, rats develop elevated blood urea nitrogen levels, 
decreased urea and creatinine clearance, persistent urinary 
abnormalities, weight loss and hyperlipidaemia. In addition to 
transient elevated urine protein concentrations and weight
fluctuations, 1 out of 6 A/S-treated rats showed a doubling in serum 
urea concentations and 3 out of 6 A/S-treated rats showed
hyperlipidaemia 2 weeks after treatment. These had all returned to
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normal levels by 3 weeks after treatment. It is also possible that 
the hyperlipidaemia, seen at 2 weeks after treatment with A/S 83, was 
the result of host anti-(sheep IgG) antibodies binding to 
anti-(adipocyte) antibodies, already coating adipocytes, resulting in 
further lysis of adipocytes.
No circulating immune complexes could be measured in A/S 83- or 
non-immune sheep IgG-treated rats, although a lack of positive 
controls makes this inconclusive (results not shown). It is possible 
that the rats may have suffered from mild serum sickness about 2 
weeks after treatment, such as that commonly studied by immunisation 
of rabbits with BSA (Dixon and Cochrane, 1970). In this model, after 
a week, antibodies to BSA appear in the circulation. Complexes 
formed in antigen excess are small and persist in the circulation. 
Complex deposition along the glomerular basement membrane occurs and 
symptoms of glomerulonephritis, such as proteinurea and weight loss, 
appear. As antigen is removed from the circulation and antibody is 
in excess, complexes become larger. Large immune complexes are more 
rapidly removed from the circulation because of multiple binding of 
antibody to Fc receptors of phagocytic cells of the mononuclear 
phagocyte system (Wener and Mannik, 1986).
Circulating immune complexes in A/S 83-treated rats would be 
composed of either A/S 83 bound to adipocyte plasma membrane antigens 
or A/S 83 bound to rat anti-(sheep IgG) antibodies. Complexes of the 
first type would be likely to be formed in the greatest quantity 
within the first few days after treatment. The appearance of 
nephritis about 2 weeks after treatment and the presence of nephritis 
in some non-immune sheep IgG-treated rats implicates a rat immune 
response as the cause. Since there was a considerable rat immune
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response against sheep IgG, it is not possible to be certain whether 
anti-(kidney) antibodies or circulating immune complexes were
responsible for the transient nephritis seen in A/S 83-treated rats.
3.2.4 Conclusions
1. The administration of A/S 83 to 120-140 g female rats caused a
50% reduction in parametrial adipocyte numbers, which persisted 
at least until 24 weeks after treatment. The absence of 
recovery of lost adipocyte numbers may have been because the 
pre-adipocyte population was damaged in some way. 
Alternatively, since the ability of parametrial adipocytes to 
accumulate lipid was reduced for the first 8 weeks after 
treatment, the remaining adipocytes may not have attained the 
'critical size' necessary for the triggering of new adipocyte 
production.
2. The ability of parametrial adipocytes to accumulate lipid was
reduced for the first 8 weeks after treatment and had recovered 
by 24 weeks after treatment. Damage to supporting tissues may 
have resulted in a reduced blood supply or innervation of 
parametrial adipose tissue during the first 8 weeks or, 
remaining adipocytes, while apparently intact, may have been 
damaged and were gradually replaced by newly-formed adipocytes 
after 8 weeks.
3. A/S 83 had a greater effect on parametrial than on subcutaneous
or peri-renal adipose tissue, possibly because of the site of 
injection of A/S 83 or because of intrinsic differences in 
different adipose depots.
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4. While A/S 83 showed cross-reactivity with non-adipose tissues 
in vitro, there was no gross anatomical evidence of 
cross-reactivity with non-adipose tissues in vivo.
5. A/S 83 caused a 75% reduction in food intake on the first day
of treatment, possibly because of an increase in serum 
metabolites, such as free fatty acids and triglycerides, 
released from adipose tissue. Food intake recovered by the 
fourth day of treatment.
6. Body composition analysis at 5% and 8 weeks after treatment
indicated that lost fat was replaced by protein and there was 
repartitioning of food intake from fat into protein deposition. 
This may be due either to direct effects of A/S 83 on muscle or 
liver, to effects on hormone levels or to effects on adipose 
tissue, thus reducing competition between adipose tissue and 
muscle for common precursors.
7. A/S 83 caused the transient development of nephritis about 2
weeks after treatment, which was manifested by fluctuations in 
body weight gain and proteinurea. The nephritis was either due 
to immune attack of the kidney by A/S 83 or due to the 
deposition of circulating immune complexes, formed as the 
result of the immune response to sheep IgG, in the kidney.
3.3 AN ASSESSMENT OF THE EFFECTS OF THE SITE OF INJECTION AND
DURATION OF TREATMENT WITH A/S 83
3.3.1 Experimental
Female Wistar rats, weighing 120-140 g, were injected
intraperitoneally with the equivalent of 2 ml of A/S 83 y globulin,
between 9.00 h and 11.00 h, for 0, 1 , 2  and 4 days. An additional
group of rats were injected subcutaneously with the equivalent of 
2 ml of A/S 83 on 4 consecutive days. Food intakes and body weights 
were recorded daily for the first 2 weeks and every 3 days 
thereafter. Rats were killed upon reaching a weight of approximately 
250 g, which was about weeks after treatment. The dry weights of 
the parametrial, peri-renal, omental, interscapular subcutaneous 
white adipose tissue and the wet weight of the interscapular brown 
adipose depots were determined.
3.3.2 Results
While intraperitoneal injection of A/S 83 caused a drop in body 
weight of 10 g during the first day after treatment, the injection of 
A/S 83 subcutaneously caused no drop in body weight gain on the first 
day (Fig. 3.13). Body weight gain in intraperitoneally injected rats 
partially recovered on the second day and was normal by the third day 
after treatment. Subcutaneously injected rats showed a reduction in 
body weight of 4 g on the second day of treatment. In this group of 
rats, weight gain fluctuated around 0 on the third and fourth day 
after treatment before achieving slightly greater than normal levels 
5 days after treatment.
There was a 75% reduction of food intake in intraperitoneally 
injected rats during the first day of treatment, compared with a 40% 
reduction in subcutaneously injected rats (Fig. 3.13). Food intakes 
were similar in intraperitoneally and subcutaneously injected rats 
after the first day of treatment and there were no differences in 
weight gain and food intake between controls and intraperitoneally 
and subcutaneously injected animals during the final 4^ weeks of the 
experiment.
Fig. 3.13. The effects of the site of injection of A/S 83
on body weight gain and food intake
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Rats were injected intraperitoneally or subcutaneously with the 
equivalent of 2 ml of A/S 83 y globulin for h consecutive days. 
Control rats were allowed to feed ad libitum. Results are means 
+ SEM of 4-6 observations. *P<0.01, ***P<0.001, compared with
intraperitoneally injected rats (Studentfs unpaired t test)
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Table 3.5 shows the effects of different sites of injection on 
adipose tissue 5% weeks after treatment. The dry weight of 
subcutaneous adipose tisue was significantly less in subcutaneously 
than in intraperitoneally injected rats, whilst the dry weight of 
parametrial and omental adipose tissue was significantly less in 
intraperitoneally than in subcutaneously injected animals. The wet 
weight of interscapular brown adipose tissue was significantly 
greater in intraperitoneally injected rats than in controls.
There were no significant differences in body weight gain or 
food intake between rats injected with 1ml, 2 x 1 ml or 4 x 1 ml of 
A/S 83 (Fig 3.14). There were no signficiant differences in adipose 
tissue weight between rats given 1 ml, 2 x 1 ml or 4 x 1 ml of A/S 83 
(Table 3.6).
3.3.3 Discussion
The reduction in food intake and body weight induced by A/S 83 
was delayed, but not prevented, in subcutaneously, compared with 
intraperitoneally, injected rats (Fig. 3.13). Since an antiserum 
injected subcutaneously would enter the circulation more slowly than 
if injected intraperitoneally, the reduction in food intake may have 
resulted from the interaction of circulating antibodies with cells or 
proteins of the circulation, or with a non-adipose target tissue 
reached via the circulation. The slower release of antiserum from 
subcutaneous sites may have permitted a more controlled effect with 
less dramatic adverse reactions. As parametrial adipose tissue was 
most affected by intraperitoneal injection of A/S 83 and subcutaneous 
adipose tissue was most affected by subcutaenous injection (Table 
3.5), the antiserum probably does not need to enter the general
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Fig. 3-1^. The effects of the duration of treatment
with A/S 83 on body weight gain and food intake
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Bats were injected intraperitoneally with the equivalent of 2 ml 
of A/S 83 y globulin for 1, 2 or I consecutive days. Control rats 
were allowed to feed ad libitum. Results are means _+_ SEM of 3-6 
observations.
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circulation before interaction with target adipocytes. The reduction 
of food intake may have resulted from the release of lipid and lipid 
breakdown products into the circulation, as a result of immune attack 
of adipose tissue. As parametrial adipose tissue is more highly 
vascularised than subcutaneous adipose tissue, products of 
parametrial adipocyte lysis may have been released more rapidly into 
the circulation than those of subcutaneous adipocytes.
In the experiments described above all rats treated with A/S 83 
showed an increase in brown adipose tissue weight, although only in 
rats given 4 intraperitoneal injections of A/S 83 was this difference 
significant. It is not known whether the increase in mass of the 
tissue was due to hyperplasia or to enlargement of existing brown 
adipocytes. Hyperplasia in brown adipose tissue occurs, in some 
rodents, upon prolonged exposure to a cafeteria diet, where, despite 
marked hyperphagia, the animal gains little weight, due to an 
increased rate of non-shivering thermogenesis (Rothwell and Stock, 
1979). However, since the A/S 83-treated rats gained slightly more 
weight and showed a slightly greater food conversion efficiency than 
controls, it is unlikely that there was a significant increase in 
non-shivering thermogenesis in A/S-treated animals. A rise in the 
weight of brown adipose tissue was more likely to have been due to an 
increase in triglyceride storage in the tissue.
3.3.4 Conclusions
1. Differential effects of A/S 83 on different adipose depots were 
due, largely, to the site of injection.
2. The same effects could be achieved on adipose tissue and food 
intake by a single treatment with A/S 83 as with the same 
treatment on 4 consecutive days.
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3. Treatment with A/S 83 induced an increase in brown adipose 
tissue mass which was more likely to have been the result of 
increased triglyceride storage in the tissue than to increased 
non-shivering thermogenesis.
3.4 AN INVESTIGATION OF THE SHORT-TERM EFFECTS OF A/S 83
3.4.1 Experimental
130-160 g female Wistar rats were anaesthetised at 09.30 a.m. 
by intraperitoneal injection of 40 mg/kg body weight of 10 mg/ml 
pentobarbital in pyrogen-free saline. Once anaesthetised, rats were 
wrapped in cotton wool to maintain body temperature. 0.5 ml blood 
samples were taken, by cardiac puncture, 20 minutes after onset of 
anaesthesia. Rats were then injected with either the equivalent of 
2 ml of A/S 83 or non-immune sheep y globulin or were uninjected. 
Blood samples were taken, as described above, at 3, 6, 12 and 24 
hours after administration of y globulin. Rats were allowed to 
recover after anaesthesia and 2 sets of animals were used so that 
rats were not bled more than 3 times in 24 hours. Blood samples were 
obtained 2 and 4 days after treatment, using ether anaesthesia. At 
6 days rats were killed by cervical dislocation and blood samples 
taken from the jugular vein. Wet and dry weights of parametrial 
adipose tissue were determined.
All serum samples were allowed to clot at 4° C for 3 h, 
centrifuged at 11,000 g for 5 mins at 4° C, snap frozen and stored at 
-20° C. Serum glucose, triglyceride, free fatty acids, urea, 
complement and insulin concentrations were measured as described in 
Chapter 2. Serum A/S 83 concentations were measured by ELISA.
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3.4.2 Results
A/S 83-treated rats showed a doubling of serum non-esterified 
free fatty acids 6, 12 and 24 hours after treatment, compared with 
non-immune sheep y globulin-treated controls (Fig. 3.15). There was 
also a doubling of triglyceride levels 6 and 12 hours after A/S 
treatment. There was no difference in either free fatty acid or 
triglyceride levels by 48 hours after treatment. Serum glucose and 
insulin levels were not significantly affected, although 24 hours 
after treatment insulin levels tended to be reduced in A/S-treated 
rats (Fig. 3. >6). The administration of both A/S 83 and normal sheep 
Y globulin caused a 50% reduction in circulating complement levels 
but this had returned to nearly normal levels in non-jimme sheep r 
globulin-treated rats by 12 hours (Fig. 3.15). Complement levels of 
A/S-treated rats had fallen to about 20% of normal levels by 12 
hours, returning to near normal levels by 24 hours. A/S S3 was 
detectable in the serum by 3 hours after treatment and had reached 
maximum levels (0.23 //1/ml) by 6 hours after treatment (Fig. 3.16). 
This level was maintained until 24 hours after treatment, when if 
declined and was undetectable by 6 days.
The dry weights and percentage dry weights of parametrial 
adipose tissue of A/S 83-treated rats showed similar reductions, 
compared with controls, as had been seen with A/S 83-treated rats in 
previous experiments (results not shown).
3.4.3 Discussion
Pentobarbital anaesthesia was used in these experiments so that 
rats could be anaesthetised 20 minutes before blood sampling to allow
any stress-induced release of metabolites or hormones to cease before
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Fig. 3-15. The short-term effects of A/S 83
on serum complement, triglyceride and free fatty acid levels
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and free fatty acids were measured, as described in Section 2.12. 
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Fig- 3.16. The short-term effects of A/S 83
on serum insulin, glucose and antibody levels
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in Section 2.12. Results are means + SEM of 3~8 observations.
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sampling. The increase in serum free fatty acids and triglycerides, 
seen at 6-24 hours after treatment with A/S 83 (Fig. 3.15) was 
probably the result of adipocyte lysis. Serum glucose (Mayer, 1953), 
free fatty acids and insulin (Liebel, 1977) have all been implicated 
in the control of food intake and so the rise in serum free fatty 
acids may have contributed towards the reduction in food intake seen 
during the first 24 hours after treatment (Fig. 3.8). The reduction 
in insulin levels seen in some A/S-treated rats 24 hours after 
treatment (Fig. 3.16) may have been the result of cross-reaction of 
A/S 83 with pancreatic tissue, temporarily affecting insulin 
secretion, but is more likely to have been the result of a reduction 
in food intake in A/S-treated rats. Since the rats in this 
experiment were anaesthetised for long periods, meaningful 
measurements of food intake could not be obtained.
The reduction in circulating complement levels, seen in both 
non-immune sheep y globulin- and A/S 83-treated rats (Fig. 3.15) may 
have been due to the presence of complement fixing aggregates in both 
preparations. The decline of complement levels to 20% of normal 12 
hours after treatment with A/S 83, while those of non-immune sheep y 
globulin-treated rats had returned to normal, suggests that the 
binding of A/S 83 to target tissues in vivo resulted in complement 
activation, but does not necessarily demonstrate the importance of 
complement in mediating the fat-reducing effects of the antiserum.
The maximum level of circulating anti-(adipocyte plasma 
membrane) antibodies measured after treatment with A/S 83 was a more 
than 1,000-fold dilution of the anti-(adipocyte plasma membrane) 
activity of A/S 83. As 1 ml of A/S 83 was injected and the blood 
volume of the rats would have been no more than 10 ml, a considerable
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proportion of the antibodies must have been either cleared from the 
circulation very rapidly, bound to the tissues or circulating in the 
form of immune complexes and so not detectable by the assay used.
3.4.4 Conclusions
1. Treatment with A/S 83 resulted in a doubling of serum free
fatty acids and triglycerides 6 and 12 hours after treatment 
which returned to normal levels by 48 hours. This was probably 
the result of the release of the contents of lysed adipocytes 
into the circulation and may have contributed towards the
reduction in food intake seen on the first day of treatment 
with A/S 83.
2. The doubling of serum free fatty acids and triglycerides 12
hours after treatment was accompanied by a reduction in 
circulating complement to 20% of the normal level, showing the 
ability of A/S 83 to activate rat complement in vivo.
3. A/S 83 reached maximum levels in the serum by 6 hours after
treatment, when the anti-(adipocyte plasma membrane) activity 
was more than 1,000-fold diluted, compared with A/S 83.
3.5 DETERMINATION OF THE IMPORTANCE OF COMPLEMENT IN MEDIATING
THE IN VIVO EFFECTS OF A/S 83
3.5.1 Experimental
The dose of cobra venom factor (CVF) required to deplete rats 
of complement for at least 5 days was determined by injecting 
120-140 g female Wistar rats, intraperitoneally, with 10 or 30 //g of 
CVF in 200 /ul of PBS, 3 times, at 8-hour intervals. One rat that had
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received 3 x 10 /yg of CVF on day 0 was given a second 3 x 10 //g dose 
on day 4. Rats were bled daily, from the tail, under ether
anaesthesia. Serum was prepared and stored as described in Section
3.4.1. Complement was assayed as described in Section 2.12.1. The
effects of CVF on body weight and food intake were determined.
To assess the role of complement in mediating the in vivo 
effects of A/S 83, 120-140 g female Wistar rats were injected with 3 
x 10 /yg of CVF on day 0, as described above. Rats received the 
equivalent of 2 ml of A/S 83 y globulin intraperitoneally on days 1, 
2, 3 and 4. On day 4 they also received a second 3 x 10 //g dose of
CVF. A second group of rats received the same treatment, but with no 
CVF, and a third group were pair fed with the second group. Body 
weights and food intakes were measured daily. Rats were killed 6
days after the first treatment with A/S 83. Wet and dry weights of
parametrial, peri-renal and inguinal subcutaneous adipose depots
were determined. These depots were also scored by visual appearance 
on a scale of 0-3 for lymphocytic infiltration, as shown by a nodular 
appearance. Mean adipocyte volumes and adipocyte numbers of
parametrial adipose tissue were also determined.
3.5.2 Results
Treatment of rats with 3 x 10 /yg of CVF on days 0 and 4 caused 
decomplementation for 5 days (Fig. 3.17). Treatment with CVF alone 
had no effect on food intake or body weight. CVF treatment prevented 
the A/S 83-induced reduction in food intake and weight gain (Fig. 
3.18). Six days after treatment with A/S 83, lymphocytic 
infiltration was clearly visible in parametrial, peri-renal and
omental adipose tissue, while that of A/S 83-treated rats, that had
Fig. 3.1?. The effects of Cohra Venom Factor
on serum complement levels
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30 yg on day 0 and 30 yg on day h (open triangles) of CVF in 3 
intraperitoneal injections separated by 8 h. Rats were bled from 
the tail and serum complement was measured as described in Section 
2.12. Results are single observations.
Fig. 3.18. Body weight gain and food intake
of CVF and A/S 83~treated rats
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also received CVF, showed no lymphocytic infiltration (Table 3.7). 
Dry weights of parametrial, peri-renal, omental and subcutaneous 
adipose tissue were reduced in A/S 83-treated animals, but not in 
rats also given CVF. The percentage dry weights of these depots, 
used as an indication of lymphocytic infiltration, were slightly 
reduced in rats that had received A/S 83 and CVF but were reduced to 
a much greater extent in animals given A/S 83 alone (Table 3.7). 
Parametrial adipocyte numbers were not significantly reduced in rats 
given A/S 83 and CVF, while those of rats given A/S 83 alone were
significantly reduced by 60%.
3.5.3 Discussion
As treatment with CVF alone had no effect on food intake or 
body weight gain, the A/S 83-induced reduction in food intake could 
not be due to complement activation and the resulting liberation of 
anaphylatoxins.
Lymphocytic infiltration of adipose tissue and immediate 
reductions in adipocyte number were shown to be, at least in part, 
dependent on the presence of circulating complement. It is not 
clear, however, whether the role of complement in mediating 
reductions in adipocyte number was the attraction of
polymorphonuclear leucocytes and lymphocytic cells, which then
participated in antibody-dependent cell-mediated cytotoxicity, or the 
direct lysis of adipocytes through the formation of the membrane 
attack complex. The lowest A/S concentration, where in vitro
cytotoxicity against adipocytes was measurable, was 4 fj 1/ml, while 
the highest measured concentration of A/S 83 in vivo in the 
circulation was 0.23 /yl/ml (Fig. 3.16). However, the portion of A/S
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83 of physiological significance may have been bound to the tissues, 
rather than in the circulation. In vitro assays cannot completely 
represent the in vivo situation, so a lower concentration of 
antiserum may be adequate for in vivo cytotoxicity. Maximum 
measurable antibody levels in vivo persisted for at least 18 h, while 
in vitro cytotoxicity assays were performed over a period of 1 h, to 
minimise non-specific LDH release. Prolonged exposure to low 
antibody concentrations may have been as cytotoxic as short exposure 
to high concentrations. Alternatively, the main role of complement 
in mediating the in vivo effects of A/S 83 may have been the 
attraction of phagocytic cells to the site of antibody deposition, as 
has been suggested for the effects of anti-(kidney) antibodies in the 
induction of passive nephrotoxic nephritis (Ulich, Bannister and 
Wilson, 1987). It would be of interest to determine whether the 
infiltration of adipose tissue with phagocytic cells occurred before 
or after the rise in serum free fatty acids and triglycerides seen in 
A/S 83-treated rats. If the latter, the role of the cellular 
infiltrate may be the phagocytosis of the products of the breakdown 
of adipose tissue, rather than attack of the intact tissue.
Complement was not shown in these experiments to be necessary 
for the A/S 83-induced reduction in adipocyte numbers, seen at 3, 8 
and 24 weeks. Clearly, long-term experiments investigating the in 
vivo effects of complement are necessary, although CVF is highly 
immunogenic, rendering it impossible to decomplement rats for more 
than 6 days. Antibody may still be present after this time point and 
so complement-mediated adipocyte damage may only be delayed, rather 
than prevented.
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3.5.4 Conclusions
1. The cellular infiltration of adipose tissue and the immediate 
reduction in adipocyte numbers, induced by A/S 83, was clearly 
dependent on the presence of complement.
3.6 EFFECTS OF A/S 83 ON PREGNANCY AND LACTATION
3.6.1 Experimental
Female Wistar rats, weighing 120-140 g, were given a single 
intra-peritoneal injection of the equivalent of 2 ml of A/S 83 y 
globulin. Control rats were pairfed with the treated group for 4 
days. Three weeks after treatment, treated and control rats were
.j-oiV'V' no? ivM
mated,. Body weights and food intake were monitored throughout 
pregnancy and lactation. Two treated and 2 control rats were killed 
on day 20 of pregnancy. Dry weights of parametrial, omental and 
peri-renal adipose depots and a combination of mammary and inguinal 
subcutaneous adipose tissue were determined. Litters were adjusted 
to 8 pups at birth and pup weights were monitored during lactation. 
Pups were removed from dams on day 21 of lactation. A/S-treated and 
control rats were killed 3 weeks after day 21 of lactation, which was 
12 weeks after A/S treatment. Virgin A/S 83-treated and control rats 
were also killed 12 weeks after treatment. Dry weights of 
parametrial, peri-renal, omental and inguinal subcutaneous adipose 
tissue were determined.
3.6.2 Results
Treatment with A/S 83 3 weeks before mating had no effect on 
the ability of rats to mate or on body weight gain during pregnancy.
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There were no differences in foetal numbers and weights, mammary 
weights and adipose tissue weights between the 2 controls and 2 
A/S-treated rats killed on day 20 of pregnancy (Table 3.8). There 
were no significant effects of treatment with A/S 83 on the body 
weight of the dam or on weight gain of the litter (Fig. 3.19).
Twelve weeks after treatment, the dry weights of parametrial 
adipose tissue of A/S 83-treated rats, whether they were virgin or 
had undergone a cycle of pregnancy and lactation, were almost 
identical (Table 3.9). Parametrial adipose mass of A/S 83-treated 
rats, whether virgin or ex-lactating, was less than that of virgin 
controls and of controls that had undergone a cycle of pregnancy and 
lactation, although this only achieved statistical significance when 
compared with virgin controls. Control lactating rats showed a 
slightly lower parametrial.adipose mass than virgin controls and both 
groups of rats that were ex-lactating showed more variability in 
adipose mass than virgin rats. A/S-treated rats, whether virgin or 
ex-lactating, showed no significant changes in subcutaneous, 
peri-renal and omental adipose mass, compared with controls.
3.6.3 Discussion
Since A/S 83-treated rats showed no abnormalities in their 
ability to mate or in their foetal numbers or weights, the massive 
cellular infiltration of parametrial adipose tissue, induced by A/S 
83, cannot have caused lasting damage to the uterus or ovaries.
The A/S 83-treated rats killed at the end of pregnancy had the 
same amount of parametrial adipose tissue as control rats, implying 
that pregnancy induced recovery of lost adipose mass. However, A/S 
83-treated rats, killed after a cycle of pregnancy and lactation, had
Fig. 3-19- The effects of A/S 83
on dam and litter weight gain during lactation
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less parametrial adipose tissue than controls (Table 3.9), implying 
that pregnancy did not induce recovery of lost adipose mass. This 
discrepancy may be partly the result of the very small numbers of 
rats killed at the end of pregnancy. Both sets of results imply that 
the reduction in fat deposition, seen in parametrial adipose tissue 
of A/S 83-treated rats between 1 and 8 weeks, was due to a defect in 
a proportion of the total adipocyte population and the remaining 
adipocytes were capable of accumulating large quantities of lipid, 
given the stimulus of pregnancy. However, for unknown reasons, the 
reduction in adipose mass in virgin A/S 83-treated rats was not as 
great as had been observed in previous experiments. The degree of 
A/S 83-induced reduction of adipose tissue mass was probably not 
sufficient to affect any possible competition between adipose and 
mammary tissue during lactation.
3.6.4 Conclusions
1. The results of this experiment suggested that treatment with 
A/S 83 did not affect the rat's ability to mate and undergo a 
normal pregnancy and lactation. However, the numbers of 
animals used were low and A/S 83 did not, in this experiment, 
have as great an effect on adipose tissue as had been seen in 
previous experiments.
CHAPTER 4 
IN VITRO AND IN VIVO CHARACTERISATION 
OF ANTI SERA RAISED AGAINST RAT ADIPOCYTE, 
HEPATOCYTE AND ERYTHROCYTE PLASMA MEMBRANES 
AND ADIPOCYTE SPECIFIC ANTIGENS
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IN VITRO AND IN VIVO CHARACTERISATION OF ANTI SERA 
RAISED AGAINST RAT ADIPOCYTE, HEPATOCYTE 
AND ERYTHROCYTE PLASMA MEMBRANES AND ADIPOCYTE SPECIFIC ANTIGENS
4.1 INTRODUCTION
In this chapter the sheep anti-(adipocyte plasma membrane) 
antiserum (A/S 83), used in the experiments described in Chapter 3, 
is compared with antisera from a more recent bleed from the same 
sheep and a number of other sheep antisera against rat adipocyte 
plasma membranes, as well as hepatocyte and erythrocyte plasma 
membranes.
Attempts were made to examine the role of antibodies that 
cross-react with non-adipose tissues in mediating the in vitro and in 
vivo effects of anti-(adipocyte plasma membrane) antisera. It would, 
clearly, be desirable to increase the specificity of the antisera as 
much as possible, without removing the effects on adipose tissue. 
Whilst A/S 83 caused no gross abnormalities of non-adipose tissue in 
vivo, the function of non-adipose tissues, with the exception of the 
kidney, was not monitored at a biochemical level. A/S 83 showed 
considerable cross-reactivity with other tissues in vitro (Fig. 3.6). 
The possibility of effects on non-adipose tissues in vivo cannot, 
therefore, be excluded. In addition, a reduction in the cross 
reactivity of A/S 83 with kidney tissue may reduce the transient 
nephritis seen in A/S 83-treated rats. It is also possible that the 
reduction in food intake during the first day after A/S 83 treatment, 
in some way, related to cross-reaction with other tissues.
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In order to determine whether cross-reacting antibodies were 
necessary for the fat-reducing properties of anti-(adipocyte plasma 
membrane) antisera, the antisera were adsorbed with a liver 
homogenate to render the antisera more specific for adipose tissue.
In addition, an antiserum was raised against adipocyte specific
antigens prepared by the method described in Section 2.9. Antisera 
were also raised against erythrocyte and hepatocyte plasma membranes, 
in order to determine whether adipocyte specific antibodies were 
necessary for the in vivo reduction of adiposity or whether the
apparently adipocyte specific effects of A/S 83 were due to the site
of injection or to the nature of the tissue itself.
All of the antisera described above were characterised by 
ELISA, in vitro cytotoxicity assays, Western blotting and short-term 
in vivo experiments. Discrepancies in apparent cytotoxicity and 
tissue specificity between in vitro and in vivo assays resulted in 
efforts to design in vitro assays that could effectively predict the
likely effects of an antiserum in vivo.
The characteristics of adipose tissue development and the 
response to lipectomy and repartitioning agents partly depend on sex 
and genetic composition (Willham, 1976; Hood, 1977; Bern, Novakofski 
and Bechtel, 1985; Moran, 1986). Due to the lack of in vivo effects 
of recent bleeds of A/S 83, it was not possible to compare the 
effects of A/S 83 on male and female rats, or on rats of different
strains. It was possible, however, to compare the binding of this
antiserum to plasma membranes from male and female Wistar and female 
Sprague-Dawley rats, using the small quantities of early A/S 83 
available.
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4.2 A COMPARISON OF THE IN VITRO AND IN VIVO EFFECTS OF EARLY
AND LATE BLEEDS OF A/S 83
4.2.1 Experimental
A/S 83 was raised according to the method described in Section 
2.4. Both early and late bleeds were obtained from the same sheep, 
10-14 days after a booster immunisation of adipocyte plasma membranes 
in incomplete Fruends adjuvant. The late bleed of A/S 83 was 
obtained about 18 months after the early bleed. Binding of the 2 
antisera to adipocyte, hepatocyte, erythrocyte and kidney plasma 
membranes by ELISA, cytotoxicity against adipocytes and erythrocytes 
and Western blotting against adipocyte and hepatocyte plasma 
membranes and adipocyte specific antigens were all performed 
according to the methods described in Chapter 2.
4.2.1.1 In vivo effects of early and late A/S 83 in female rats 
Female Wistar rats, weighing 120-130 g, were injected
intraperitoneally, between 09.00 h and 11.00 h on 3 consecutive days, 
with either 2 ml of early A/S 83, 2 ml of late A/S 83, 1 ml of late 
A/S 83, a mixture of 1 ml of early and 1 ml of late A/S 83 or were 
untreated. Body weights and food intakes were recorded. Rats were 
killed 6 days after the first treatment. Wet and dry weights of 
parametrial, peri-renal, omental and inguinal subcutaneous adipose 
depots were determined. These depots were also scored by visual 
appearance on a scale of 0-3 for lymphocytic infiltration, as shown 
by the nodular appearance of the tissue.
4.2.2 Results
The antibody binding of the late bleed of A/S 83 to adipocyte 
plasma membranes (APM), hepatocyte plasma membranes (HPM) and kidney
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plasma membranes (KPM) were reduced by about 50%, compared with early 
bleeds, while the binding to erythrocyte plasma membranes (EPM) was 
reduced by 90% in the late bleed (Table 4.1). Relative antigen 
abundances against these antigens were also reduced but not to the 
same extent as the antibody binding. The 2 bleeds of A/S 83 showed 
similar levels of in vitro cytotoxicity against adipocytes and 
erythrocytes (Fig. 4.1). Western blotting showed that the late bleed 
of A/S 83 apparently recognised only 15 APM polypeptides, compared 
with 21 polypeptides recognised by early A/S 83, but this may have 
been due only to a lower titre of late A/S 83 (Fig. 4.2). Late A/S 
83 bound more strongly to a polypeptide of a molecular weight of 
about 85 kD of the adipocyte specific antigen preparation (ASA) than 
early A/S 83. Late A/S 83 bound to only 5 HPM polypeptides, compared 
with 12 recognised by early A/S 83, although, again, this may have 
been due to differences in titre of the 2 bleeds.
The administration of late A/S 83 caused only 30% of the fall 
in body weight and food intake caused by an equivalent amount of A/S 
83 (Table 4.2). Late A/S 83 caused less lymphocytic infiltration of 
adipose depots than early A/S 83. A mixture of early and late A/S 83 
caused similar drops in food intake and body weight and more 
lymphocytic infiltration than A/S 83 alone.
While the results described above were obtained using a single 
bleed of late A/S 83 and pooled bleeds of early A/S 83, subsequent 
experiments showed that several bleeds of late A/S 83, taken after 
the same and after a subsequent booster immunisation, gave similar 
results (results not shown).
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Fig. U.l. In vitro cytotoxicity against adipocytes 
and erythrocytes of early and late bleeds of A/S 83
Heat-inactivated antisera were incubated with isolated adipocytes 
(a) or erythrocytes (b) for 1 h at 37° C. Adipocytes were separated 
from the medium by spinning through oil and the medium was assayed 
for LDH, as described in Section 2.7.2. Erythrocytes were separated 
from the medium by centrifugation and the medium was assayed for 
haemoglobin by measuring absorbance at 405 nm. LDH or haemoglobin 
release in the presence of non-immune serum was subtracted from that 
in the presence of antiserum and expressed as a percentage of total 
LDH release (determined in the presence of 2% Triton X-100). Results 
are mean +_ SEM of 3—5 observations. The cytotoxicity of an early 
bleed of A/S 83 (filled circles) was compared with a bleed taken 
from the same sheep more than 18 months later (open circles).
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Fig. h.2. Antibody binding 
to adipocyte and hepatocyte plasma membranes 
and adipocyte specific antigens 
by early and late bleeds of A/S 83, 
as determined by Western blotting
Adipocyte specific antigens (ASA), adipocyte plasma membranes (AH4) 
and hepatocyte plasma membranes (HPM) were separated by SDS PAGE 
and transferred to nitrocellulose and binding of early and late bleeds 
of A/S 83 to transferred proteins was detected, as described in 
Section 2.11. Proteins mentioned in the text have been labelled 
by P, followed by the approximate molecular weight in kD.
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4.2.3 Discussion
The reduction in the in vivo effects of late bleeds of A/S 83, 
compared with earlier bleeds, may be due, either to differences in 
the immunogen used to boost the sheep prior to bleeding, or to 
differences in the response of the sheep to the same immunogen.
The bleeds tested were separated by at least 18 months and the 
APM were prepared up to a month before immunisation. Outbreeding of 
the Wistar rat colony used to provide the adipocytes may have 
resulted in differences in the expression of adipocyte surface 
antigens, particularly highly polymorphic proteins, such as those 
encoded by the Major Histocompatibility Complex (MHC). However, the 
differences between the 2 bleeds of A/S 83 were detected using rats 
likely to be of similar genetic composition to those used to provide 
the immunogen for boosting the sheep prior to obtaining the late 
bleed. The differences between the 2 bleeds, therefore, were not 
likely to be entirely due to differences in the immunogen. Western 
blotting of the 2 different bleeds against ASA showed that late A/S 
83 bound more strongly to an 85 kD protein than early A/S 83 (Fig. 
4.2) suggesting that this protein may have been expressed at a higher 
frequency on APM used to boost the late bleed, compared with those 
used for early immunisations (Fig. 4.2).
Studies of mitogen responsiveness and T lymphocyte-dependent 
and T lymphocyte-independent immune responses in humans, rats and 
mice have shown that B cell responses decline with age (Makinodan and 
Kay, 1980). A decline in secondary immune responses with age has 
been demonstrated, characterised by decreases in antibody avidity and 
selective losses of IgG-producing cells (Goidl, Innes and Webster,
1976). This decline was thought to be due to specific suppression or
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defective T cell help (Segre and Segre, 1976; Krogsrud and Perkins,
1977). An increase in the production of suppressive anti-idiotypic 
antibodies in aged animals has also been demonstrated (Goidl, 
Thorbecke, Webster, and Siskund, 1980; Szewezyuk and Campbell,
1981). Since the treatment of rats with a mixture of early and late
A/S 83 induced an anti-fat response of a greater magnitude than early 
A/S 83 alone, suppressive anti-idiotypic antibodies were unlikely to 
be responsible for the reduced in vitro and in vivo effects of late 
A/S 83 (Table 4.2).
Late A/S 83 was as cytotoxic in vitro against erythrocytes as 
early A/S 83, implying that the antiserum had not lost the ability to 
fix guinea pig complement (Table 4.1). However, when rat serum was 
used as a source of complement, neither early nor late A/S 83 showed 
measurable cytotoxicity (results not shown). Different classes or 
subclasses of immunoglobulin differ in their ability to fix 
complement (Borsos and Rapp, 1965). It is possible, therefore, that
an immunoglobulin class or subclass switch occurred, with time and
repeated immunisation of sheep 83, such that later bleeds of the 
antiserum were composed, predominantly, of a subclass of IgG unable 
to fix rat complement. Time did not permit this possibility to be 
examined.
4.2.4 Conclusions
1. Recent bleeds of A/S 83 did not reproduce the in vivo effects 
on food intake, body weight gain and adiposity of early bleeds. 
This did not appear to be due to the presence of suppressive 
antibodies in recent bleeds.
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2. Recent bleeds of A/S 83 had a lower titre or affinity of anti- 
(APM) antibodies than early bleeds, as shown by ELISA and 
Western blotting, possibly due to an age-dependent decline in 
the function of the immune system of the sheep used as 
antiserum donor.
4.3 A COMPARISON OF THE IN VITRO AND IN VIVO EFFECTS OF ANTISERA
RAISED AGAINST ADIPOCYTE, HEPATOCYTE AND ERYTHROCYTE PLASMA 
MEMBRANES AND ADIPOCYTE SPECIFIC ANTIGENS
4.3.1 Experimental
The following antisera were raised, in sheep, by S. Kestin at 
the Institute of Food Research (Bristol Laboratory), according to the 
method described in Section 2.4:
Antiserum Immunising antigen
A/S 164 Adipocyte plasma membranes (APM)
A/S 283 Adipocyte plasma membranes (APM)
A/S 361 Adipocyte specific antigens (ASA)
A/S 479 Hepatocyte plasma membranes (HPM)
A/S 217 Erythrocyte plasma membranes (EPM)
The results of immunisation of a sheep at the Hannah Research 
Institute with ASA suggested that this detergent solubilized 
preparation was not very immunogenic. Consequently, for the raising
of A/S 361, 250 /jg of ASA was conjugated to 250 /jg of rabbit serum
albumin (RSA) by co-incubating the 2 proteins with 50 //I of 0.5%
glutaraldehyde (EM grade, Sigma, Poole, Dorset) for 30 minutes at 
22° C. Three immunisations of the conjugated ASA, followed by 2
immunisations with ASA alone, were performed.
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Antibody binding of all the antisera described above was 
measured, by ELISA, to the following antigens: adipocyte plasma
membranes (APM), hepatocyte plasma membranes (HPM), kidney plasma 
membranes (KPM), erythrocyte plasma membranes (EPM), brain membranes 
(BM), adipocyte specific antigens (ASA), myelin basic protein (from 
rabbit brain, Sigma Chemical Co., Poole, Dorset) and sphingomyelin 
(from bovine brain, Sigma Chemical Co., Poole, Dorset). Coating of 
plates with sphingomyelin was performed by dissolving the lipid in a 
solution of 10% chloroform in methanol. 100 /j1 of 10 //g/ml
sphingomyelin was added to each well and the solvent allowed to 
evaporate at 37° C. Binding of A/S 83 to interscapular brown 
adipocyte plasma membranes, prepared by the same method as white 
adipocyte plasma membranes, was also measured.
ASA were characterised by SDS PAGE, using carbonic anhydrase, 
ovalbumin, BSA, phosphorylase b, |3 galactosidase and myosin (Sigma 
Chemical Co., Poole, Dorset) as molecular weight markers. APM, 
prepared by digestion of adipose tissue in the presence of BSA and by 
homogenisation of the tissue in the absence of BSA, and HPM were also 
characterised by SDS PAGE. Western blotting of all the antisera 
against APM, ASA and HPM was performed. Antibody binding of all the 
antisera to BSA, rat albumin and APM prepared in the presence and 
absence of BSA was compared, by ELISA.
Cytotoxicity against erythrocytes and adipocytes of all the 
antisera was measured, according to the method described in Section 
2.7. In addition, cytotoxicity against erythrocytes in the presence 
of guinea-pig, sheep and rat complement was compared. The effects of 
coating ELISA plates with antigen using poly-L-lysine (see Section 
2.6.1) and the effects of temperature on antibody binding to EPM were 
also examined, as described in the Results Section.
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Each of the antisera described above were tested in vivo by 
injecting female Wistar rats, weighing 120-140 g, intraperitoneally 
with 1 or 2 ml of antiserum at 09.00 h to 11.00 h, for 4 consecutive 
days. Some antisera showed anaesthetic-like effects in some animals 
and, where this persisted, the treatment was discontinued and the 
affected animal killed. The remaining rats were killed 6 days after 
treatment and examined, as described in the previous Section.
4.3.2 Results
The antibody binding of A/S 83 to ASA, BAT, HPM and KPM was 
between 20 and 30% of the anti-(APM) binding, assuming that all the 
antigens bound equally well to micro-titre plates (Fig. 4.3). The 
antibody binding to EPM and BM was less than 10% of the anti-(APM) 
binding. Relative antigen abundances of A/S 83 against HPM and BAT 
were over 90% of that against APM, while antigen abundances against 
ASA, KPM and BM were between 55 and 70% of that against APM. The
antigen abundance against EPM was 37% of that against APM. Little or
no antibody against myelin basic protein or sphingomyelin could be 
detected, although there were no positive controls for these antigens 
(results not shown).
Antibody binding and antigen abundances of the other antisera 
tested were, for the most part, less than those of A/S 83 against all 
the antigens tested (Fig. 4.4 and 4.5). However, there were some 
exceptions. A/S 164 and 283 (anti-(APM)) showed twice the binding to 
APM of A/S 83. A/S 164 and A/S 361 (anti-(ASA)) showed about twice 
the binding to ASA of A/S 83. A/S 479 (anti-(HPM)) and A/S 217
(anti-(EPM)) showed about 8 times and 3 times, respectively, the 
binding to HPM of A/S 83. A/S 283 (anti-(APM)) and A/S 479
Fig. it.3- The tissue specificity of A/S 83, 
as determined hy ELISA
Antibody activity of A/S 83 was measured, by ELISA, against adipocyte 
plasma membranes (APM), adipocyte specific antigens (ASA), hepatocyte 
plasma membranes (HPM), kidney plasma membranes (KPM), erythrocyte 
plasma membranes (EPM), brain membranes (EM) and brown adipose tissue 
membranes (BAT). Relative antibody binding and relative antigen 
abundance were determined as described in Section 2.6.3.
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(anti-(HPM)) showed 2.3 and 1.6 times the anti-(KPM) binding of A/S 
83. The greatest reductions in antibody binding, compared with A/S 
83, included those of A/S 479 (anti-(HPM)) and A/S 217 (anti-(EPM)) 
to APM and ASA. A/S 479 showed no binding to ASA and only 5% of the 
binding of A/S 83 to APM, while A/S 217 showed about 15% of the 
binding of A/S 83 to APM and ASA. A/S 164 and 283 (anti-(APM)) and 
A/S 361 (anti-(ASA)) showed less than 7% of the binding to EPM of A/S 
83. No antigen abundance of any antiserum against any antigen tested 
was greater than that of A/S 83.
An outline of the preparation of the ASA, using 3 affinity
columns, was given in Chapter 2 (see Fig. 2.2). Table 4.3 
summarizes the performance of the affinity columns used to prepare
the rat ASA. Only 3% of the IgG fraction of A/S 83 was bound by the
APM column, resulting in the bound fraction being enriched in 
anti-(APM) activity by a factor of 3.4, compared with the fraction 
added to the column. 33% of this enriched fraction was bound by the 
HPM, KPM, and EPM column and the fraction that did not bind to this 
column contained less than 2% of the anti-(HPM) activity of the 
fraction added to the column. Binding to KPM and EPM was similarly 
reduced in the unbound fraction (results not shown). This apparently 
adipocyte specific fraction was used to prepare a third affinity 
column which bound approximately 5% of the total solubilized APM 
protein added.
SDS PAGE of HPM, APM and ASA showed that APM consisted of at 
least 20 major polypeptides of molecular weights varying from 35 to 
200 kD (Fig. 4.6). The ASA preparation was greatly enriched in 6 
major polypeptides of apparent molecular weights of approximately 53, 
59 (a doublet), 72, 85 and 96 kD, while also including very small
Tabl© 4.3. The performance of affinity columns 
used for the preparation of adipocyte specific antigens
ADIPOCYTE PLASMA MEMBRANE COLUMN
IgG binding 
capacity
mg.antibody bound per mg 
membrane protein on column 0.49
mg.antibody bound per mg.added IgG 0.031
Purification 
factor (fold)
Anti-(APM) activity of bound 
IgG vs. initial IgG 3.4
NON-ADIPOCYTE PLASMA MEMBRANE COLUMN
IgG binding 
capacity
mg.antibody bound per mg 
membrane protein on column 0.004
mg antibody bound per mg.added IgG 0.33
Purification 
factor (fold)
anti-(HPM) activity of 
unbound IgG vs. added IgG
<0.02
ADIPOCYTE SPECIFIC ANTIBODY COLUMN
Membrane
binding
mg. antigen bound per mg IgG 
on column
0.02®
capacity
mg antigen bound per mg.added 
membrane protein
0.050
The affinity columns were used to prepare adipocyte specific agaritigpeos 
according to the method summarised in Fig. 2.2. IgG binding capacity 
of affinity columns was measured where that amount of antibody fBrat 
gave maximum binding to the column was added. Purification factors 
were calculated by comparing the relative antibody binding to tftne 
column ligand pec mg, of antibody in added, bouod and iMtamnd 
fractions, by ELISA,
Fig. U.6. Polyacrylamide gel electrophoresis 
of adipocyte and hepatocyte plasma membranes 
and adipocyte specific antigens
HPM APM ASA
Adipocyte specific antigens (ASA), adipocyte plasma membranes (APM) 
and hepatocyte plasma membranes (HPM) vere separated by SDS PAGE 
and stained with Coomassie blue, as described in Section 2.10.
Ill
amounts of 4 further polypeptides. The HPM consisted of more then 35 
major polypeptides of a similar molecular weight range to that of 
APM.
Difficulties were experienced in the interpretation of Western 
blots, as the same dilution of each antiserum was used for detection 
of protein bands, resulting in widely differing intensities of colour 
development of individual blots. This problem could not be overcome 
by varying the time for which the blot was incubated in the substrate 
responsible for colour development, as increasing the length of this
incubation resulted in higher levels of background staining while not
greatly increasing the intensity of the signal. Consequently 
recognition of protein bands has been classified on a scale ranging
from +++, where bands appear black in the photographs, to -, where
bands are either not visible or are just visible as a very faint 
discoloration of the photograph. Dark, mid- and light grey bands are 
represented by ++, + and ± respectively, ± representing a band that 
was only very weakly recognised. The number of bands of the APM and 
HPM recognised, at least weakly, by the different anti sera varied as 
follows (see Figs. 4.7, 4.8):
APM HPM
A/S 83 (anti-(APM)) 21 9
A/S 164 (anti-(APM)) 11 8
A/S 283 (anti-(APM)) 8 5
A/S 361 (anti-(ASA)) 9 -3
A/S 217 (anti-(EPM)) 2 5
A/S 479 (anti-(HPM)) 4 12
No bands of the APM were clearly recognised by any antiserum 
that were not also recognised by A/S 83. Only A/S 479 and A/S 217
Fig- h.J. Antibody binding to adipocyte 
and hepatocyte plasma membranes 
and adipocyte-specific antigens 
by antisera raised against adipocyte plasma membranes, 
as determined by Western blotting.
Abbreviations and methods as for Fig- U.2.
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Fig. U.8. Antibody binding to adipocyte 
and hepatocyte plasma membranes 
and adipocyte-specific antigens 
by antisera raised against hepatocyte and erythrocyte plasma membranes
and adipocyte specific antigens, 
as determined by Western blotting
Abbreviations and methods as for Fig. h.2
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clearly recognised HPM protein bands that were not also recognised by 
A/S 83.
There was also variation in the binding of different antisera 
to ASA, both in the total number of bands recognised and in which 
bands were recognised. In the following table, proteins have been 
given the letter P, followed by their molecular weight in kD and 
recognition of each band has been analysed using the scale described 
above. P59 was not recognisable as a doublet on any Western blots and 
so is referred to as a single band.
COMPONENTS OF THE ASA
P96 P85 P72 P59 P53
A/S 83 (anti-(APM)) +++ + +++ - -
A/S 164 (anti-(APM)) +++ - + - -
A/S 283 (anti-(APM)) + - + - +
A/S 361 (anti-(ASA)) +++ ++ +++ ++ ++
A/S 217 (anti-(EPM)) - +++ - -
A/S 479 (anti-(HPM)) - - + + +
Ini addition to the 5 protein bands shown above, A/S 361
recognised at least 5 other bands of the ASA, some of which were
visible as very minor components of the ASA by SDS PAGE. A/S 217
also bound to an ASA protein not clearly recognised by any of the
other antisera and not clearly visible by SDS PAGE of the ASA.
Similarly A/S 164 bound to an ASA protein with an approximate 
molecular weight of 110 kD, not visible by SDS PAGE. Unfortunately 
pre-immune serum was not available for any of the antisera tested, 
but pooled non-immune sheep serum showed no binding to APM, HPM or 
ASA when the antigens were added directly to nitrocellulose and then 
treated in the same way as the Western blots described above.
113
SDS PAGE of APM (prepared after digestion of whole adipose 
tissue in the presence of BSA) showed that a major proportion of the 
APM preparation consisted of a protein with electrophoretic mobility- 
identical to that of BSA (Fig. 4.9). None of the antisera tested 
showed a significant anti-(BSA) response, while A/S 361 (anti-(ASA)) 
showed a small response to rat albumin (Table 4.4). There was little 
difference between the binding to APM, prepared in the presence or in 
the absence of BSA, of any of the antisera, with the exception of A/S 
217 (anti-(EPM)) which showed 5 times the antibody binding to APM, 
prepared in the absence of BSA, compared with APM prepared in the 
presence of BSA.
Relative cytotoxicity of different antisera was determined by 
comparing the dilutions of antisera required to lyse a given number 
of target cells, as shown by the amount of haemoglobin or LDH 
released for erythrocytes and adipocytes respectively. A/S 83, 283 
and 164 (anti-(APM)) and A/S 361 (anti-(ASA)) showed similar levels 
of cytotoxicity against adipocytes, while A/S 479 (anti-(HPM)) and 
A/S 217 (anti-(EPM)) showed about 40% and 15% of the relative 
cytotoxicity respectively, of A/S 83 (Fig. 4.10). Total cytolysis 
was not achieved by any of the antisera tested, even at antiserum 
concentrations of 15%
A/S 283, 164 and 361 showed more than 10 times the relative
cytotoxicity of A/S 83, A/S 479 and A/S 217 against erythrocytes in 
the presence of guinea-pig complement (Fig. 4.11). While A/S 283, 
164 and 361 achieved total lysis of erythrocytes at 3% antiserum, A/S 
83 appeared capable of lysing only 40% of the total erythrocyte 
population since both 3% and 15% antiserum lysed only 40% of the 
erythrocytes. There was little difference in the cytotoxicity of A/S
Fig. h.9. Polyacrylamide gel electrophoresis 
of adipocyte plasma membranes prepared in adipocytes 
isolated in the presence of BSA
BSA RSA APM
Adipocyte plasma membranes were prepared from adipocytes isolated 
from adipose tissue by collagenase digestion in the presence of BSA, 
separated by SDS PAGE and stained with Coomassie blue, as described 
in Section 2.10. BSA and rat serum albumin (RSA) are included for 
comparison.
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Fig. 4.10. In vitro cytotoxicity against adipocytes 
of antisera raised against adipocyte, 
hepatocyte and erythrocyte plasma membranes 
and adipocyte-specific antigens
Cytotoxicity assays were performed as for Fig. 4.1. Three 
anti-(adipocyte plasma membrane) antisera, A/S 83 (filled circles) 
A/S l64 (filled triangles) and A/S 283 (filled squares) are shown 
in (a). A/S 83 (filled circles), an anti-(adipocyte-specific antigen) 
antiserum, A/S 36l (open circles), an anti-(hepatocyte plasma 
membrane) antiserum, A/S 479 (open squares) and an anti-(erythrocyte 
plasma membrane) antiserum, A/S 271 (open triangles) are shown in
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Fig. U.ll. In vitro cytotoxicity against erythrocytes 
of antisera raised against adipocyte, 
hepatocyte and erythrocyte plasma membranes 
and adipocyte-specific antigens
Cytotoxicity assays were performed as for Fig. ^.1. Symbols as for 
Fig. 10.
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217 (anti-(EPM)) against erythrocytes, in the presence of guinea-pig,
sheep or rat complement (Fig. 4.12). The cytotoxicity of all the
other antisera tested, against erythrocytes, was considerably reduced 
in the presence of rat complement, compared with guinea-pig or sheep 
complement. In the presence of sheep complement A/S 83, at low 
concentations, showed greater cytotoxicity against erythrocytes than 
A/S 283, 164 or 361 but, at high concentrations, A/S 83 was able to
lyse only 40-50% of erythrocytes, while A/S 283, 164 and 361 lysed
75% of the same number of erythrocytes at the same anti serum 
concentration.
The only antiserum of those described above able to
haemagglutinate erythrocytes was A/S 217 (anti-(EPM)) (results not 
shown). Relative differences in antibody binding to EPM of all the
antisera tested was the same, whether the ELISA was performed at
37° C or 22° C (Fig. 4.13). Coating EPM to ELISA plates using 
poly-l-lysine increased the apparent binding of A/S 164 and 361, 
compared with A/S 83, but A/S 83 still showed 10 times the binding to 
EPM of A/S 164 and 361 (Fig. 4.13).
The in vivo administration of 1 ml of A/S 164, 283 or 361
caused anaesthetic-like effects and the adoption of strange postures, 
indicative of hindlimb weakness, in some rats. These symptoms were 
evident within 2-5 minutes of injection and lasted for 30 minutes to 
a few hours after injection. The rats did not appear to be in pain 
and showed no signs of sensitivity in the area of the injection. When 
stimulated, by handling, all symptoms disappeared, thus mimicking the 
outward signs of onset of anaesthetic. The dose of antiserum for 
these antisera was not increased to 2 ml because of these effects but 
2 ml of A/S 83 and 3 ml of A/S 217 and A/S 479 caused only slight 
anaesthetic-like effects.
Fig. h.12. A  comparison of the ability of complement 
from different species to support the cytotoxicity 
against erythrocytes of antisera raised against adipocyte 
and erythrocyte plasma membranes and adipocyte specific antigens
Cytotoxicity assays were performed as for Fig. U.l in the presence 
of guinea-pig complement (a), sheep complement (b) or rat complement 
(c). Symbols are as for Fig. U.10.
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Fig- ^.13- The effects of temperature 
and method of coating antigen to ELISA plates 
on apparent anti—(erythrocyte plasma membrane) binding 
of different antisera, as determined by ELISA
Erythrocyte plasma membranes vere adsorbed onto uncoated ELISA plates 
(a and b) or poly-l-lysine coated plates (c), as described in Section 
2-6.1- The ELISA was performed at 22° C (a and c) or at 37° C (b). 
Symbols are as for Fig. 4-10-
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Administration of all the antisera caused a drop in food intake
and body weight gain which was most severe in A/S 83-treated rats and
least severe in rats treated with A/S 217 and A/S 479 (Table 4.5). 
All the anti-(APM) antisera caused a significant reduction in the dry 
weight of parametrial adipose tissue of about 50% and significant 
reductions in the % dry weight of the tissue (Table 4.5). Visual 
evidence of lymphocytic infiltration of parametrial adipose tissue 
was greater in A/S 283- and 83-treated rats than in A/S 164-treated 
rats. The dry weight of parametrial adipose tissue of A/S 
361-treated rats was not significantly reduced but the % dry weight 
of the tissue was significantly reduced and lymphocytic infiltration 
of the tissue could be seen in most animals, although this was not as
great as in A/S 83- and A/S 283-treated rats. No effects on adipose
tissue could be seen following treatment with A/S 217 or A/S 479.
While A/S 83, A/S 361, A/S 217 and A/S 479 caused no gross
abnormalities to the liver, A/S 164 and A/S 283 caused abnormalities 
of the liver, characterised by fusion of liver lobes, a rounded
appearance of the liver lobe margins and, in some cases, an
abnormally pale colour. Histology, performed at the Veterinary 
Pathology Laboratory of the West of Scotland College of Agriculture, 
reported an unidentified cellular infiltration of the tissue. Recent 
experiments in this laboratory have shown that the administration of 
6 ml of A/S 479 (anti-(HPM)) caused gross liver abnormalities, but 
had no effect on adipose tissue (results not shown).
Table 4.5. In vivo effects of antisera raised against adipocyte, 
hepatocyte and erythrocyte plasma membranes 
and adipocyte specific antigens
Female Wistar rats were injected intraperitoneally with 1, 2 or 3 ml 
of antiserum for 3 or 4 consecutive days, as indicated. Rats were 
sacrificed 6 days after the first treatment and infiltration of 
adipose tissue and liver abnormalities were scored on a scale of 0-3, 
as indicated by yellow nodules and disrupted liver lobes 
respectively. ***P<0.001, *P<0.01 compared with controls (Student's
unpaired t test)
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4.3.3 Discussion
4.3.3.1 A comparison of 3 antisera raised against adipocyte plasma 
membranes
Following the discovery that recent bleeds of sheep 83 did not 
reproduce the in vivo effects of earlier bleeds, new antisera were 
raised against APM, in the hope of providing an anti serum that had in 
vivo effects that mimicked those of early bleeds of A/S 83. The 
results of ELISA suggested that A/S 164 and 283 showed twice the 
binding to APM of A/S 83, but did not recognise as many antigenic 
determinants as A/S 83 (Fig. 4.4). Western blotting suggested that 
A / S  83 bound more strongly to APM than A/S 164 and 283, as well as 
binding to more APM proteins (Fig. 4.7). These conflicting results 
emphasize the caution required in the interpretation of the results 
of ELISA and Western blotting. Both techniques measure a combination 
of titre and affinity but, since the binding of antisera to antigen 
was performed under different conditions (for 2 hours in ELISA, 
compared with 16 hours in Western blotting) the relative influences 
of titre and affinity on the final result may vary in the 2 
techniques. A/S 83 may consist of a higher proportion of low 
affinity antibodies than A/S 164 or 283, and such antibodies may be 
able to bind more effectively given the longer incubation period in 
Western blotting. The technique of Western blotting relies on the 
retention of antigenicity of proteins after denaturation and running 
on SDS polyacrylamide gels under reducing conditions. The results 
described above show that some proteins did retain antigenicity under 
such conditions, but it is not known how many antigenic determinants 
Of APM, HPM or ASA were lost in this process. Binding to proteins 
resistant to solubilization by SDS would not be detected by Western
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blotting. While, in ELISA, the native proteins are immobilized on 
the solid phase support, different proteins may vary in efficiency of 
adsorption to FVC wells and some adherent proteins may be orientated 
in such a way as to render some epitopes inaccessible to antibody. 
Quantitation of the results of ELISA and Western blotting also 
presents difficulties. The quantitation of the results of ELISA was 
discussed in detail in Section 2.6.3. It should be noted that, for 
many antisera, dose-response curves obtained by ELISA did not plateau 
at high antiserum concentrations and so the values shown for antigen 
abundance give only an indication of the relative number of epitopes 
recognised by different antisera. Quantitation of the results of 
Western blotting had to be performed by eye as densitometrical 
scanning of the blots was not possible.
Despite the possible limitations of ELISA and Western blotting, 
it was clear that all 3 anti-(APM) antisera bound to components of 
the adipocyte plasma membrane. This conclusion was supported by the 
demonstration of in vitro cytotoxicity against isolated adipocytes 
(Fig. 4.10) and in vivo fat-reducing properties of all 3 antisera 
(Table 4.5). A/S 83, 283 and 164 showed similar levels of in vitro 
cytotoxicity and each caused a reduction in parametrial fat pad 
weight of a similar magnitude 6 days after treatment. A/S 164 
induced a lesser degree of lymphocytic infiltration of the tissue 
than did A/S 83 or 283. This, perhaps, suggests that lymphocytic 
infiltration was not the only or the direct cause of the reduction in 
fat pad mass, but more observations are required before such a 
conclusion can be drawn. However, 2 undesirable side effects of A/S 
164 and 283 led to a reluctance to pursue further studies with these 
antisera. While mimicking the effects of A/S 83 on adipose tissue.
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A/S 164 and 283 caused anaesthetic-like effects immediately after 
treatment, seen only to a much lesser extent in A/S 83-treated rats, 
as well as gross abnormalities of the liver, never seen in A/S
83-treated rats. Non-immune sheep serum, from a sheep of the same 
breed and from the same establishment as those from which A/S 164 and 
283 were obtained, did not have these effects. The cause was 
unlikely, therefore, to have been the presence of toxins or microbial 
infection in A/S 164 or 283 and is more likely to have been the 
presence of antibodies directed against antigens not recognised, or 
recognised only weakly, by A/S 83. Recent experiments in this 
laboratory have shown the anaesthetic-like effects to be dependent on 
the presence of complement. Complement activation results in the 
release of the anaphylatoxins, C3a and C5a and the anaesthetic-like 
effects shared some of the properties of anaphylactic shock. 
However, the administration of cobra venom factor, which induces 
massive complement activation, did not have anaesthetic-like effects.
The speed of onset of the A/S 164- and 283-induced anaesthetic­
like effects suggests that interference with synaptic transmission, 
in a way similar to that caused by general anaesthetics, might have 
occurred. As adipose tissue is innervated, it is possible that the 
APM preparation, used for raising of the anti sera, could have been 
contaminated with nervous tissue. Antibodies within these antisera 
may, therefore, have been directed against components of APM that 
cross-react with nervous tissue or against antigens specific for 
nervous tissue. One of the most extensively studied autoimmune 
diseases associated with the nervous system is Myasthenia gravis 
(MG), characterised by circulating antibodies to the acetylcholine 
receptor (Ach-R). The injection of antibodies to the Ach-R into
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experimental animals induces symptoms, such as muscle fatigue, 
similar to those seen in patients with MG. The mechanism of action 
of the antibodies in unclear, but blocking of the Ach-R, 
complement-mediated lysis of the post-synaptic membranes and 
cross-linking of Ach-R, increasing the rate of receptor
internalization, have all been proposed (Newson-Davis, 1981). It is 
possible that A/S 164 or 283 bound to the Ach-R or some other 
component of the post-synaptic membrane and, by one of these 
mechanisms, interfered with nervous stimulation of muscle. It is, 
clearly, of importance to examine the binding of these antisera to 
the muscle cell surface. Acetylcholinesterase, found on the
post-synaptic membrane, is a major component of erythrocyte 
membranes. Since A/S 164 and 283 were highly cytotoxic against 
eythrocytes, this enzyme might be a useful starting point in the 
examination of binding to muscle membrane protein.
Antibodies directed against components of the central nervous 
system can also occur. Multiple sclerosis (MS), a demyelinating 
disease, is characterised, in most cases, by anti-(myelin) 
antibodies. Experimental autoimmune encephalomyelitis (EAE), 
proposed as a model of MS, is induced by immunisation against Myelin 
basic protein (MBP). In its acute form, animals suffer weight loss, 
develop hindleg weaknesses and ascending paralysis (Kallen and 
Nilsson, 1986). Although EAE is characterised by antibodies to MBP, 
the pathogenesis of the disease appears to be T-cell rather than 
antibody-mediated (Silberg and Swanborg, 1986) and so, despite the 
similarities of some of the symptoms to the immediate effects of A/S 
283 and 164, it is not a good model for the effects of passive 
immunisation. No significant responses of A/S 164 or 283 against
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sphingomyelin or MBP could be measured by ELISA. Both anti sera 
recognised antigens of brain tissue, although antibody binding to 
brain membranes of A/S 164 and 283 was less than that of A/S 83 (Fig.
4.4). Under normal circumstances, antibodies cannot cross the 
blood-brain barrier. However, circulating immune complexes can 
deposit in the choroid plexus in the same way as in the glomerulus 
(Lampert and Oldstone, 1973). Theoretically immune complex 
deposition in the choroid plexus could activate complement, causing 
damage to the blood-brain barrier and leakage of anti-(brain) 
antibodies into the brain parenchyma. There is some evidence of
increases in albumin and IgG levels in the cerebrospinal fluid of
animals with immune complex disease (Harbeck, Hoffman, Hoffman and 
Shucard, 1979). It is difficult to envisage entrance of antibodies 
into the bloodstream quickly enough to mediate the anaesthetic-like 
effects through immunological attack of the brain. However,
antibodies may bind to that part of the central nervous system 
directly responsible for innervation of the lower limbs.
The liver damage seen in A/S 283- and 164-treated rats shares 
some characteristics with that seen in patients suffering from 
autoimmune chronic active hepatitis (CAH). This disease is
characterised by infiltration of the liver with mononuclear cells, 
which starts in the portal tract and spreads into the liver 
parenchyma, disrupting the limiting plate of periportal hepatocytes. 
The parenchyma tends to be subdivided by fibrous septa accompanying 
the inflammation and this, together with the appearance of 
regenerating hepatocytes, leads to the development of cirrhosis 
(Vento and Eddleston, 1987). Histological examination of the livers 
of A/S 164-treated rats showed a cellular infiltration of the tissue,
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although the nature of these cells was not clear. The edges of the 
liver lobes were disrupted and the gross appearance of the liver was 
reminiscent of that of regenerating livers following partial 
hepatectomy. Several lines of evidence suggest that antibodies 
directed against surface membrane antigens may contribute towards the 
liver damage seen in CAH. The first is the demonstration of liver- 
directed autoantibodies in the serum of CAH patients. Incubation of 
the serum from these patients with peripheral blood lymphocytes of 
normal subjects resulted in cytotoxicity against hepatocytes, which 
has lead to the suggestion that ADCC may contribute towards liver 
damage in CAH (Vento and Eddleston, 1987). In addition, the
immunisation of experimental animals with crude liver proteins can 
induce the production of autoantibodies against the liver and
inflammatory effects similar to those seen in CAH (Watanabe et al., 
1987). The precise nature of the target antigens on the hepatocyte 
surface for damaging immune reactions has not been identified. A/S 
164 and 283 are unlikely to bind to liver specific antigens. The 2 
antigen pareparations that have received most attention in studies of 
liver-associated autoimmune diseses are liver specific protein and 
liver membrane antigen and both include organ-specific and non-organ- 
specific determinants (Frazer and Mackay, 1984). According to ELISA, 
the binding of A/S 283 and 164 to HPM was less than that of A/S 83,
which was devoid of apparent anti-(liver) activity in vivo. The
possibility that A/S 283 and 164 might bind to one or more liver 
membrane proteins, not recognised by A/S 83, was investigated by 
Western blotting (Fig. 4.7). No HPM polypeptide band, not bound by 
A/S 83, was clearly recognised by A/S 283 or 164 but, because of the 
limitations of this technique described above, this does not prove
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conclusively that such a protein does not exist. Unfortunately, 
preliminary efforts to obtain a viable hepatocyte population suitable 
for in vitro cytotoxicity assays were unsuccessful.
It is possible that the liver abnormalities seen in A/S 164- 
and 283-treated rats resulted, not from an anti-(liver) component of
the antiserum, but from non-specific effects of the presence of
circulating immune complexes. A major portion of the 
reticulo-endothelial system responsible for the uptake of circulating 
immune complexes resides in the Fc and C3b receptor-bearing Kupffer 
cells of the liver (Shogh, Blomhoff, Eskild and Berg, 1985). A/S 164 
and 283 showed a higher in vitro level of cytotoxicity against 
erythrocytes than A/S 83 (Fig. 4.10). If antibody coating or 
antibody-mediated cytolysis of erythrocytes occurred in vivo upon 
injection of A/S 164 or 283, such complexes would, in the presence of
complement, be rapidly taken up by the liver (Veerhuis, Krol, van Es
and Daha, 1986). The gross abnormalities seen in the liver may, 
therefore, be the result of gross overloading of the hepatic 
reticulo-endothelial system. CAH is characterised by hyper- 
gammaglobulinaemia and, in some cases, circulating immune complexes, 
but a direct causal link with the pathogenesis of the disease has not 
been demonstrated. Recent experiments in this laboratory 
demonstrated the in vivo effects of A/S 164 to be dependent upon the 
presence of complement but since complement increases the rate of 
hepatic uptake of particulate immune complexes (Veerhuis et al., 
1986), this does not resolve the question of whether anti-(liver) 
antibodies or non-specific clearance of antibodies and immune 
complexes was responsible for the liver damage.
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4.3.3.2 The characterisation of antisera raised against hepatocyte 
and erythrocyte plasma membranes and adipocyte specific 
antigens
The characterisation of antisera raised against HPM, EPM and 
ASA, both in vitro and in vivo, has yielded information on the true 
adipocyte specificity of the ASA, the possible causes of the liver 
abnormalities seen in A/S 283- and 164-treated rats and the role of 
adipocyte specificity in the fat-reducing properties of antisera in 
vivo.
The performance of the affinity columns used for the 
preparation of the ASA is summarised in Table 4.3. Only 3% of the 
IgG fraction of A/S 83 was bound by the APM column, which was less 
than would be expected for a high titre antiserum. Some antigenic 
components of the APM may have been resistant to Triton X-100 
solubilization or may have had reduced antigenicity after 
solubilizaton or binding to the affinity column. It is, therefore, 
possible that antibodies binding to adipocyte specific antigens were 
lost at this stage in the ASA preparation. The bound fraction
contained only 3.4 times as much anti-(APM) activity as the original
IgG fraction (per mg of protein) which further suggests that a 
significant proportion of the anti-(APM) activity of A/S 83 was not 
bound by the column and that there may have been non-specific
adsorption of protein by the column. Further purification of
anti-(APM) fraction on a column bearing non-adipocyte plasma 
membranes resulted in the isolation of antibodies from which more 
than 95% of the cross-reactivity with HPM, KPM and EPM had been 
removed. It was, therefore, hoped that this antibody fraction could 
be used for the purification of adipocyte specific antigens (ASA).
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The first indication that these antigens were not totally 
adipocyte specific came from ELISA of an antiserum raised against 
EPM, which showed that this anti serum recognised components of the 
ASA. When cross-reactivity with non-adipose tissues of an antiserum 
raised against ASA was examined by ELISA, it was found that, while 
the antiserum (A/S 361) was considerably more adipocyte specific 
than antisera raised against whole APM, antibody binding to HPM, EPM, 
KPM and BM was nevertheless detectable (Fig. 4.4). In order to 
determine which of the proteins of the ASA, if any, were adipocyte 
specific, binding of antisera raised against APM, ASA, HPM and EPM to 
the different components of the ASA was examined by Western blotting 
(Figs. 4.7, 4.8).
A/S 83 (anti-(APM)) did not, apparently, recognise the 2 lowest 
molecular weight components of the ASA, P59 and P53. This was, 
perhaps, surprising as the antibodies used to isolate the ASA were 
purified from A/S 83. It is possible that the antigenicity of P59 
and P53 had not been retained after denaturation and transfer onto 
nitrocellulose. If this were the case, however, other antisera might 
also not be expected to bind to these polypeptides, unless some 
epitopes on the protein were destroyed and others were not. A/S 361 
(anti-(ASA)) bound to all the major components of the ASA, including 
P59 and P53. A/S 361 may include antibodies of a higher titre or 
affinity against P59 and P53 than A/S 83. Immunoblotting at a single 
anti serum dilution does not allow determination of whether or not a 
protein is recognised, but only gives an indication of the strength 
of the response to particular proteins. If the ASA did contain
V/
proteins, not recognised by A/S 83, they may h^p been the result of 
non-specific adsorption of proteins to the affinity columns used in
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the ASA preparation or leeching of antibody from the ^epharose
affinity-support. Passage of solubilized APM down an affinity column 
bearing non-immune sheep IgG would give an indication of the 
potential for non-specific adsorption to the column. Time and the 
scarcity of APM material did not permit this important control 
experiment to be performed. In addition, since the purified ASA was 
of a greatly different composition to the APM material from which it 
was purified, it was assumed that non-specific adsorption was not a 
major problem. It is, however, possible that some APM proteins were 
adsorbed preferentially to sepharose or sheep IgG. A rabbit 
antiserum, raised against sheep IgG, recognised the ASA, when 
measured by ELISA, providing strong evidence for the contamination of 
the ASA with sheep IgG (results not shown). SDS PAGE of 
immunoglobulins, under reducing conditions, breaks intra-chain but 
not inter-chain disulphide bonds so, if sheep IgG constituted a
significant proportion of the ASA, a polypeptide of a molecular 
weight of 150 kD would be visible after SDS PAGE of ASA. Such a 
protein was not clearly visible by SDS PAGE, but Western blotting of 
A/S 361 against ASA did reveal a protein with a molecular weight of 
approximately 150 kD, suggesting that, in terms of percentage 
protein, sheep IgG constituted a very small part of the total ASA.
However, it is not known whether the intact sheep IgG molecule or
only part of it became detached from the affinity column following 
repeated washings in buffers of extreme pH. Unfortunately time did 
not allow Western blotting of an anti-( sheep IgG) antiserum against 
the ASA to be performed, which might have shown whether P59 or P53 
were components of the sheep IgG molecule. An alternative 
explanation for the apparent lack of recognition of some components
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of ASA by A/S 83 is that incomplete solubilisaton of APM may have 
resulted in the co-purification of non-specific antigens (such as P59 
or P53) with adipocyte specific antigens.
A/S 479 (anti-(HPM)) recognised P59 and P53, suggesting that
these polypeptides were non-adipocyte specific components of the ASA, 
rather than sheep IgG, resulting either from non-specific adsorption 
to the affinity column or from incomplete solubilisation of APM from 
which ASA were prepared. Since the recognition of these proteins by 
A/S 479 was weak, they may only be minor components of HPM and, as 
such, may still be 'useful' antigens of a 'relatively specific' 
nature. It should also be noted that different antisera that bound to 
proteins of similar electrophoretic mobility may not have recognised 
the same protein. Two-dimensional gel electrophoresis would seem an 
appropriate way to further this examination.
P72 was apparently recognised by anti-(APM), anti-(ASA),
anti-(HPM) and anti-(EPM) anti sera. Rat albumin has a molecular
weight of 68 kD, raising the possibility that P72 was albumin. Fig. 
4.8 shows that APM (prepared following digestion of adipose tissue in 
the presence of BSA) was heavily contaminated with BSA. This 
material was used to raise A/S 83, which was then used to purify the 
ASA. The ASA, however, were prepared exclusively from homogenised 
whole adipose tissue, in the absence of BSA. Contamination of the 
ASA with albumin would, therefore, have had to have been due to
contamination of APM with rat albumin. Table 4.4 shows that antibody 
binding of A/S 83 to both BSA and rat albumin were very poor.
Antibody components of A/S 83 that cross-reacted with liver (a tissue 
likely to have a higher albumin content than adipose tissue) were 
removed prior to preparation of the ASA. Any contamination of the
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ASA with albumin, therefore, is likely to have been due to 
non-specific adsorption on to the column. A/S 361 (anti-(ASA)) 
showed slightly higher binding to rat albumin than did A/S 83, but 
the ASA were conjugated to rabbit serum albumin for immunisation of 
sheep 361 and rabbit and rat albumin are likely to show antigenic 
cross-reactivity. Several of the antisera tested recognised a 
protein with a molecular weight of approximately 72 kD of HPM 
providing a further indication that this protein is not adipocyte 
specific. However, A/S 283 bound to P72 of APM and ASA, but did not 
apparently recognise a protein with a similar molecular weight of 
HPM. The liver polypeptide, therefore, may not have been the same 
protein as the P72 of APM and ASA.
Several groups have identified 2 prominant glycoproteins with
molecular weights of 74-84 and 88-100 kD by SDS PAGE of rat APM 
(Czech and Lynn, 1973; Avruch, 1976; Kawai and Spiro, 1977; Tume 
et al., 1985). It is possible that P85 and P96 were these 2
glycoproteins. Czech and Lynn (1973) suggested that these proteins 
constituted a large proportion of the protein on the exterior of the 
adipocyte surface, and so might be expected to be recognised strongly 
by antisera raised against APM.
P96 was strongly bound by anti-(APM) and anti-(ASA) antisera, 
but was apparently not recognised by anti-(EPM) and anti-(HPM) 
antisera and so may be a true adipocyte specific antigen. P85 was 
recognised weakly by A/S 83 and more strongly by A/S 361 
(anti-(ASA)), but again was not apparently recognised by anti-(EPM)
or anti-(HPM) antisera. The weak recognition of P85 by A/S 83 and 
the absence of recognition by other antisera may be because the 
protein had reduced antigenicity as a result of the procedure of
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Western blotting and so it is not possible to be entirely confident 
of the adipocyte specificity of this protein from these results.
Lee et al. (1986) have identified 3 adipocyte specific
'differentiation' antigens on the rat APM, with molecular weights of 
124, 92 and 59 kD. P85 and P59 may be the same polypeptides as Lee's 
92 and 59 kD polypeptides. There are several possible causes of the 
differences between the ASA described here and those of Lee et al. 
(1986). Both preparations were isolated using antisera raised against 
whole APM. However, the antigens used for immunisation were not 
identical. Al-jafari, Lee, Tume and Cryer (1986) and Thompson and 
Abraham (1979) found it necessary to condition isolated adipocytes 
for at least 3 h after enzymatic digestion of the tissue to allow 
restoration of surface antigens. In this laboratory, APM were 
prepared from freshly isolated cells, since antisera raised against 
this material showed strong anti-(adipocyte) activity, both in vitro 
and in vivo (Flint et al., 1985). These differences may relate to 
the amount of tryptic activity in the collagenase used for tissue 
digestion. The APM used here were isolated from female Wistar rats, 
while those of Lee were isolated from Hooded rats. Tume et al. 
(1985) have demonstrated differences in the polypeptide composition 
of APM of rats of different strains.
While it was obviously disappointing to find evidence of 
cross-reacting antigens in the ASA preparation, A/S 361, raised 
against ASA, was considerably more adipose tissue specific than 
antisera raised against whole APM. According to ELISA, while 
retaining 63% of the binding to APM, binding to HPM, EPM and brain 
membranes was reduced by more than 75% compared with A/S 83 (Fig.
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4.4). The only exception measured was the anti-(KPM) response, which 
was similar to that induced by immunisation with whole APM. These 
results suggest that, while the ASA were not 100% adipocyte specific, 
the majority of cross-reacting antigens had been excluded or reduced 
to levels such that their immunogenicity was reduced.
In the previous Section, liver abnormalities caused by the 
administration of 2 antisera raised against whole APM, A/S 283 and 
164, were described. It was proposed that these abnormalities might 
result, either from antibodies directed against components of the 
liver, or from overloading of the hepatic reticulo-endothelial system 
responsible for the clearance of immune complexes. The failure to 
demonstrate higher anti-(HPM) activity in A/S 283 and 164, compared 
with A/S 83 by in vitro assays provided evidence against the first 
possibility. However, in vitro assays have inevitable limitations and 
so it was hoped that an investigation of the in vivo effects on the 
liver of antisera raised exclusively against liver components and an 
antiserum devoid of reactivity against liver might help to resolve 
the cause of the effects of A/S 283 and 164 on the liver. If 
anti-(liver) antibodies were responsible, an antiserum raised against 
liver should induce similar or more severe liver abnormalities than 
A/S 283 and 164 and an anti serum raised against adipocyte specific 
antigens only should not cause liver abnormalities. These 2 
conditions were satisfied, in that A/S 479 (anti-(HPM)), when 
administered at a sufficiently high dose, reproduced the effects of 
A/S 283 and 164 on the liver and A/S 361 had no apparent effect on 
the liver. However, A/S 479 cross-reacted with and was cytotoxic 
against erythrocytes in vitro. The anti-(liver) effects of the 
antiserum may have been due to overloading of the hepatic
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reticulo-endothelical system with circulating immune complexes 
composed of antibody-coated erythrocytes or of antibody and another 
target cell or protein, rather than due to anti-(liver) antibodies. 
More A/S 479 than A/S 283 and 164 was required to produce the same 
effect on the liver, although A/S 479 apparently bound more strongly 
and to more HPM proteins than A/S 283 and 164, as suggested by ELISA 
and Western blotting (Figs. 4.5, 4.8). This, coupled with the fact 
that A/S 361 did show some anti-(HPM) activity in vitro but no 
anti-(liver) effects in vivo, suggests that anti-(HPM) antibodies may 
not have been the only factor involved in the induction of liver 
abnormalities in A/S 283- and 164-treated rats. It should also be 
noted that A/S 479 probably bound to liver-specific proteins that 
would not be recognised by A/S 283 or A/S 164. Consequently, despite 
the apparent similarities in the gross appearance of livers from A/S 
479-, 283- and 164-treated rats, different mechanisms may have been
responsible for the abnormalities.
The presence of liver abnormalities in the absence of an effect 
on adipose tissue in A/S 479-treated rats and the absence of liver 
abnormalities in the presence of an effect on adipose tissue in A/S 
361- and 83-treated rats strongly suggests that liver abnormalities 
were not a consequence of the release of lipid induced by 
immunological attack of adipose tissue.
While A/S 361 had no apparent effect in vivo on the liver, 
increasing the adipocyte specificity of the antiserum did not remove 
the immediate anaesthetic-like effects or the decline in food intake 
and body weight gain on the first day of treatment, although both 
effects were of a reduced severity, compared to those seen with some 
antisera raised against whole APM. A decline in food intake was
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observed in all rats treated with antisera that had fat-reducing 
properties and so may be an inevitable consequence of fat 
mobilization, possibly mediated by a rise in serum free fatty acids 
or triglycerides (see Fig. 3.15). A/S 83 induced only very mild 
anaesthetic-like effects and this antiserum had very potent 
fat-reducing properties, implying that the anaesthetic-like effects 
are not an inevitable consequence of treatment with a fat-reducing 
antiserum. As antibodies used to isolate the ASA had only been 
preadsorbed against HPM, EPM and KPM, the antigens to which 
antibodies responsible for the anaesthetic-like effects bind, may not 
be present on these tissues. It is, clearly, of great importance 
that this antigen or antigens should be identified.
Despite the demonstration of cytotoxicity against adipocytes in 
vitro of a similar magnitude to that seen with A/S 83, A/S 361 showed 
variable effects on adipose tissue in vivo (Table 4.5). In most 
rats treatment with A/S 361 induced lymphocytic infiltration of 
adipose tissue and a reduction in parametrial fat pad weight, but the 
effects were not as great or as consistent as those caused by 
treatment with antisera raised against whole APM. It is possible 
that, since A/S 361 bound to a restricted number of antigens on the 
adipocyte surface, a reduced number of antibodies bound to adipose 
tissue in vivo, resulting in reduced complement activation and, 
hence, reduced cytotoxicity or reduced production of chemotactic 
factors for phagocytic cells, compared with A/S 83, 164 and 283.
Anti sera raised against HPM and EPM had no effects on adipose 
tissue in vivo, suggesting that adipocyte specific components are an 
essential part of an anti serum with in vivo fat-reducing properties. 
However, the absence of an in vivo effect of any anti serum on a
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particular tissue may simply be because the dose administered was not 
sufficiently high.
4.3.3.3 Discrepancies between ELISA and in vitro cytotoxicity assays
Some of the limitations of ELISA and Western blotting were 
discussed in 4.3.3.1. In this section emphasis is placed on the 
limitations of both ELISA and in vitro cytotoxicity assays by 
comparing antibody binding to EPM with cytotoxicity against 
erythrocytes by different antisera.
Two anti-(APM) antisera, A/S 283 and A/S 164, showed equivalent 
levels of cytotoxicity against erythrocytes at antiserum dilutions of 
nearly 100-fold greater than A/S 83 (Fig. 4.11). However, the 
relative antibody binding and antigen abundances of A/S 283 and 164 
to EPM were nearly 100-fold less than those of A/S 83, as measured by 
ELISA (Fig. 4.13). An antiserum raised against erythrocytes showed 
intermediate cytotoxicity and antibody binding between A/S 283 and 
164 and A/S 83.
All ELIS As were performed using an anti-(goat IgG) second 
antibody. IgM is a far more effective activator of complement than 
IgG (see Section 1.4.1) and so cytotoxicity of A/S 283 and 164 may 
have been due to IgM antibodies which were not detected by ELISA. 
Time did not permit this possibility to be examined. ELISAs were 
performed at 22° C, while in vitro cytotoxicity assays were performed 
at 37° C. Low affinity antibodies tend to bind more effectively at 
low temperatures and so ELISA may measure low affinity antibodies 
that are not cytotoxic. This possibility was tested by comparing the 
results of ELISAs where antibody binding was performed at room 
temperature with those performed at 37° C (Fig. 4.13). While 
absorbances were higher in assays performed at 37° C than at room 
temperature, relative differences between antisera remained constant.
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The protein adsorbed to the ELISA plate may not have been a 
representative sample of the total EPM protein. It is possible that 
proteins, to which binding is important for mediating cytotoxicity, 
did not adsorb effectively to PVC wells. Poly-l-lysine was, 
therefore, used to coat ELISA plates in an attempt to adsorb more EPM 
protein onto the plate (Fig. 4.13). While the relative differences 
between antisera were reduced under these conditions, A/S 83 still 
apparently bound more strongly to EPM than did A/S 283 or 164.
A/S 283 and 164 may have been particularly good activators of 
guinea-pig complement. To test this possibility, sheep, rat and 
guinea-pig complement were compared in cytotoxicity assays, with 
erythrocytes as the target cell (Fig. 4.12). In the presence of 
sheep complement, at low antiserum concentrations, A/S 83 showed 
greater cytotoxicity against erythrocytes than A/S 283 or 164, but at 
high concentrations, A/S 83 was able to lyse only 40-50% of 
erythrocytes, while A/S 283 and 164 could achieve total lysis. This 
implies either that there are 2 populations of erythrocytes bearing 
different antigenic determinants, or that high doses of A/S 83 are 
anti-complementary. In the presence of rat complement, the 
cytotoxicity of all the anti sera measured was so much reduced that 
relative differences between antisera were difficult to determine. 
Any differences in the relative cytotoxicity in the presence of rat 
and guinea-pig complement may be due to differences in the antibody 
binding to rat erythrocyte homologous restriction factor, which 
interferes with the formation of the C5-9 membrane attack complex 
(Shin et al., 1986). Binding to the restriction factor may mask it 
and render the erythrocyte more susceptible to lysis by homologous 
complement. Such an effect would preclude the necessity for antibody 
binding and cytotoxicity to be closely related.
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In vitro assays of antibody binding to and cytotoxicity against 
erythrocytes were the best characterised in this study, as 
erythrocytes were easy to obtain and could be stored for several 
days. There were no clear discrepancies between antibody binding to 
APM and cytotoxicity against adipocytes. It would, clearly, be of 
interest to examine more closely antibody binding to HPM and 
cytotoxicity against hepatocytes and compare the relative effects of 
different antisera on liver components in vitro and in vivo.
4.3.3.4 Conclusions
1. Three different antisera, raised in sheep, against APM were 
cytotoxic to adipocytes in vitro and had fat-reducing 
properties in vivo, despite apparent differences in the titre 
or affinity of anti-(APM) antibodies, as determined by ELISA 
and Western blotting.
2. Two out of 3 anti-(APM) anti sera caused gross liver 
abnormalities in vivo. The presence or absence of an 
anti-(liver) effect in vivo could not be correlated with 
differences in titre or affinity of anti-(HPM) antibodies or 
differences in binding to particular HPM antigens by ELISA or 
Western blotting.
3. Anti-(APM) antisera with anti-liver effects in vivo showed 
greater in vitro cytotoxicity against erythrocytes than the 
anti-(APM) antiserum that had no apparent effect on the liver 
in vivo. This raised the possibility that liver abnormalities 
might be caused by overloading of the hepatic 
reticulo-endothelial system with immune complexes, formed as a 
result of reaction of antibodies with non-hepatic antigens, 
such as erythrocytes.
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4. Two out of 3 anti-(APM) anti sera, in addition to causing liver 
abnormalities, had transient anaesthetic-like effects in vivo 
whose speed of onset (within 5 minutes of administration) 
suggested that antibodies bound rapidly to a component of 
nervous tissue, in some way interfering with synaptic 
transmission.
5. An anti-(HPM) anti serum, when given in a sufficiently high 
dose, caused liver abnormalities in vivo but had no effect on 
adipose tissue, suggesting that the fat-reducing properties of 
anti-(APM) anti sera were due to a specific anti-fat component 
of the antisera.
6. Polyacrylamide gel electrophoresis showed that the ASA 
preparations were composed of 6 major polypeptides with 
approximate molecular weights of 53 (a doublet), 59, 72, 85 and 
96 kD and 6 minor polypeptides.
7. Antisera raised aainst EPM and HPM recognised components of the 
ASA, and an anti serum raised against ASA recognised components 
of EPM and HPM, suggesting that not all the components of the 
ASA were truly adipocyte specific. This could be due to 
inadequate adsorption of anti-(AH*!) antibodies with non-adipose 
tissues, before their use to immuno-isolate the ASA or 
non-specific adsorption by imnuno-adsorbants. Despite some 
cross—reactivity with other tissues, the anti—CASA)) antiseroam 
was more adipocyte—specific than anti—(APM) antisera, as shown 
by ELISA and Western blotting.
8. The anti-(ASA) anti serum retained, at least partly, the effects 
of anti—(APM) anti sera on adipose tissue, food intake and body 
weight gain and had immediate anaesthetic—like effects boat did
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not cause liver abnormalities. This suggests that a reduction 
in food intake on the first day of treatment may be an
inevitable consequence of massive lipid mobilization from 
adipose tissue and that the antigens responsible for the
production of anaesthetic-like properties of antisera remain in 
the ASA preparation.
4.4 THE EFFECTS OF ADSORPTION OF ANTISERA RAISED AGAINST
ADIPOCYTE PLASMA MEMBRANES WITH LIVER
4.4.1 Experimental
Whole female Wistar rat livers were homogenised in an equal 
volume of PBS, using a Waring blender on high speed for 1 minute. The 
homogenate was washed 3 times with PBS by centrifugation at 2400 g 
for 20 minutes. Equal volumes of packed liver homogenate were
incubated with A/S 83 or A/S 164 for 16 h at 4° C in an end-over-end
mixer. The adsorbed antiserum was centrifuged at 50,000 g for 1 h to 
remove the liver homogenate.
Binding of the adsorbed antisera to all the antigens tested in
the previous Section was measured by ELISA and Western blotting.
Cytotoxicity against erythrocytes was measured but the LDH content of 
the adsorbed anti sera was too high to allow measurement of 
cytotoxicity against adipocytes.
The effects of adsorption against liver on the in vivo effects
of A/S 164 were examined by injecting female Wistar rats, weighing
CO
120-140 g, intraperitoneally at 10,Ah with 1 ml of unadsorbed, 1 ml of 
adsorbed or 3 ml of adsorbed antiserum for 4 consecutive days. The 
rats were killed 6 days after the first treatment and examined as 
described in Section 4.2.1.
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4.4.2 Results
While adsorption of A/S 83 and A/S 164 with liver homogenate
removed approximately 60% of the antibody binding to APM and ASA, the 
adsorption removed 85-99% of the binding to non-adipocyte plasma
membranes (Tables 4.6 and 4.7). Both adsorbed antisera were more
than 10 times more APM specific with respect to HPM and approximately 
10 times more APM specific with respect to KPM than the antisera 
before adsorption, as shown by relative antibody binding. Binding to 
EPM and brain membranes by the adsorbed anti sera was less than or 
equal to 1% of that by the antisera before adsorption.
While adsorption of A/S 83 and A/S 164 with liver homogenate
removed approximately 20% of the antigen abundance against APM, the 
adsorption removed about 50% of the antigen abundance against ASA. 
A/S 83 after adsorption was 2-5 times more APM specific with respect 
to non-adipocyte plasma membranes than A/S 83 before adsorption and 
A/S 164 after adsorption was about 10 times more APM specific with 
respect to HPM and brain membranes and 1-3 times more APM specific 
with respect to KPM and EPM than A/S 164 before adsorption, as shown 
by relative antigen abundances.
Adsorption of A/S 83 and A/S 164 with liver homogenate removed 
at least 85% of the in vitro cytotoxicity against erythrocytes (Fig. 
4.14).
Western blotting showed that the adsorbed antisera clearly 
recognised only 1 HPM polypeptide, with a molecular weight of 
approximately 65 kD, compared with at least 9 and 8 recognised by 
A/S 83 and A/S 164, respectively, before adsorption (Fig. 4.15). 
Both adsorbed antisera bound strongly to APM polypeptides with
Table 4.6 The effects of adsorption of A/S 83 
with liver homogenate on tissue specificity, 
as determined by ELISA
A/S 83 was adsorbed with packed liver homogenate (1 vol. of serum: 1 
vol. of packed liver) for 16 h at 4° C. Relative antibody binding 
and antigen abundances were calculated as described in Section 2.6.3. 
Relative APM specificity was calculated by dividing antibody activity 
against APM by the antibody activity against the non-APM antigen.
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Table 4.7. The effects of adsorption of A/S 164 
with liver homogenate on tissue specificity, 
as determined by ELISA
P/S 164 was treated as described for A/S 83 in Table 4.6.
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Fig. h.lh. The effects of adsorption of A/S 83 and A/S 16^ 
with liver homogenate on in vitro cytotoxicity against erythrocytes
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Cytotoxicity against erythrocytes of A/S 83 (open circles), A/S 83 
adsorbed with liver homogenate (filled circles), A/S 1.6k (open 
triangles) and A/S 16h adsorbed with liver homogenate (filled 
triangles) was measured as for Fig. U.l. Results are means SEM 
of 3~5 observations.
Fig. 4.15- The effects of adsorption of A/S 83 and A/S 164 
with liver homogenate on antibody binding to adipocyte 
and hepatocyte plasma membranes and adipocyte specific antigens, 
as determined by Western blotting
Abbreviations and methods as for Fig. 4.2
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molecular weights of approximately 59, 96 and 150 kD and recognised 
at least 8 other APM polypeptides. Clear binding to APM polypeptides 
within a molecular weight range of 60-90 kD was not visible by the 
adsorbed antisera, while a number of APM polypeptides within this 
range were recognised before adsorption. P59 and P96 of the ASA were 
clearly recognised by the adsorbed antisera but binding to P53, P72 
and P85 was not clearly visible.
The treatment of rats with 3 ml of A/S 164 adsorbed with liver 
homogenate caused a slightly greater reduction in the dry weight and 
percentage dry weight of parametrial adipose tissue and had a much 
reduced effect on the liver, compared with treatment with 1 ml of A/S 
164 before adsorption (Table 4.8). Treatment with 1 ml of adsorbed 
A/S 164 caused some reduction in dry weight and percentage dry weight 
of parametrial adipose tissue but these effects were not as great as 
those observed using 1 ml of A/S 164 before adsorption. No liver 
abnormalities were observed in rats treated with 1 ml of adsorbed A/S 
164. Adsorption with liver homogenate had little effect on the 
inhibitory effects of A/S 164 on food intake and body weight gain on 
the first day of treatment.
4.4.3 Discussion
The removal by adsorption with liver homogenate of 60% of the 
antibody binding to APM of A/S 83 and A/S 164, while removing more 
than 85% of the binding to non-adipocyte plasma membranes, suggests 
that 60% of the antibody activity of these anti-(APM) sera was 
directed against cross-reacting antigens. This may be higher than 
the true figure, however, because of non-specific adsorption of 
antibody by the liver. Liver was used for the adsorption because it
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was 9 tissue that could be obtained in relatively large cjuanitites 
but was, otherwise, perhaps not the ideal tissue for adsorption 
because of the presence of Fc receptors on Kupffer cells. ELISA and 
Western blotting showed that, while the majority of the anti-(HPM) 
activity of A/S 83 and A/S 164 was removed by adsorption with liver 
homogenate, some binding to HPM was retained, particularly to a 
polypeptide with a molecular weight of about 60 kD. The antisera 
were adsorbed with a liver homogenate, harvested by low speed 
centrifugation, while the antisera were screened against HPM, 
harvested only by high speed centrifugation. It is possible that the 
60 kD HPM protein was barely visible when Western blotting was 
performed using the antisera before adsorption, suggesting that 
antibodies directed against this protein are very minor components of 
the antisera.
ELISA suggested that adsorption with liver homogenate removed 
some of the antibody activity of A/S 83 and A/S 164 against ASA. 
Western blotting suggested this was due to a reduction in the binding 
of both P72 and P96 but that to P72 suffered the greatest reduction. 
This casts further doubt on the true adipocyte specificity of these 
antigens but it is possible that non-specific adsorption by the liver 
homogenate may have resulted in the reduction in binding to ASA. The 
binding of the adsorbed antisera to P59 of the ASA, which was not 
clearly recognised before adsorption, was surprising but may have 
been the result of a longer incubation of the blots in the peroxidase 
substrate.
The majority of the in vivo anti-(liver) effects of A/S 164 
were removed by adsorption with liver homogenate and, by increasing 
the dose of adsorbed A/S 164, it was possible to induce an effect on
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adipose tissue of a magnitude at least as great as that induced by 
A/S 164 before adsorption. This indicates that antibodies that 
cross-react with the liver are not an essential component of an 
antiserum with fat-reducing properties and that the liver 
abnormalities were not a consequence of fat reduction. These results 
support those obtained using A/S 361, raised against ASA (see Section 
4.3.2). The adsorbed antiserum, like A/S 361, retained the immediate 
anaesthetic-like effects and the effects on food intake and body 
weight gain, seen using A/S 164 before adsorption. Therefore, 
despite the greater apparent specificity of adsorbed A/S 164 than A/S 
361, the antigens responsible for anaesthetic-like effects were still 
recognised by the adsorbed antiserum.
4.4.4 Conclusions
1. Adsorption of anti-(APM) antisera with liver homogenate
rendered the antisera considerably more adipocyte specific than 
the anti-(ASA) antiserum, as indicated by ELISA and Western 
blotting. This suggests that the anti-(APM) antisera do 
contain adipocyte specific components.
2. The anti-(APM) antiserum, after adsorption, retained the
effects on adipose tissue, food intake and body weight gain of 
the unadsorbed antiserum and had anaesthetic-like effects but
had no effects on the liver, thus supporting the results of the
in vivo administration of an anti-(ASA) antiserum. This
suggests that adipocyte-specific antisera can have fat-reducing 
properties in vivo.
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4.5 ANTIBODY BINDING TO PLASMA MEMBRANES FROM MALE AND FEMALE
WISTAR AND FEMALE SPRAGUE-DAWLEY RATS BY ANTI SERA RAISED 
AGAINST ADIPOCYTE PLASMA MEMBRANES AND ADIPOCYTE SPECIFIC 
ANTIGENS
4.5.1 Experimental
The binding of A/S 83 (anti-(APM)), A/S 361 (anti-(ASA)) and 
A/S 83 adsorbed with liver homogenate to APM and HPM prepared from 
female Wistar, male Wistar and female Sprague-Dawley rats was 
compared, by ELISA.
4.5.2 Results
A/S 83, A/S 361 and A/S 83 adsorbed with liver homogenate 
showed reduced binding to male compared with female Wistar APM and 
HPM (Tables 4.9, 4.10). Adsorption of A/S 83 with female Wistar
liver homogenate removed more antibody binding to male than to female 
Wistar APM but removed the same amount of antibody binding to male 
and female Wistar HPM. A/S 361 (raised against ASA isolated from 
female Wistar APM) showed less binding to male Wistar APM than A/S 
83, (raised against whole female Wistar APM).
Adsorption of A/S 83 with female Wistar liver homogenate 
removed more antibody binding to female Sprague-Dawley APM than to 
female Wistar APM but removed less antibody binding to female 
Sprague-Dawley HPM than to female Wistar HPM. A/S 361 showed less 
binding to female Sprague-Dawley APM than to female Wistar APM.
The relative antigen abundances showed similar trends to the 
relative antibody binding but the relative differences between 
different antisera and antigens were reduced.
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4.5.3 Discussion
Antibody binding of A/S 83 to APM prepared from male Wistar and 
female Sprague-Dawley rats was reduced, compared with binding to 
female Wistar APM. This suggests that there are differences in the
I
antigenic composition of the APM prepared from the 3 different 
sources. There was little difference in the relative antigen 
abundances of A/S 83 against female Wistar or Sprague-Dawley or male 
Wistar APM. It is possible, therefore, that minor differences in the 
expression of antigens on adipocytes from the 3 different sources, 
due to slight alterations in polypeptide composition or orientation 
on the cell surface, resulted in differences in antibody affinity for 
the APM antigens.
Studies of the effects of adsorption with female Wistar liver 
homogenate and A/S 361 (raised against female Wistar ASA) provide an 
indication of whether the differences in antigenic composition of APM 
from rats of different strains and sex concern adipocyte specific or 
cross-reacting antigens. In the ensuing discussion, 'adipocyte 
specific' refers to antigens present on female Wistar adipocyte but 
not on female Wistar hepatocyte plasma membranes. Female 
Sprague-Dawley or male Wistar APM may bear adipocyte-specific or 
cross-reacting antigens not present on female Wistar APM but these 
antigens would not be detected by the antisera described above, 
which were all raised against female Wistar antigens. Adsorption of 
A/S 83 with female Wistar liver homogenate removed more binding to 
Sprague-Dawley and male Wistar APM than to female Wistar APM, but 
removed the same amount or less binding to male Wistar and 
Sprague-Dawley HPM. This suggests that A/S 83, before adsorption, 
bound to a similar number of cross-reacting antigens with a similar
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affinity on APM from all 3 sources but bound to a smaller number of 
adipocyte specific antigens, or to the same number of adipocyte 
specific antigens but with a lower affinity on male Wistar and 
Sprague-Dawley APM than female Wistar APM. Thus, adsorption with 
female Wistar liver would remove a large proportion of the male 
Wistar and Sprague-Dawley APM binding, since most of this binding 
was to cross-reacting antigens. If the proportion of binding of A/S 
83 to cross-reacting antigens on the APM from the 3 different sources 
was the same, then adsorption with a tissue containing those 
cross-reacting antigens would be expected to have a similar effect on 
binding to HPM of the 3 different sources. It is clearly impossible 
to draw firm conclusions about the antigenic composition of plasma 
membranes from different sources from the study of a single 
antiserum, especially as the method of study was ELISA which has all 
the limitations discussed in Section 4.3.3.1. However, the 
suggestion that male Wistar and Sprague-Dawley APM bear fewer 
adipocyte specific antigens than female Wistar APM is supported by 
the results of binding of A/S 361 (anti-(ASA)) to APM of the 3 
different sources. A/S 361 showed less binding to APM from male 
Wistar and Sprague-Dawley APM than to female Wistar APM. However, in 
view of the questionable adipocyte specificity of A/S 361, these 
results should be interpreted with caution.
4.5.4 Conclusions
1. Antisera raised against APM or ASA (isolated from female Wistar 
rats) showed reduced binding to APM from male Wistar or female 
Sprague-Dawley rats. These results suggest that there are both 
differences and similarities between the antigenic compositon 
of APM from rats of different strain and sex.
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2. Adsorption of anti-(Wistar APM) antisera with female Wistar 
liver homogenate removed more of the anti-male Wistar and 
female Sprague-Dawley HPM than APM activity. The differences 
between APM of different strain and sex may reside, therefore, 
predominantly in the adipocyte specific antigens. This 
hypothesis is supported by the fact that the anti-(female 
Wistar ASA) antiserum bound less well to APM from male Wistar 
or female Sprague-Dawley than female Wistar rats.
CHAPTER 5 
ACTIVE IMMUNISATION 
AGAINST THE ADIPOCYTE PLASMA MEMBRANE IN RATS
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ACTIVE IMMUNISATION AGAINST THE ADIPOCYTE PLASMA MEMBRANE IN RATS
5.1 INTRODUCTION
The induction of autoantibody production directed against a 
variety of 'self tissues' has been achieved, in experimental animals, 
by immunisation with homologous or heterologous antigens, usually in 
Freunds adjuvant (Germuth et al., 1967; Kallen and Nilsson, 1986;
Watanabe et al., 1987). The aim of the work described in this
chapter was to extend this approach to the induction of 
autoantibodies directed against adipose tissue.
Initial experiments involved immunisation of rats with rat ARM 
conjugated to BSA, in the hope that BSA would stimulate T helper 
lymphocytes to provide the necessary helper signals to stimulate ARM 
reactive B cells to secrete autoantibodies. The conjugate was 
emulsified in complete Freunds adjuvant since this is still the most 
potent stimulator of both B and T cell immune responses known.
Subsequent experiments involved attempts to augment this imnune 
response by the use of Pertussis vaccine and 2'-deoxyguanosine. 
Pertussis vaccine and toxin have been shown to enhance the induction, 
of experimental autoimmune encephalomyelitis and autoimmune 
uveoretinitis in rats, when administered in conjunction with complete 
Freunds adjuvant and encephalogenic protein and retinal specific 
antigen respectively (McAllister et al., 1974; Kallen and. Nilsson, 
1986). Deoxyguanosine is an inhibitor of ribonucleotide reductase 
and, therefore, inhibits DMA synthesis (Bril, van den Akker, 
Molendijk, Bianchi and Benner, 1984). 2f-deoxygiiaeosinie prevents an 
antigen dose-dependent suppression of antibody responses. at
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supra-optimal concentrations (Dosh, Mausour, Cohen, Shore and 
Gelfand, 1980). These authors found that T helper cells and B 
lymphocytes were more than 1000-fold more resistant to 
2'-deoxyguanosine than T suppressor cells and suggested that 
suppressor cells are low in 5' nucleotidase and high in 
deoxyguanosine kinase activity, resulting in the accumulation of 
intracellular deoxyguanosine triphosphate. As T cell suppression is 
thought to play a crucial role in the prevention of autoimmunity, it 
was hoped that the administration of 2'-deoxyguanosine in conjunction 
with autoantigen might augment the autoimmune response by inhibiting 
T suppressor function.
Attempts were also made to induce an autoimmune response to 
adipose tissue by manipulation of the idiotype network. Bigazzi 
(1986) found that the immunisation of rats, suffering from autoimmune 
thyroiditis (due to the presence of anti-(thyroglobulin) antibodies) 
with anti-(thyroglobulin) antibodies increased the severity of the 
disease, possibly through the production of anti-anti-idiotypic 
antibodies. It was hoped, therefore, that immunisation of rats with 
an affinity purified anti-(APM) antibody would induce the formation 
of anti-idiotypic antibodies, bearing an internal image of APM 
antigens (Fig. 5.1). Such a disturbance of the idiotype network 
might provoke the formation of anti-anti-idiotypic antibodies, 
recognising APM antigens.
5.2 EXPERIMENTAL
5.2.1 Experiment 1
In this experiment different members of the same litters were 
placed in different treatment groups so that littermates could be
Fig. 5-1. The induction of anti-(adipocyte plasma membrane) antibodies 
by manipulation of the idiotype network
1. Rats are immunised with sheep anti-(rat APM) antibodies
S
AB1
2. Rats respond by the production of anti-idiotypic antibodies 
that bear internal images of APM antigens
S
AB1 AB2
3- Anti-idiotypic antibodies induce the formation of anti-anti- 
idiotypic antibodies that recognise APM antigens
R
AB2 AB3
R
AB3
The above is a diagrammatic representation of the proposed means 
whereby anti-(APM) antibodies might be induced by manipulation of 
the idiotype network. S and R indicate sheep and rat antibodies 
(AB) respectively, while A represents adipocyte.
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compared. Four-week-old female Wistar rats, weighing 40-50 g, were 
immunised subcutaneously at 2 sites, with 100 /jg of rat APM 
conjugated to 100 //g of BSA emulsified in 200 fjl of complete Freunds 
adjuvant. Conjugation was performed by incubating 100 fjg of APM with 
100 /jg of BSA and 20 /j1 of glutaraldehyde (0.5%) in 100 /j1 of PBS for 
30 minutes at 22° C. Rats were boosted with APM conjugated to BSA in 
incomplete Freunds adjuvant at 2 and 4 weeks after the first 
immunisation and with unconjugated APM in incomplete Freunds adjuvant 
at 6 and 10 weeks. Control rats were given the same treatment, with 
the exclusion of APM, at 0, 2 and 4 weeks and received no
subsequent boosts. Body weights were recorded daily. Blood samples 
were taken from the tail, under ether anaesthesia, at 6, 8, 10 and 16 
weeks after the first treatment and assayed for anti-(APM) antibodies 
by ELISA. Rats were killed 16 weeks after the first treatment and the 
dry weights of the inguinal subcutaneous, interscapular 
subcutaneous, parametrial, peri-renal and omental adipose depots were 
determined.
5.2.2 Experiment 2
Experiment 2 was carried out in the same way as Experiment 1 
except that littermates were not used and a group of control rats 
were included that received no immunisations. Adipocyte numbers and 
mean adipocyte volumes of parametrial and inguinal subcutaneous 
adipose tissue were determined.
5.2.3 Experiment 3
Experiment 3 included a repeat of Experiment 2. Additional 
groups of rats received either APM conjugated to BSA plus 0.5 ml of
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Pertussis vaccine (Wellcome, London) (given subcutaneously at the 
same time as the first immunisation), or APM conjugated to BSA and 
4 mg of 2’—deoxyguanosine (Sigma Chemical co., Poole, Dorset) (given 
intraperitoneally at the same time as the first immunisation and for 
the 6 days following each immunisation). Another group of rats 
received 50 fjg of ASA conjugated to BSA. The final group of rats 
received either 100 /jg of affinity-purified anti-(APM) antibody, from 
the same pool that was used to prepare the ASA. In all groups, 
antigens were emulsified in complete Freunds adjuvant for the first 
immunisation, whilst subsequent immunisations on weeks 2, 4, 6 and 10 
were given in incomplete Freunds adjuvant. All immunisations were 
given at 2 subcutaneous sites and, where initially antigens were 
conjugated to BSA, the final 2 immunisations were given in the 
absence of BSA.
Body weights and food intakes were measured weekly. Blood 
samples were taken as for Experiment 1 at 2, 4, 6, 8, 10, 12 and 16 
weeks after the first treatment and assayed, by ELISA, for antibody 
binding to APM, HPM, KPM, EPM and ASA. Delayed type hypersensitivity 
tests were performed on 2 rats that had received APM conjugated to 
BSA and Pertussis vaccine 2 weeks after the fourth immunisation. A 
small area of the skin was shaved and 10 /vl of BSA (1 mg/ml) and 
10 a/1 of APM (1 mg/ml) were injected just under the skin at different 
sites. At 24 and 48 h the injection sites were examined for 
swelling.
Rats were killed 16 weeks after the first immunisation and the 
dry weights, mean adipocyte volumes and adipocyte numbers of the 
parametrial, peri-renal and inguinal subcutaneous adipose depots were 
determined.
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Binding of sera from all actively immunised rats to APM, 
prepared from adipocytes isolated in the presence of BSA, and to 
APM, prepared by homogenisation of whole tissue in the absence of 
BSA, was compared by ELISA. In addition, the ability of 
pre—incubation with BSA to reduce the binding capacity of sera to 
APM, prepared in the presence of BSA, was examined. 100 /y1 of test 
serum (4%) was incubated with either 100 yl of PBS or 100 /jl of BSA 
(2 mg/ml) (Fraction V, Sigma Chemical Co., Poole, Dorset) or casein 
(Technical, from Bovine milk, Sigma Chemical Co., Poole, Dorset) for 
2 h at 22° C. Casein was included in order to determine the effects 
of pre-incubation with a non-specific protein. After pre-incubation, 
the binding capacity of the sera to APM, prepared in the presence of 
BSA, and to BSA alone, was examined by ELISA.
The ability of pre-incubation with sheep y globulin (prepared 
by ammonium sulphate precipitation of whole serum) to reduce binding 
to ASA was examined for all groups of actively immunised rats. 
Pre-incubations were performed as described in the previous Section. 
ELISA plates, coated with ASA, were blocked with casein. Therefore, 
after pre-incubation, binding of sera to casein alone, as well as to 
ASA and sheep y globulin, was tested.
5.3 RESULTS
5.3.1 Apparent anti-(adipocyte plasma membrane) titres in actively 
immunised rats
In Experiment 1 serum from rats immunised with APM conjugated 
to BSA or with BSA alone (controls) bound to APM coated onto ELISA 
plates. There were no s ig n i f i c a n t - differences i n  the absorbances
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achieved between serum from the 2 groups of rats, when apparent 
anti-(APM) responses were measured by ELISA (Fig. 5.2). The APM 
used for this screening were prepared from adipocytes isolated in the 
presence of BSA and which were probably contaminated with BSA (see 
Fig. 4.9). However, the use of APM prepared from adipocytes isolated 
in the presence of gelatin gave similar results (results not shown). 
The rats of Experiment 2 showed similar antibody responses to those 
achieved in Experiment 1 and the apparent anti-(APM) titres were 
relatively constant between 6 and 16 weeks after the first 
immunisation in both groups of rats (Fig. 5.3). Apparent anti-(APM) 
titres in APM- and BSA-immunised rats from Experiment 3 reached a 
peak of about 5 times those achieved in Experiments 1 and 2 6 weeks 
after the first immunisation, before falling to levels similar to 
those observed in Experiments 1 and 2 (Fig. 5.3)
Treatment of rats with Pertussis vaccine and 2'-deoxyguanosine 
did not augment apparent anti-(APM) titres (Fig. 5.4). Immunisation 
with anti-(ASA) antibody induced an apparent anti-(APM) response that 
was more than 100-fold less than that induced by APM conjugated to 
BSA, although there was still a positive apparent anti-(APM) response 
suggesting perturbation of the idiotypic network (Fig. 5.1).
Immunisation of rats with Freunds adjuvant alone or Freunds 
adjuvant and glutaraldehyde did not induce an apparent anti-(APM) 
response. However, immunisation with BSA in Freunds adjuvant, in the 
absence of glutaraldehyde, induced similar apparent anti-(APM) 
responses to those achieved by immunisation with BSA and 
glutaraldehyde in Freunds adjuvant (Fig. 5.4).
Absorbances achieved by sera from actively immunised rats of 
Experiment 3, when tested by ELISA against APM, prepared by
Fig. 5-2. The apparent antibody response
to adipocyte plasma membranes in actively immunised rats
Bats were immunised with either BSA (open circles) or APM conjugated 
to BSA (closed circles) in CFA. Antibody binding to AIM (prepared 
in the presence of BSA) was measured 6 weeks after the first 
immunisation, by ELISA. The results of experiments 1, 2 and 3 are 
shown in (a), (b) and (c) respectively. Results are means jh SEM
of 5-8 observations.
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Fig- 5-3- The change in "the apparent antibody response
to adipocyte plasma membranes in actively immunised rats,
with time
Rats were immunised with either BSA (open symbols) or APM conjugated 
to BSA (closed symbols) in CFA. Antibody binding to APM (prepared 
in the presence of* BSA) was measured by ELISA. The results of 
experiments 1 and 2 were pooled (squares) and compared with those 
of experiment 3 (circles).
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ELISA, 6 weeks after the first immunisation. Results in (a) are 
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of 3 observations.
jnoq jad a6ueq3 aaueqjosqy
jnoq jad a6ueqo aoueqjosqy
Lo
g.
 
re
cI
p.
 
A/
S 
di
lu
ti
on
 
Lo
g.
 
re
ci
pr
oc
al
 
A/
S 
d
il
u
t
i
o
n
151
homogenisation of adipose tissue in the absence of BSA, were not 
significantly above those achieved by sera from untreated rats (Table
5.1). Binding to BSA alone by sera from the same actively immunised 
rats was only about 10% of that to APM prepared in the presence of 
BSA, as determined by ELISA.
Pre-incubation with BSA of serum from rats immunised with BSA, 
APM or ASA (both conjugated to BSA) or anti-(ASA) antibody reduced 
the binding to APM, prepared in the presence of BSA, and to BSA alone 
to a level such that the absorbances achieved in ELISA were not 
significantly greater than those of serum from untreated rats (Table
5.2). Pre-incubation with casein caused some reduction of binding to 
APM but the absorbances achieved were still significantly greater 
than those achieved using untreated rat serum (Table 5.2).
Pre-incubation with sheep y globulin of serum from rats 
immunised with BSA, APM, ASA or anti-(ASA) antibody reduced the 
binding to ASA and sheep y globulin to a level such that the 
absorbances achieved in ELISA were not significantly greater than 
those of untreated rat serum (Table 5.3). Again pre-incubation with 
casein caused some reduction of binding to ASA and sheep y globulin 
but the absorbances achieved were still significantly greater than 
those achieved with untreated rat serum (Table 5.3).
5.3.2 The tissue specificity of antibody responses of actively 
immunised rats
Antibody binding to APM (prepared in the presence of BSA) of 
serum from rats immunised with APM or BSA alone was more than 
100-fold greater than that of serum from rats immunised with 
anti-(APM) antibody (Fig. 5.5). However, antibody binding to HPM of
Table 5.1. The role of anti-(BSA) responses 
in apparent anti-(adipocyte plasma membrane) responses 
of actively immunised rats
Antigen
Relative binding of serum from rats 
immunised with APM 
in presence of BSA as % 
of anti-(APM in presence of BSA) response
BSA
APM in absence of BSA 
APM in presence of BSA
10
0
100
Antibody binding to BSA, APM prepared by homogenisation of adipose 
tissue in the absence of BSA and APM prepared from cells isolated by 
collagenase digestion of adipose tissue in the presence of BSA in 
serum of rats from Experiment 3, immunised with APM conjugated to 
BSA, was measured by ELISA.
Table 5.2. The effects of preincubation with BSA and casein on 
anti-(BSA) and apparent anti-(adipocyte plasma membrane) antibodies 
in sera from actively immunised rats
Sera from rats immunised with BSA, APM conjugated to BSA, ASA
conjugated to BSA or anti-(APM) antibody were preincubated with
either PBS, casein or BSA before measuring antibody binding (AB
binding) and antigen abundance (AG abund.) against BSA and APM
prepared in the presence of BSA, by ELISA.
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Table 5.3. The effects of preincubation with sheep IgG and casein
on anti-(sheep IgG) 
and apparent anti-(adipocyte specific antigen) antibodies
Sera from rats immunised with BSA, APM conjugated to BSA, ASA 
conjugated to BSA or anti-(APM) antibody were preincubated with 
either PBS, casein or sheep IgG before measuring antibody binding (AB 
binding) and antigen abundance (AG abund.) against sheep IgG and ASA, 
by ELISA.
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serum from rats immunised with APM or BSA was more than 100-fold less 
than that of serum from rats immunised with ASA or anti-(ASA) 
antibody. Antibody binding to KPM and EPM was also greater by serum 
from rats immunised with ASA or anti-(ASA) antibody than by serum 
from rats immunised with APM or BSA (Fig. 5.5).
5.3.3 The effects of active immunisation on adipose tissue
Immunisation of rats with APM conjugated to BSA caused a 
significant reduction in mass of peri-renal, omental and inguinal 
subcutaneous adipose tissue, compared with BSA-immunised controls in 
Experiment 1 (Table 5.4). While the mass of virtually all measured 
adipose depots was also reduced in APM compared with BSA-immunised 
rats in Experiments 2 and 3, these reductions were not significant. 
In Experiment 2, totally untreated controls, in general, showed lower 
fat pad weights than APM- or BSA-immunised rats. Mean adipocyte 
volumes of parametrial and subcutaneous depots of rats immunised with 
APM, in Experiments 2 and 3, were elevated compared with those of 
BSA- and untreated controls but these differences were not 
significant (Table 5.5). Adipocyte numbers of these depots were 
reduced in APM-treated rats and these differences were significant in 
Experiment 3.
Rats immunised with APM and also treated with 2'-deoxyguanosine 
or Pertussis vaccine showed similar fat pad weights, mean adipocyte 
volumes and adipocyte numbers as those immunised with APM alone in 
Experiment 3 (Table 5.6). Rats immunised with anti-(ASA) antibody 
showed elevated weights and mean adipocyte volumes of internal fat 
depots, compared with controls, but these differences were not 
significant (Table 5.6). Rats immunised with ASA also showed
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Table 5.6. The effects of immunisation 
with adipocyte plasma membranes and Pertussis vaccine 
and 2'-deoxyguanosine, adipocyte specific antigens 
and anti-(adipocyte plasma membrane) antibody on fat pad weight, 
adipocyte volume and adipocyte numbers
Rats were immunised with either APM or ASA conjugated to BSA or 
anti-(APM) antibody or were untreated. Some APM-immunised rats also 
received Pertussis vaccine or 2' deoxyguanosine as described in 
Section 5.2. The dry weights of fat pads, mean adipocyte volumes and 
adipocyte numbers were determined 16 weeks after the first 
immunisation. *P<0.01, **P<0.005, compared with controls (Student's
unpaired t test).
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elevated fat pad weights and significantly elevated mean adipocyte 
volumes and reduced adipocyte numbers of internal fat depots, 
compared with controls.
5.3.4 Effects of active immunisation on body weight gain, food 
intake and food conversion efficiency
In Experiment 1, rats immunised with APM showed a reduced body 
weight gain compared with BSA-immunised controls, which became 
significant by 10 weeks after the first treatment (Fig. 5.6). In 
Experiment 2, rats immunised with APM and totally untreated controls 
showed a reduced body weight gain compared with BSA-immunised 
controls between 5 and 6 weeks after the first treatment. There were 
no significant differences in body weight gain between any of the 
treatment groups of Experiment 3.
In Experiment 3 food intakes were measured, allowing food 
conversion efficiency, as defined by food intake divided by body 
weight gain, to be determined (Table 5.7). In general, APM-treated 
rats had a slightly lower food intake and a similar body weight gain 
compared with untreated controls, resulting in a slightly increased 
food conversion efficiency. BSA-treated rats had a similar food 
intake to controls but gained slightly more weight which resulted in 
a similar food conversion efficiency to APM-treated rats. There was 
little difference between the food intakes or food conversion 
efficiencies of rats immunised with anti-(ASA) antibody, ASA, or APM 
with 2 '-deoxyguanosine or Pertussis vaccine when compared with 
untreated controls.
Fig. 5*6. Body weight gain in actively immunised rats
Eats were immunised with either BSA (open circles), APM conjugated 
to BSA (filled circles) or were untreated (filled squares). The 
results of experiments 1, 2 and 3 are shown in (a), (b) and (c)
respectively. *P<0.01 compared with BSA-immunised controls (Student*s 
paired t test). *P<0.01 compared with BSA-immunised controls 
(Student*s unpaired t test).
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5.4 DISCUSSION
5.4.1 Apparent antibody responses to adipocyte plasma membranes in
actively immunised rats
The detection of apparent anti-(APM) antibodies in rats 
immunised with BSA alone immediately raised the question of 
contamination of the APM preparation with BSA. In order to test 
this, the same sera were tested, by ELISA, against APM, prepared from 
adipocytes isolated in the presence of gelatin, rather than BSA. As 
the sera bound to APM, prepared in the absence of BSA (results not 
shown), it was assumed that immunisation with BSA induced a genuine 
anti-(APM) response. Such a response could be induced by the 
injection of a powerful non-specific stimulator of the immune system,
Freunds adjuvant, into an adipose depot, or by BSA acting as a
carrier in situ, stimulating T helper cells to provide 'help' for
autoreactive B cells. In subsequent experiments, a totally untreated 
group was always included.
In the third active immunisation experiment, the cause of the 
apparent anti-(APM) antibodies in BSA-immunised rats was examined in 
more detail and found to be due to immunisation with BSA in Fruends 
adjuvant, rather than Freunds adjuvant or glutaraldehyde alone (Fig.
5.4). This, coupled with the discovery of contamination of APM with 
BSA, as indicated by SDS PAGE (see 4.9), prompted a re-examination of 
the role of anti-(BSA) responses in apparent anti-(APM) responses.
Rats immunised with BSA, APM or ASA showed little or no binding 
to APM prepared from homogenised whole adipose tissue (Table 5.1). 
Binding to APM, prepared in the presence of BSA, by the same sera
could be completely removed by pre-incubation of the sera with BSA
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(Table 5.2). These results indicate that little or no genuine 
anti-(APM) responses were induced in these rats. Gelatin is formed 
by hydrolysis of collagen. Therefore, apparent anti-(APM) responses, 
measured against APM prepared in the presence of gelatin, may have 
represented anti-(collagen) responses or responses to its degradation 
products. Measurement of antibody binding to BSA of APM-treated rats 
by ELISA did not show as much binding as would be expected if all the 
apparent anti-(APM) response measured against APM, prepared in the 
presence of BSA, were due to anti-(BSA) antibodies (Table 5.1). 
Since BSA is a soluble protein, it may not have adsorbed as 
efficiently to PVC ELISA plates as the insoluble APM. Time did not 
permit the testing of this possibility using poly-L-lysine to promote 
the adsorption of BSA to the plates. Alternatively, the rats may 
have responded to neo-antigens on the APM, formed by collagenase 
digestion of adipose tissue or to epitopes formed by the combination 
of BSA with APM.
5.4.2 The tissue specificity of antibody responses in actively 
immunised rats
Anti sera, raised in rats by immunisation with whole APM 
conjugated to BSA, showed very little cross-reaction with non-adipose 
tissues while antisera, raised by immunisation with ASA conjugated to 
BSA, showed considerable cross-reaction with HPM, KPM and EPM (Fig.
5.5). This is not easy to explain since, while the ASA preparation 
probably contained non-adipocyte specific antigens, this would not 
explain why immunisation with ASA would induce a less adipocyte 
specific response than immunisation with whole APM. It is possible 
that a non-adipocyte specific antigen(s) was co-purified with a
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specific antigen due to incomplete solubilization of the APM used to 
prepare the ASA. If the non-specific antigen were present at a very 
low frequency on the APM but was concentrated in the ASA preparation, 
a greater non-specific immune response might be elicited by
immunisation with ASA than by immunistion with APM. The ASA 
preparation was clearly contaminated with sheep igG. Since 
pre-incubation with sheep y globulin removed virtually all the 
binding to ASA of serum from rats immunised with ASA, sheep Ig G was 
the major immunogenic component of the ASA preparation in rats (Table 
5.3). Anti-(sheep IgG) antibodies are likely to cross-react with rat 
IgG. If the HPM, KPM and EPM preparations showed greater
contamination with rat IgG (present in serum) than the APM
preparation, this could account for the apparent cross-reaction of 
antisera, raised gainst ASA, with these tissues. There is no
evidence, however, to suggest that this is the case. Alternatively, 
sheep IgG and rat HPM, KPM and EPM, may share common epitopes,
although this, again, seems unlikely. However, the fact that rats 
immunised with sheep anti-(ASA) antibodies alone showed even more
binding to HPM, KPM and EPM than those immunised with ASA does 
suggest that the cross-reaction with non-adipose organs relates, in 
some way, to the anti-(sheep IgG) response.
5.4.3 Effects of active immunisation on adiposity, body weight 
gain and food intake 
In Experiment 1, APM-immunised rats showed significant 
reductions in the dry weight of adipose depots compared with
BSA-immunised controls (Table 5.4). The reduction in adiposity may 
have been antibody-mediated, despite the absence of differences in
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apparent anti-(APM) antibody responses between APM and BSA-immunised 
rats (Fig. 5.2) and despite the absence of a convincing demonstration 
of true anti-(APM) antibodies in either group of rats. Only 
circulating antibodies were measured and anti-(APM) antibodies may 
have been sequestered in adipose tissue of APM-treated rats. 
Alternatively, the reduction in adiposity, seen in APM-immunised 
rats, may have been due to antibody-independent cell-mediated 
autoimmune reactions. In experimental autoimmune encephalomyelitis 
(McAllister et al., 1974) and experimental autoimmune synovitis 
(Goldberg et al., 1974), induced by the injection of autoantigens in 
Fruends adjuvant, T-cell mediated immune responses have been shown to 
play a greater part in the pathogenesis of the disease, despite the 
presence of autoantibodies. Delayed type hypersensitivity tests on 2 
actively immunised rats showed some response to BSA but not to APM 
but alternative measures of in vivo T cell activation should be 
employed before conclusions can be drawn about the role of T cell 
responses in mediating the effects of active immunisation on adipose 
tissue.
In Experiment 2, the dry weights of none of the adipose depots 
measured in APM-immunised rats were reduced 16 weeks after the first 
treatment, compared with BSA-immunised controls (Table 5.4). However, 
adipocyte numbers of parametrial and subcutaneous adipose depots were 
reduced in APM-immunised rats, but this reduction was compensated for 
by an increase in adipocyte size (Table 5.5). The rats in Experiment 
2 did not reach the body weight of those in Experiment 1 (Fig. 5.6). 
It is possible, therefore, that the maximum capacity for fat storage 
was reached in the APM-immunised rats of Experiment 1, while the rats 
of Experiment 2 did not reach a sufficiently high body weight to
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reach their maximum capacity for fat storage. A reaching of the 
maximum capacity for fat storage must result in either a reduction in 
food intake, a repartitioning of nutrients into protein deposition or 
the formation of new adipocytes. Food intake was not measured in the 
first experiment but there was a reduction in body weight gain in 
APM-treated rats (Fig. 5.6). Therefore, a mechanism similar to that
proposed by Faust et al (1977) to explain the reduction in food
intake in lipectomised rats, fed a high fat diet, may have been 
operating. They found that rats whose adipocyte numbers had been 
reduced by lipectomy had a normal food intake, when fed a low fat 
diet, but the feeding of a prolonged high fat diet resulted in a 
reduction in food intake, compared with sham-operated controls. It 
was suggested that the fat storage capacity of lipectomised rats had 
been reduced such that, while there were sufficient numbers of 
adipocytes to accommodate fat deposition when fed a low fat diet, the 
feeding of a high fat diet caused an accelerated attainment of a 
maximum adipocyte size and, hence, a reduction in fat storage 
capacity. A feedback mechanism, whereby elevated adipocyte size in 
some way elicited a signal that caused a reduction in food intake, 
was proposed.
In Experiment 3, adipocyte numbers of parametrial and 
subcutaneous adipose tissue were significantly reduced in APM-treated 
rats, compared with BSA-treated and untreated controls (Table 5.5). 
There was, again, a compensatory increase in adipocyte size in 
APM-treated rats resulting in a slight, but not significant, 
reduction in adipose tissue mass. These animals had reached 
body weights similar to those attained by the APM-treated rats of 
Experiment 1 but there was no evidence of a reduction in body weight
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gain. The reason for the difference in response to active 
immunisation in Experiments 1 and 3 is not clear. It is possible 
that, since the experiments were separated by about 18 months and 
fresh immunogens were prepared for each experiment, the APM used for 
immunisation differed in antigenic composition. Alternatively,
genetic variation, induced by outbreeding of the Wistar rat colony, 
may have resulted in a different response to the same immunogen. The 
importance of a genetic component in the response to active
immunisation was shown in Experiment 1 where littermates were used.
While there was considerable overlap between APM- and BSA-treated 
rats, in terms of body weight gain and adiposity, when littermates 
were compared, all APM-treated rats showed reduced body weight gain 
and adiposity compared with their BSA-treated littermates.
Rats immunised with anti-(ASA) antibody were heavier and had a 
greater adipose tissue mass and mean adipocyte volume than
BSA-treated or untreated controls and showed no reduction in
adipocyte numbers (Table 5.6). None of these differences, however, 
were significant. A/S 83, at low doses, stimulated glucose 
incorporation into lipid (Flint et al., 1986). It is possible that 
the anti-(APM) response induced in anti body-immunised rats was of too 
low a titre or affinity to be cytotoxic but had stimulatory effects 
on lipid deposition. It would be of interest to examine the effects 
of sera from actively immunised rats on glucose incorporation into 
lipid in isolated adipocytes. The majority of the apparent 
anti-(APM) response of antibody-immunised rats could be removed by 
pre-incubation of the sera with BSA (Table 5.2). This was surprising 
as these rats were not deliberately immunised with BSA. The sheep 
anti-(ASA) antibodies, used for immunisation, may have been
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contaminated with ovine albumin and induced the production of 
antibodies that cross-react with BSA. Alternatively, some of the 
anti-(APM) antibodies may have been directed against rat albumin (a 
possible contaminant of the rat APM) and activation of the idiotype 
network may have resulted in the production of anti-(rat albumin) 
antibodies that cross-react with BSA.
5.5 CONCLUSIONS
1. Despite the absence of a convincing demonstration of 
circulating anti-(APM) antibodies, rats immunised with APM 
conjugated to BSA in Freunds adjuvant showed significantly 
reduced adipocyte numbers, compared with BSA-immunised 
controls. This reduction may have been due to anti-(APM) 
antibodies sequestered in adipose tissue, or to T-cell mediated 
immune responses.
2. In Experiment 1, the APM-immunised rats showed reduced fat pad 
weights and body weights, suggesting that a critical adipocyte 
size had been reached, resulting in a reduction in food intake, 
fat deposition and body weight gain. However, in 2 out of 3 
experiments, loss of adipocyte numbers was compensated for by 
enlargement of remaining adipocytes, so that total dissected 
fat mass was the same as in control rats, suggesting that total 
fat mass rather than adipocyte size is regulated.
3. The differences in the response of different groups of rats to 
the same treatment emphasizes the influence of variation in 
individual's immune response on the results of active 
immunisation, which may limit the use of this approach 
commercially.
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4. Immunisation of rats with ASA apparently induced antibodies 
showing a higher degree of cross-reactivity with non-adipose 
tissues than did immunisation with APM. As the ASA was 
contaminated with sheep IgG and immunisation with 
affinity-purified sheep anti-(ASA) antibodies also induced an 
antibody response showing a high degree of cross-reactivity 
with non-adipose tissues, this cross-reactivity may have 
related, in some way, to an anti-(sheep IgG) response.
CHAPTER 6
PRELIMINARY ATTEMPTS TO EXTEND THE USE 
OF PASSIVE AND ACTIVE IMMUNISATION 
AGAINST THE ADIPOCYTE 
TO SPECIES OTHER THAN THE RAT
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PRELIMINARY ATTEMPTS TO EXTEND THE USE 
OF PASSIVE AND ACTIVE IMMUNISATION AGAINST THE ADIPOCYTE 
TO SPECIES OTHER THAN THE RAT
6.1 INTRODUCTION
Passive immunisation of meat-producing animals, on a large 
scale, with antisera raised against adipocyte plasma membranes would 
probably only be practical for the treatment of avian species. For 
the treatment of larger species or humans, active immunisation or 
passive immunisation with monoclonal antibodies linked to a cytotoxic 
agent may be required. However, the most convincing demonstration of 
a reduction in adiposity, in the rat, was achieved by passive 
immunisation with polyclonal antisera raised against whole APM. 
Therefore, in order to determine whether a reduction in body fat in 
species other than the rat was possible, by an immunological 
approach, antisera were raised against chicken, pig and sheep APM.
The work described in this Chapter involves the in vitro
characterisation of these antisera and their use to prepare adipocyte 
specific antigens. The antisera and ASA were compared with antisera 
raised against rat APM and rat ASA with 3 main aims. The first was 
to determine whether high titre antisera could be generated against 
APM of other species, the second was to determine whether, like rat 
APM, the APM of other species were composed of both adipocyte 
specific and non-adipocyte specific antigenic components. The final 
aim was to investigate the species cross-reactivity between APM 
antigens and hence the possibility of using the same antiserum to 
treat animals of different species.
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The majority of the work described in this thesis describes 
efforts to characterise the effects of passive and active 
immunisation against the adipocyte in the rat, as it was hoped that 
the rat would prove a useful model for the effects of similar 
approaches in other species. In order to give some indication as to 
whether this was the case, active immunisation experiments were 
performed with lambs, based on those performed in the rat. 
Preliminary investigations at the Hannah Research Institute suggested 
that conjugation of rabbit serum albumin to sheep APM provided an 
immunogen that stimulated the production of anti-(sheep APM) 
antibodies of a similar titre to those induced by a similar approach 
in the rat. Rabbit, rather than bovine albumin, was chosen as it was 
thought to show less antigenic similarity to ovine albumin. The 
first experiment was set up, in collaboration with Dr. S. Rhind at 
Hill Farming Research Organisation (Penicuik, Midlothian), using the 
approach described above. When sheep ASA became available, a second 
experiment was performed using this more highly purified immunogen.
6.2 A COMPARISON OF ANTISERA RAISED AGAINST ADIPOCYTE PLASMA
MEMBRANES OF DIFFERENT SPECIES
6.2.1 Experimental
The following antisera were raised against whole APM, either at 
the Hannah Research Institute or by S. Kestin at the Institute of 
Food Research (Bristol Laboratory), according to the method described 
in 2.4, with the exception of the goat anti-(sheep APM) antiserum. 
Since it was likely that sheep and goat APM were antigenically 
similar, the sheep APM were conjugated to rabbit serum albumin, by
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the method described in Section 5.2.1, for the first 3 immunisations 
but were not conjugated for subsequent boosts.
ANTISERUM SPECIES OF ANTISERUM DONOR
SPECIES OF 
IMMUNOGEN
A/S 83 Sheep Rat
A/S 642 Sheep Chicken
A/S 816 Sheep Pig
A/S Perky Goat Sheep
The anti sera were adsorbed with liver homogenate of the same 
species as that from which the immunogen was prepared, according to 
the method described in Section 4.4.1. Binding of adsorbed and 
unadsorbed antisera to APM (prepared in the absence of BSA) and HPM 
of rats, chickens, pigs and sheep was measured by ELISA.
6.2.2 Results
Antisera raised against chicken, pig and sheep APM showed 45, 
33 and 9% of the relative antibody binding to homologous APM, 
compared with A/S 83 (anti-(rat APM)) and about 70% of the relative 
antigen abundance against homologous APM, compared with A/S 83, as 
measured by ELISA (Fig. 6.1).
Antisera raised against chicken, pig and sheep APM showed less 
cross-reactivity with homologous HPM than A/S 83 but, after 
adsorption with homologous liver homogenate, A/S 83 showed slightly 
less cross-reactivity with HPM than the other adsorbed antisera 
(Table 6.1). Adsorption with liver homogenate removed about 60% of 
the antibody binding to homologous APM of anti-(rat APM), anti— (sheep 
APM) and anti-(pig APM) antisera and about 75% of that of the 
anti-(chicken APM) antiserum.
Fig. 6.1. Antibody binding to homologous adipocyte plasma membranes 
of antisera raised against adipocyte plasma membranes 
of different species, as determined by ELISA
Antibody binding to APM of the same species as those against which 
the antiserum was raised, by antisera raised against rat AIM (RAT), 
chicken AIM (CHK), pig AIM (PIG) and sheep APM (SHP), was measured 
by ELISA. The AIM used for screening were prepared in the absence 
of BSA. Relative antibody (AB) binding and antigen (AG) abundances 
were determined, as described in Section 2.6.3.
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Table 6.1. The effects of adsorption with liver homogenate 
on the specificity of antisera 
raised against adipocyte plasma membranes of different species,
as determined by ELISA
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antibody binding and antigen abundances were calculated as described 
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6.2.3 Discussion
The antibody activity against homologous APM of antisera, 
raised against chicken, pig and sheep APM, were not as high as those 
of A/S 83. However, the relative antibody binding and antigen 
abundances of antisera, raised against rat, chicken and pig APM, were 
all of the same order of magnitude. The antisera described here were 
obtained from the best responders of only 2 or 3 animals and so it is 
not possible to draw firm conclusions from this data about the 
antigenicity of APM of different species. Antigenic similarities 
between sheep and goat APM may have contributed towards the rather 
poor response of a goat to sheep APM.
A/S 83 showed more than twice as much binding to homologous HPM 
as did antisera raised against sheep, pig and chicken APM. However, 
adsorption of A/S 83 with homologous liver homogenate removed a 
greater proportion of the anti-(HPM) binding than did adsorption of 
the antisera raised against APM of other species. After adsorption 
A/S 83 showed greater relative adipocyte specificity, as defined by 
the ratio of APM to HPM binding, than the adsorbed anti-(pig, sheep 
and chicken APM) antisera. Adsorption with liver homogenate removed 
approximately 60% of the antibody binding to rat, pig and sheep APM, 
while removing about 75% of that of the anti-(chicken APM) antiserum, 
suggesting that chicken APM may bear a particularly high proportion 
of non-adipocyte specific antigens. The anti-(chicken APM) antisemm 
did not appear to have high anti-(HPM) activity before adsorption but 
anti-(HPM) activity was measured against purified HPM, while the 
antisera were adsorbed against a crude liver homogenate. The crude 
homogenate may have been contaminated with other tissues, 
particularly erythrocytes and connective tissue, so the antisera may
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also have been adsorbed with non—hepatic tissues. Again, since 
single antisera were tested, it is not possible to draw conclusions 
about the relative proportions of antigens that cross-react with 
liver of the APM of different species.
6.2.4 Conclusions
1. High titre antisera can be generated against APM of chicken and 
pig APM, in addition to rat APM.
2. Antisera raised against rat, chicken, pig and sheep APM all
cross-react with liver but the majority of this 
crosS-reactivity can be removed by adsorption with liver 
homogenate of the species against which the antiserum was 
raised.
6.3 A COMPARISON OF ADIPOCYTE SPECIFIC ANTIGENS OF DIFFERENT
SPECIES
6.3.1 Experimental
Rat, chicken and sheep ASA were prepared using the anti-(rat 
APM), anti-(chicken APM) and anti-(sheep APM) antisera described 
above, by the method described in Section 2.9. The antigens were 
characterised by SDS PAGE as described in Section 2.4.
6.3.2 Results
Table 6.2 summarizes the performance of affinity columns used 
to prepare the chicken, sheep and rat ASA. The maximum amount of 
anti— (APM) antibody that could be bound by the APM columns was 
greatest for the anti-(rat APM) antiserum, 3% of which could be bound
Table 6.2. The performance of affinity columns 
used for the preparation of adipocyte specific antigens 
of different species
The affinity columns were used to prepare adipocyte specific 
antigens, according to the method summarized in Fig. 2.2. IgG 
binding capacity of affinity columns was measured where that amount 
of antibody that gave maximum binding to the column was added. 
Purification factors were calculated by comparing the relative 
antibody binding to the column ligand per mg of antibody in added, 
bound and unbound fractions, by ELISA.
Species Chicken Sheep Rat
ADIPOCYTE PLASMA MEMBRANE COLUMN
IgG
binding
mg antibody bound 
per mg membrane 
protein on column
0.27 0.38 0.49
capacity
mg antibody bound 
per mg added IgG 0.27 0.015 0.031
Purification
factor
(fold)
Anti-(APM) activity 
of bound IgG vs. 
initial IgG
5.0 4.4 3.4
NON-ADIPOCYTE PLASMA MEMBRANE COLUMN
IgG
binding
mg antibody bound 
per mg membrane 
protein on column
0.030 0.027 0.064
capacity
mg antibody bound 
per mg added IgG 0.20 0.23 0.33
Purification
factor
(fold)
Anti-(HPM) activity 
of unbound IgG vs. 
added IgG
<0.02 <0.02 <0.02
ADIPOCYTE SPECIFIC ANTIBODY COLUMN
Membrane
mg antigen bound 
per mg IgG on column
0.049 0.014 0.028
binding
capacity mg antigen bound 
per mg added 
membrane protein
0.022 0.022 0.050
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by the column and was least for the anti-(sheep APM) antiserum, 1.5% 
of which could be bound. When binding to APM by the antibody
fraction, purified from the APM column, was compared with that of the 
original antiserum, anti-(APM) activity was found to be increased by
3.4 to 5 fold, when expressed per mg of protein. Adsorption of 
antibodies with HPM, KPM and EPM resulted in anti-(APM) antibodies of 
similar specificities for all 3 species. The adsorption removed 20,
23 and 33% of the anti-(APM) antibody fraction for the chicken, sheep
and rat respectively. The specific anti-(rat APM) antibody column 
was able to bind 5% of the total solubilised rat APM protein while
the specific anti-(chicken APM) and anti-(sheep APM) antibody columns 
were able to bind only 2.2% of solubilised chicken and sheep APM.
SDS PAGE showed that rat, sheep and chicken APM consisted of at 
least 19, 18 and 31 major polypeptides respectively (Fig. 6 . 3 ) ,  while 
the ASA of chickens and rats consisted of 5 and 6 major polypeptides 
respectively, and that of sheep consisted of 7 major polypeptides 
with the following approximate molecular weights.
SPECIES MOLECULAR WEIGHT (kD)
Rat 96 88 72 59 53
Sheep 112 96 85 72 44
Chicken 102 88 72 38 36
The 59 kD protein of the rat ASA was a doublet
Each preparation also included a small number of minor 
polypeptide bands.
Fig. 6.3. Polyacrylamide gel electrophoresis 
of rat, sheep and chicken adipocyte plasma membranes 
and adipocyte specific antigens
CHK MM RAT SHP CHK RAT SHP
ASA ASA ASA APM APM APM
Chicken (CHK), rat (RAT) and sheep (SHP) AIM and ASA were prepared, 
as described in Section 2.9 and were separated by SDS PAGE and stained 
with Coomassie blue, as described in Section 2.10. The molecular 
weight markers (MM) were carbonic anhydrase, ovalbumin, BSA, 
phosphorylase 6, B galactosidase and myosin with molecular weights 
of 29, ^5, 66, 97. 1 1 6  and 205 kD respectively.
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6.3.3 Discussion
The APM columns of all 3 species, used for the affinity 
purification of anti-(APM) antibodies, did not bind as much antibody 
as would be expected for high titre antisera. Possible reasons for
this were discussed in Section 4.3.3.2. Adsorption of the
anti-(chicken APM) antiserum using the HPM, KPM and EPM affinity
column did not remove as much antibody as did a corresponding 
adsorption of the anti-(rat APM) antiserum. This contrasts with the 
effects of adsorption of the whole antiserum with liver homogenate, 
which removed more anti-(APM) activity of the anti-(chicken APM) than 
the anti-(rat APM) antiserum. The HPM, KPM and EPM used for the
preparation of the affinity column were purified plasma membrane 
preparations while, as discussed in Section 6.2.3, the liver 
homogenate may have included non-hepatic components, such as 
connective tissues.
The rat ASA apparently constituted more than twice as much of 
the total APM protein as the chicken and sheep ASA. However, this
conclusion can only be drawn if it is assumed that the APM of all 3
species were solubilized with equal efficiency and that the 
anti-(APM) antibodies of the 3 species, used to prepare the affinity 
columns, were of equal affinity and, once bound to the
immuno-absorbant, were equally able to bind antigen. There is no 
evidence that these conditions were satisfied and, hence, it is not 
possible to draw conclusions about the relative proportions of APM of 
the different species which comprised the ASA.
The ASA of the 3 species were all considerably enriched in 
certain polypeptides, compared with the whole APM. The sheep ASA 
appeared to contain more major components than the rat and chicken
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ASA, although SDS PAGE of chicken ASA was difficult to interpret 
because, while apparently equivalent amounts of protein were loaded 
on the gel for the ASA of the 3 species, bands on the chicken ASA 
were difficult to visualise using Coomassie blue.
6.3.4 Conclusions
1. The affinity purification of APM antigens, using anti-(APM) 
antibodies from which more than 95% of the cross-reactivity 
with HPM, KPM and EPM had been removed, resulted in 
preparations considerably enriched in 5, 6 and 7 polypeptides 
for the chicken, rat and sheep respectively.
6.4 CROSS-REACTIVITY BETWEEN ADIPOCYTE PLASMA MEMBRANES AND 
ADIPOCYTE SPECIFIC ANTIGENS OF DIFFERENT SPECIES
6.4.1 Experimental
Binding of antisera raised against rat, chicken, sheep and pig 
APM to APM of the same and of the 3 different species was measured by 
ELISA. Binding to rat, sheep and chicken ASA of the anti-(rat APM) 
and the anti-(chicken APM) antiserum was measured by Western
blotting. Satisfactory Western blots could not be obtained using the 
anti-(sheep APM) antiserum.
6.4.2 Results
All anti-(APM) antisera showed less than 5% of the antibody 
binding to heterologous compared with homologous APM. Relative 
antigen abundances against heterologous APM, however, ranged from 5 
to 60% of those against homologous APM.
Fig. 6.2. Species cross-reactivity of antisera 
raised against adipocyte plasma membranes 
of different species, as determined by ELISA
Antibody activity against rat APM (RAT), pig APM (PIG), sbeep APM 
(SHP) and chicken AIM (CHK) by antisera raised against rat APM, pig 
APM, sheep APM and chicken AIM was measured by ELISA. The APM used 
for screening were prepared in the absence of BSA. Relative antibody 
binding and antigen abundances were determined as described in Section
2.6.3 and are expressed as a percentage of that to homologous APM.
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Difficulties experienced in the interpretation of Western blots 
were discussed in Section 4.3.3. Using the same scale as was used in 
that Section, the components of the ASA of the 3 species recognised 
by the anti-(rat APM) and the anti-(chicken APM) are shown in Table 
6.5« The antisera bound more strongly and recognised more bands on 
homologous than heterologous ASA but both antisera recognised some 
bands on heterologous ASA. Proteins with approximate molecular 
weights of 96, 85 and 72 kD were recognised by the anti-(rat APM) 
antiserum in ASA of all 3 species while the 85 kD protein was not 
recognised by the anti-( chicken APM) antiserum in any of the ASA 
preparations.
6.4.3 Discussion
Despite the low antibody binding of all the anti-(APM) antisera 
tested against heterologous APM, the relative antigen abundances 
showed that there was some cross-reactivity between APM of different 
species. It is possible that antigens shared between species were 
present at a low frequency on the APM. Alternatively, minor changes 
in amino acid sequence of antigens of different species might result 
in antibodies having a lower affinity for antigens of a different 
species than for corresponding antigens of the species against which 
the antibodies were raised.
As was discussed in Section 4.3.3, the use of single antiserum 
dilutions for Western blotting does not allow conclusive 
determinations of whether or not a polypeptide is recognised by an 
antiserum. The Western blots did, however, provide evidence of 
cross-reactivity between ASA of different species and show additional 
polypeptides in the ASA preparations, not visible by Coomassie blue
Fig. 6.U. Species cross-reactivity of adipocyte specific antigens 
of different species, as determined by Western blotting
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The binding to sheep (SHP), chicken (CHK) and rat (RAT) ASA by 
antisera raised against rat APM (A/S 83) and chicken APM (A/S 6^2) 
was measured by Western blotting, as described in Section 2.11. 
Polypeptide bands mentioned in the text have been indicated by P, 
followed by the approximate molecular weights in kD.
P72
•P59
SHP CHK RAT
SHP CHK RAT
Table 6.3. Binding of anti-^ ( adipocyte plasma membrane) antisera
to adipocyte specific antigens,
as determined by Western blotting
Rat ASA P96 P90 P85 P72 P59 P53 P47 P43
Anti-(rat APM) +++ + + +++ + ± + +
Anti-(chicken APM) - - - + + - - -
Chicken ASA P102 P96 P88 P85 P72 P42 P38 P36
Anti-(rat APM) - + - + ± - - -
Anti-(chicken APM) + +++ + - + + + +
Sheep ASA P96 P85 P72
Anti-(rat APM) + ± ++
Anti-(chicken APM) + +
Binding of antisera raised against rat, chicken and sheep APM to rat, 
chicken and sheep ASA was measured by Western blotting, according to 
the methods described in Section 2.11. Intensity of bands was 
assessed on a scale from - to +++, as described in Section 4.3.2. 
Bands are denoted by the letter P, followed by the approximate 
molecular weight (kD).
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staining following SDS PAGE. Western blotting, using iVS 83, 
revealed 2 low molecular weight proteins in the rat ASA, not clearly 
visible by coomassie blue staining or on a previous Western blot 
using A/S 83 (Fig. 4.2). Since the same ASA preparation was used for 
both blots, differences in the activity of the anti-(sheep IgG) 
antiserum or the peroxidase-anti-peroxidase preparation, used for 
detection of antiserum binding, may have contributed towards these 
differences in sensitivity. Western blotting of the anti-(chicken 
APM) antiserum against chicken ASA showed clear binding of 5 major
polypeptides, one of which had an approximate molecular weight of
v
96 kD and was not clearly visible by SDS PAGE. Western blotting also 
revealed at least 2 more minor components of the preparation. Despite 
the evidence of additional polypeptide components shown by Western 
blotting, when Western blots of antiserum binding to whole APM and 
ASA were compared, the ASA preparations still appeared to be
considerably enriched in certain polypeptides.
A/S 83 (anti-(rat APM)) recognised a 72 kD protein (P72)
strongly on the rat ASA and more weakly in the sheep and chicken ASA. 
The possibility was raised in Section 4.3.3 that P72 might be 
albumin. The presence of P72 in the chicken ASA suggests that this 
is not the case because ovalbumin has a molecular weight of 45 kD. 
Since the ASA was prepared from APM, isolated in the absence of BSA,
the only possible source of a 72 kD albumin in the chicken ASA is
ovine albumin which might have contaminated the sheep IgG used to 
prepare the affinity column, used for the isolation of the ASA. As 
described in Section 4.3.3, the rat ASA appeared to be contaminated 
with sheep IgG that had leached off the affinity column during the 
ASA preparation. While theoretically possible, significant
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contamination of the sheep IgG with albumin seems unlikely, as the 
sheep IgG was affinity purified after ammonium sulphate 
precipitation. It is possible, therefore, that P72, in addition to 
P96 and P85, both of which were recognised by A/S 83 on the rat, 
chicken and sheep ASA preparations, were common to sheep, chicken and 
rat APM, or at least bore shared epitopes in the 3 species. Since 
A/S 83 bound less strongly to P72, P85 and P96 of the sheep and
chicken ASA than to the rat ASA proteins, these proteins may be 
present at a lower frequency on the sheep and chicken ASA than on the 
rat ASA or there may be minor differences in the proteins of the 
different species, resulting in a lower affinity of A/S 83 for the 
sheep and chicken proteins, compared with the rat proteins. The 
anti-(chicken APM) antiserum did not apparently recognise P85 and did 
not recognise P96 of the rat ASA. This may be because of a 
difference in titre or affinity of this antiserum, compared with A/S 
83, or proteins of the 3 species, while having similar 
electrophoretic mobilities, may be completely unrelated proteins.
6.4.4 Conclusions
1. While there was some cross-reactivity between APM and ASA of 
different species, as shown by ELISA and Western blotting, 
binding of antisera to APM and ASA of heterologous species was 
very low, compared with that to respective homologous species.
2. While there were proteins of similar molecular weights in the 
ASA preparations of different species, binding of antisera to 
such proteins varied in strength between ASA of different 
species. Proteins of similar molecular weights in the 
different ASA preparations cannot, therefore, be 
antigenically identical.
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3. It is likely that different antisera and immunogens must be 
produced for the passive and active immunisation of different 
species against the adipocyte.
6.5 ACTIVE IMMUNISATION OF LAMBS
6.5.2 Experimental
6.5.1.1 Experiment 1
This experiment was performed in collaboration with Dr. S. 
Rhind at the Hill Farming Research Organisation (Penicuik, 
Midothian), using twin Scottish Blackface lambs. One lamb of each 
pair, when 2-4 weeks old, was immunised, subcutaneously at 3 sites, 
with 100 //g of Blackface sheep APM conjugated to 100 /jg of rabbit 
serum albumin (RSA) in complete Freunds adjuvant, by the method 
described in Section 5.2. Lambs were boosted with APM conjugated to 
RSA in incomplete Freunds adjuvant at 3 and 7 weeks and with 
unconjugated APM in incomplete Freunds adjuvant at 13 and 21 weeks. 
The other lamb of each pair received the same treatment, with the 
exclusion of APM, at 0, 3 and 7 weeks and received no subsequent 
boosts. Body weights were recorded at 2-weekly intervals. Lambs 
were bled at 7, 10, 12, 15, 18, 21, 23, 27 and 29 weeks after the 
first immunisation and the serum was assayed for anti-(APM), 
anti-(HPM) and anti-(KPM) antibodies by ELISA. Lambs were killed at 
about months of age and carcass analysis was performed as 
described in Section 2.14.4.
6.5.1.2 Experiment 2
Experiment 2 was performed as for Experiment 1, with the 
following exceptions. Control lambs received no immunisation.
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Treated lambs were immunised with sheep APM conjugated to RSA in 
complete Freunds adjuvant at 2-4 weeks of age and were boosted with 
the same immunogen in incomplete Freunds adjuvant at week 6. They 
then received sheep ASA conjugated to RSA in incomplete Freunds 
adjuvant at week 14 and unconjugated ASA in incomplete Freunds 
adjuvant at week 25. After weaning, food intake was measured weekly.
The binding of serum from the actively immunised lambs to APM, 
prepared from adipocytes isolated in the presence of BSA, and to APM, 
prepared by homogenisation of adipose tissue in the absence of BSA, 
was measured by ELISA.
Delayed type hypersensitivity of lambs was tested at week 30, 
by injecting, intradermally, 100 jjI  of RSA (1 mg/ml), APM (1 mg/ml) 
or PBS in a shaved area of the back and measuring the diameter of the 
swelling 24 and 48 h later.
6.5.2 Results
6.5.2.1 Apparent anti-(adipocyte plasma membrane) responses in 
actively immunised lambs
In Experiment 1, serum from lambs immunised with APM conjugated 
to RSA and with RSA alone bound to sheep APM (prepared in the 
presence of BSA), as determined by ELISA (Fig. 6.5). The use of APM, 
prepared from adipocytes isolated in the presence of gelatin, for 
screening of antisera gave similar results (results not shown). The 
apparent response to APM of lambs immunised with APM was 
significantly greater, by a factor of at least 100 fold, than that of 
lambs immunised with RSA alone, 15 weeks after the first 
immunisation.
Fig. 6.5- The apparent antibody response
to adipocyte, hepatocyte and kidney plasma membranes
in actively immunised lambs
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Lambs were immunised with either RSA (open symbols) or APM conjugated 
to RSA (closed symbols) in Freunds adjuvant. Antibody binding to 
APM prepared in the presence of BSA (circles), HPM (squares) and 
KIM (triangles) of serum from actively immunised lambs 15 weeks after 
the first immunisation was measured by ELISA. Results are means 
+ SEM of 8-10 observations.
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In Experiment 2, lambs immunised with APM followed by ASA
showed similar apparent responses to APM (prepared in the presence of 
BSA) to those induced by immunisation with PiP'fH in Experiment 1 
(Fig. 6.6).
Apparent anti-(APM) responses in RSA-treated
lambs were relatively constant between 5 and 28 weeks after the first 
immunisation, while those of APM-immunised lambs of Experiment 1 
reached a peak at about 18 weeks after the first immunisation, before 
gradually declining (Fig. 6.6).
The binding of serum from actively immunised lambs of 
Experiment 2 to APM, prepared by homogenisation of intact adipose 
tissue in the absence of BSA, was not significantly above those 
achieved by sera from untreated lambs (Table 6-A-).
6.5.2.2 The tissue specificity of antibody responses in actively
immunised lambs
Very little anti-(HPM) or anti-(KPM) antibody responses could 
be detected, by ELISA, in lambs immunised with RSA alone or with APM 
followed by ASA in Experiment 2 (Fig. 6.5). A low level of binding 
to HPM and KPM of sera from lambs immunised with APM in Experiment 1 
was detected.
6.5.2.3 Delayed type hypersensitivity of actively immunised lambs 
The majority of lambs of Experiment 2 that had been treated
with APM conjugated to RSA, followed by ASA, developed 1-1.5 cm 
swellings in response to RSA at 24 and 48 h after injection and 
showed virtually no response to APM or PBS.
6.5.2.4 The effects of active immunisation on adipose tissue
There was no difference in mass of any of the adipose depots
studied between APM-immunised and RSA-immunised lambs of Experiment 1
Fig. 6.6. The change in apparent antibody response
to adipocyte plasma membranes
in actively immunised lambs with time
Lambs were immunised with either RSA (open circles), APM conjugated 
to RSA (closed circles) or APM followed by ASA conjugated to RSA 
(closed squares) in Freunds adjuvant. Antibody binding to APM, 
prepared in the presence of BSA, by serum from actively immunised 
lambs was measured by ELISA. The standard was a goat anti—(sheep 
APM) antiserum.
(pjepue^s %) 6u>pu^q (WdV)-HuV
Table 6.4. The role of anti-(BSA) antibody responses
in apparent anti-(adipocyte plasma membrane) antibody responses
of actively immunised lambs
Antiserum
Binding to APM prepared in the absence 
of BSA as % of binding 
to APM prepared in the presence of BSA
Relative antibody 
binding
Relative antigen 
abundance
Goat anti-(sheep APM) 16 100
Actively immunised lambs 0 0
The goat was immunised with sheep APM conjugated to RSA and the 
lambs were immunised with sheep APM, followed by sheep ASA conjugated 
to RSA. Binding to APM prepared from adipocytes isolated in the 
presence of BSA and to APM prepared from whole adipose tissue in the 
absence of BSA was measured by ELISA. Relative antibody binding and 
antigen abundances were determined as described in Section 2.6.3.
176
(Table 6 . S ) .  Immunisation with APM followed by ASA in Experiment 2 
caused significant reductions in mass of inter-muscular, kidney 
channel and omental adipose tissue, compared with untreated controls 
(Table 6 . S ) .  When adipose tissue mass was expressed as a percentage 
of body weight, the differences between the 2 groups were reduced to 
non-significant levels. While total lean body mass was reduced in 
immunised lambs compared with controls, when expressed as a 
percentage of body weight immunised lambs showed a greater percentage 
of lean tissue than controls, although this difference was not 
significant.
6.5.2.5 The effects of active immunisation on body weight gain, food 
intake and food conversion efficiency 
There were no significant differences in body weight gain 
between APM- and RSA-treated lambs of Experiment 1 (Fig. 6.7) In 
Experiment 2, treated lambs showed significantly reduced body 
weights, compared with untreated controls, from about 8 weeks after 
the first immunisation (Ficj. 6-7 ). Food intake was measured between
22 and 28 weeks after treatment. During this period, treated lambs 
ate significantly less food but also gained less weight, resulting in 
a similar food conversion efficiency to controls (Table 6.6).
6.5.3 Discussion
6.5.3.1 Apparent anti-(adipocyte plasma membrane) antibody responses 
of actively immunised lambs 
As with the active immunisation of rats, the detection of 
apparent anti-(APM) antibodies in the sera of lambs immunised with 
RSA alone raised the question of whether anti-(BSA), rather than 
anti— (APM) responses were actually being measured. Again the sera
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Fig. 6.7- Body weights of actively immunised lambs
Lambs were immunised with either BSA (open circles), APM conjugated 
to BSA (closed circles) or APM followed By ASA conjugated to ESA 
(closed squares) or were untreated (open squares).
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Table 6.6. The effects of immunisation
with adipocyte plasma membranes and adipocyte specific antigens
on body weight gain, food intake and food conversion efficiency
Treatment None
APM-RSA
ASA-RSA
Weight gain 0.21 0.19
(kg/day/1 amb) ±0.012 ±0.016
Food intake 1.92 1.72**
(kg/day/lamb) ±0.048 ±0.077
Food intake - maintenance 1.41 1.28
requirement (kg/day/lamb) ±0.044 ±0.068
Intake - maintenance 6.90 6.91
Gain ±0.41 ±0.40
Lambs were immunised with APM followed by ASA conjugated to RSA in 
Fruends adjuvant or were untreated. Weight gain and food intake were 
measured between 20 and 36 weeks after the first immunisation. The 
daily maintenance requirement was assumed to be 12 g/kg body weight. 
Results are means ± SEM of 8 observations. **P<0.005, compared with 
controls (Student's paired t test, pairing siblings).
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bound equally well to APM prepared from adipocytes isolated in the 
presence of BSA or gelatin (results not shown), so it was assumed 
that a true anti-(APM) response was being measured. The discovery 
that serum from actively immunised rats did not bind to APM, isolated 
from homogenised adipose tissue in the absence of BSA, was not made 
until after the initiation of the second experiment involving the 
active immunisation of lambs. Consequently, in the second 
experiment, the controls were completely untreated. It would, 
clearly, have been ideal to have included 2 sets of controls, one of 
which was untreated and one of which received RSA alone. However, 
the results of the active immunisation experiments with rats 
suggested that the use of siblings in different treatment groups was 
important for the demonstration of effects and so twin lambs were 
used, allowing 2 treatment groups only.
Unlike the corresponding experiments with rats, lambs,
U.vicl
immunised with APfl^ , showed a greater apparent anti-(APM) response 
than RSA-immunised controls.
The sera of lambs immunised with ASA were subsequently 
shown to be virtually devoid of antibody activity against APM, 
prepared from homogenised tissue in the absence of BSA. While SDS 
PAGE of sheep APM, prepared in the presence of BSA, was not 
performed, it is likely that, since the method used was identical to 
that used for rat APM, sheep APM, like rat, were contaminated with 
BSA. Therefore, the apparent anti-(APM) response in RSA-immunised and 
RSA with ASA-immunised lambs may have been due to binding of 
anti-(RSA) antibodies (that cross-reacted with BSA) to BSA 
contaminating the APM used for screening. The APM-immunised lambs of
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Experiment 1 received, in addition to RSA, APM that were probably- 
contaminated with BSA and so a greater anti-(BSA) response than seen 
in the RSA-immunised lambs may have been induced, resulting in a 
greater apparent anti-(APM) response. However, it had previously 
been found that sheep immunised with rat APM, contaminated with BSA, 
produced a poorer anti-(BSA) response than rats immunised with the 
same immunogen, suggesting that BSA is poorly immunogenic in sheep. A 
higher apparent anti-(APM) response in lambs immunised with APM and 
RSA than in those immunised with RSA alone may, therefore, have been 
due to a true anti-(APM) response.
Since no convincing anti-(APM) response could be demonstrated 
in ASA-immunised lambs, sheep ASA may be poorly immunogenic in lambs. 
However, due to the scarcity of the sheep ASA, the lambs only 
received 2 immunisations of this material and it was not possible to 
screen the antisera directly against sheep ASA.
6.5.3.2 The specificity of antibody responses of actively immunised 
lambs
The serum from lambs immunised with sheep APM, in common with 
that from rats immunised with rat APM, showed little cross-reaction 
with other tissues. However, while serum from rats immunised with 
rat ASA showed considerable cross-reactivity with non-adipose 
tissues, serum from lambs immunised with sheep ASA showed no 
demonstrable binding to non-adipose tissues. It was suggested in 
Section 5.4.2 that the lack of adipose specificity of the rat sera 
may have been related to the anti-(sheep IgG) response of actively 
immunised rats. The sheep ASA may have been contaminated with goat 
IgG but this would be unlikely to be highly immunogenic to sheep. 
Alternatively, the sheep ASA may have included fewer antigens that
179
cross-reacted with other tissues than the rat ASA. However, since no 
convincing anti-(APM) response was measured in ASA-immunised lambs 
and it was not possible to screen the antisera against ASA, it is not 
known whether there was any response to the ASA preparation at all.
6.5.3.3 The effects of active immunisation on body composition, 
body weight gain and food intake
In Experiment 1 there was no difference between body weight 
gain or body composition between treated and control lambs (Table 
6.4). In Experiment 2, the most clear difference between treated and 
control animals was the reduced body weight of the treated group 
which was evident from 8 weeks after the first treatment (Fig. 6.7). 
It is possible that this was a non-specific effect relating to the 
use of Freunds adjuvant, since both groups of lambs in Experiment 1 
received Freunds adjuvant and showed reduced body weights, compared 
with the untreated group from Experiment 2. However, as the 2 
experiments were performed in different years, the difference in the 
body weights achieved in the 2 experiments may be due to factors 
unrelated to the experimental treatment. Treatment of rats with 
Freunds adjuvant had no effect on body weight gain.
The reduction in body weight of the treated lambs of Experiment 
2 was reflected in reduced weights of both adipose and lean tissue. 
However, the percentage mass of lean tissue was increased and the 
percentage mass of adipose tissue was reduced in the treated group, 
compared with controls, although these differences were not 
significant. This suggests that, in addition to a non-specific 
effect on growth, there was some repartitioning of energy from fat 
into protein deposition. As in the rat, this could not be correlated 
with the presence of circulating anti-(APM) antibodies and further
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emphasises the importance of devising assays for antibody-producing 
cells and cell-mediated immune responses. Delayed type 
hypersensitivity tests did not show a response to APM, but such tests 
are not always successful using insoluble antigens.
The reduced body weight gain in treated animals could be 
correlated with a reduction in food intake (Table 6.5). Lipectomy 
can result in a reduction in food intake in rats when the capacity 
for fat storage has been reached (Faust, 1977), but, as a reduction
in food intake was measured only 8 weeks after the first treatment,
the reduction in food intake of actively immunised lambs was unlikely 
to be due to a reaching of the maximum capacity for fat storage. It 
is not known whether actively immunised lambs had, like the rat, 
fewer but larger adipocytes than controls. Mears and Mendel (1974) 
found that food intake was greater in sheep with larger numbers of 
adipocytes. These authors suggested that the amount of glucose 
removed from a central pool might act as a feedback signal, inducing
a high long-term food intake. Such a mechanism could contribute
towards the reduced food intake in the actively immunised lambs, if 
those animals had reduced adipocyte numbers. In contrast Graham 
(1969) found that fatter sheep tended to have a reduced food intake 
compared with their leaner counterparts. However, these differences 
were only demonstrable in lambs whose degree of adiposity varied to a 
much greater extent than that achieved in the active immunisation 
experiments.
6.5.3.4 Conclusions
1. Immunisation of lambs with sheep APM conjugated to RSA in 
Freunds adjuvant had no effect on adiposity or body weight, 
compared with RSA-immunised controls.
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2. Immunisation of lambs with sheep APM followed by sheep ASA 
conjugated to RSA in Freunds adjuvant caused a significant 
reduction in body weight and fat pad weight compared with 
untreated controls.
3. Anti-(APM) antibodies could not be convincingly demonstrated in 
lambs immunised with APM or ASA conjugated to RSA.
CHAPTER 7 
FINAL DISCUSSION
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a stronger response to BSA and no clearly demonstrable response to 
rat APM. Gel electrophoresis of the APM used as immunogens showed a 
high level of contamination with BSA. Rat APM are likely to be 
highly immunogenic in sheep, whereas BSA probably shows considerable 
antigenic similarity with ovine albumin and so exhibits poor 
immunogenicity in this species. In addition, antibodies directed 
against auto-antigens frequently bind to a very restricted number of 
epitopes on that antigen, while xenogeneic antisera to the same 
antigen recognise a much wider range of epitopes. For example, the 
majority of human anti-(thyroglobulin) antibodies are directed 
against 2 epitopes of human thyroglobulin, while rabbit anti-(human 
thyroglobulin) antisera recognise about 40 epitopes on the molecule 
(Nye, Pontes de carvatho and Ratt, 1980). These authors suggested 
that some epitopes were less effective than others at inducing 
tolerance, whether through the direct tolerisation of B cells or 
through establishment of specific suppressor mechanisms, such as 
antigen or idiotype-specific T suppressors for the stimulation of 
anti-idiotype clones.
There were also differences in the immune response of sheep and 
rats to rat ASA. While the immunisation of sheep with rat ASA 
induced the production of an antiserum that, according to the 
results of ELISA and in vivo studies, showed more adipocyte 
specificity than sheep antisera raised against whole APM, the 
autoimmunisation of rats with rat ASA induced the production of 
antisera that, according to the results of ELISA, showed more 
cross-reactivity with non-adipose tissues than rat antisera raised 
against whole APM. It was suggested in Section 5.4.2 that the 
cross-reactivity with non-adipose tissue might, in some way, relate
184
to the rat immune response to sheep IgG, which was a contaminant of 
the ASA. Since sheep IgG would not be highly immunogenic in a sheep, 
this may account for the apparently more tissue-specific response 
induced by immunisation of sheep with rat ASA, compared with that 
induced in the rat by the same immunogen.
It should also be borne in mind that the measurement of 
circulating antibodies in actively immunised rats may not provide an 
accurate measure of the true antibody responses induced by 
autoimmunisation since antibodies binding to autoantigens may be 
sequestered within the target tissues.
7.1.2 Differential effects of passive and active immunisation 
against the adipocyte on adipocyte numbers and volume
Passive immunisation of rats by intraperitoneal administration 
of an anti-rat (APM) antiserum caused a 50% reduction in parametrial 
adipocyte numbers, which persisted for at least 24 weeks after 
treatment (until 30 weeks of age). Active immunisation against rat 
APM caused a 40-50% reduction in parametrial adipocyte numbers, which 
was evident 16 weeks after the first immunisation (at 20 weeks of 
age). Passive immunisation also caused a reduction in parametrial 
adipose tissue mass, which comprised of a reduction of 50% at 24 
weeks after treatment, while active immunisation did not 
consistently cause a reduction in parametrial adipose tissue mass. 
This difference was apparently due to the fact that, in actively 
immunised rats, fat reduction due to decreased numbers of adipocytes 
was compensated for by the enlargement of remaining adipocytes to an 
abnormally large volume, whereas there was no such compensatory 
increase in the size of remaining parametrial adipocytes of passively 
immunised rats.
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The ability of passive immunisation to inhibit the compensatory 
increases in adipocyte volume, seen in actively immunised rats, may 
have been the result of differences in the intensity or nature of the 
immune effector mechanisms recruited by passive, compared with 
active, immunisation. The effects of passive immunisation must have 
been dependent upon the presence of anti-(APM) antibodies and were 
also shown to be characterised by complement activation and 
infiltration of adipose tissue with polymorphonuclear leucocytes and 
lymphocytes. Whilst rat anti-(APM) antibodies arising from 
activation of the host idiotypic network in response to sheep 
anti-(APM) could not be detected in passively immunised rats, an 
increased anti-(sheep IgG) response was measured in these animals. 
Binding of rat antibodies to sheep anti-(APM) antibodies, already 
bound to adipocytes, may have resulted in the enhanced activation of 
immune effector mechanisms and contributed towards the inhibition of 
compensatory increases in adipocyte size in passively immunised rats. 
Such a mechanism has been proposed for the production of prolonged 
kidney disease in rats, passively treated with xenogeneic 
anti-(kidney) antisera (Unanue and Dixon, 1967). Circulating 
anti-(APM) antibodies could not be convincingly demonstrated in 
actively immunised rats, but this does not necessarily indicate the 
total absence of such antibodies, as already discussed. 
Alternatively, T-cell mediated immune responses may have been 
responsible for the reduction in adipocyte number in actively 
immunised rats. Clearly, the development of cell-mediated 
cytotoxicity assays and histological and immunohistochemical 
examination of adipose tissue of both passively and actively 
immunised rats will be required to determine the location and density
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of antibodies, the precise nature of any cellular infiltrates in the 
tissue and thereby the probable cell-killing mechanisms involved.
There were differences in the responses of different adipose 
depots to passive immunisation and these differences were found to be 
due, largely, to the site of injection. Passive immunisation may, 
therefore, have had a greater effect on adipose tissue mass than 
active immunisation because a high concentration of antibody could be 
targeted to the tissue by the mode of administration.
7.1.3 Differential effects of passive and active immunisation 
against the adipocyte on non-adipose tissues
Passive immunisation with A/S 83 had no effect on body weight 
with lost fat compensated for by the deposition of protein and water. 
Body composition analysis was not performed on actively immunised 
rats. However, in the single active immunisation experiment where a 
reduction in adipose tissue mass was observed, there was also a 
reduction in body weight and in subsequent experiments there was 
neither a reduction in adipose mass nor in body weight. A 
significant increase in protein deposition in actively-immunised rats 
seems, therefore, unlikely. It is possible that A/S 83 had direct 
effects on muscle which were not mimicked by antibodies induced by 
active immunisation. Alternatively, the increase in protein 
deposition in passively immunised animals may have resulted from a 
decrease in competition between adipose tissue and muscle for common 
biochemical substrates. Since fat deposition was not decreased in 
actively immunised rats, such a reduction in competition between the 
2 tissues would not occur.
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No evidence of proteinurea could be found in actively immunised 
rats, providing further evidence that the transient nephritis 
observed in passively immunised rats was related to the rat immune 
response to sheep IgG. However, circulating antibodies of rats 
actively immunised with whole APM, in contrast to A/S 83, bound very 
poorly to kidney plasma membranes. Antibodies directed against renal 
antigens may have been sequestered by the kidney and, thus, would not 
have been present in the circulation, although it could have 
represented a truly poor response to kidney antigens since 
autoimmunisation frequently produces more tissue-specific antisera 
than cross-species immunisation (Shulman, 1974). Paradoxically, rats 
immunised with rat ASA did produce circulating antibodies that bound 
to kidney plasma membranes but no signs of proteinurea were found in 
these animals. Before it can be concluded that the active 
immunisation procedures used had no effects on the kidneys, more 
frequent urine sampling would be required, since nephritis induced by 
antibody or immune complexes can be of a highly transient nature.
No gross abnormalities of the liver, such as were seen in rats 
treated with certain anti-(APM) antisera, were ever observed in 
actively immunised rats. Circulating antibodies binding to 
hepatocyte plasma membranes were barely detectable in rats immunised 
with whole APM but were detectable in rats immunised with adipocyte 
specific antigens. Again, the measurement of circulating antibodies 
may not give an accurate indication of immune responses in actively 
immunised rats.
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7.2 POTENTIAL USES AND LIMITATIONS OF PASSIVE AND ACTIVE
IMMUNISATION AGAINST THE ADIPOCYTE
The reduction of body fat in meat-producing species and
humans
The requirement for the demonstration of the reduction of
adiposity by passive or active immunisation against the
adipocyte in a species other than the rat 
The majority of the work described in this thesis was performed 
using the rat, in the hope that this species might prove to be a 
useful model for the effects of passive or active immunisation 
against the adipocyte in other species, including man. While much of 
the reported work aimed at studying the characteristics and control 
of the development of adipose tissue has been performed using the 
rat, this species is unusual in that the long bones of the rat 
continue to grow throughout life and adiposity also increases 
throughout life. Thus, the rat might prove a useful model for 
meat-producing species which are generally killed when they are still 
in a growth phase and adiposity is increasing. It might not, 
however, prove a good model for the treatment of humans since, in 
many cases, treatment would be required in the adult human when the 
growth phase has essentially stopped. Passive immunisation was 
performed exclusively with young lean animals in the experiments 
described in this thesis and it would clearly be useful to examine 
the effects of passive immunisation on mature or obese animals, where 
large amounts of adipose tissue are available for destruction and/or 
triglyceride mobilization.
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A comparison of the effects of active immunisation in rats and 
lambs gives some indication of the usefulness of the rat as a model 
for the effects of active immunisation in sheep. Similar 
immunisation protocols induced similar apparent antibody responses in 
the 2 species. There were differences in the effects of active 
immunisation on body weight gain in the 2 species which may have been 
because sheep are more susceptible than rats to the non-specific 
toxic effects of Freunds adjuvant. Unfortunately, it was not 
possible to measure adipocyte sizes of lambs and so a comparison of 
the effects of active immunisation of the 2 species on adiposity 
could not be made. While it was possible to raise antisera against 
chicken and pig APM with similar binding activities to homologous 
plasma membranes to A/S 83, time did not permit the evaluation of the 
in vitro effects on isolated adipocytes or the in vivo effects of 
these antisera. A comparison of the binding of anti-(APM) antisera 
to APM of different species showed that there are major antigenic 
differences between APM of different species, emphasizing the 
probable requirement for different immunogens and antisera for each 
species, although conserved and therefore weakly immunogenic antigens 
may exist which could be used in more than one species.
Although it can never be assumed that the results of passive or 
active immunisation against the adipocyte will be the same in other 
species as in the rat, studies with the rat could be extremely useful 
in the identification of potential problems and promising approaches. 
For instance, in vitro antiserum screening assays and methods of 
preparing adipocyte specific antigens could be developed for the rat, 
before application to other species.
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Whatever animal models are chosen for the examination of the 
effects of passive or active immunisation, efforts should be made to 
improve the adipocyte specificity of immunogens and antisera and in 
vitro assays able to predict the in vivo effects of antisera would 
greatly improve the screening of potentially useful antibodies. In 
addition, more information is required about the effects of
immunization in the short and long-term, both on adiposity and animal 
health.
7.2.1.2 The requirement for adipocyte specificity
The failure to reproduce the in vivo effects of early bleeds of
A/S 83 with later bleeds of A/S 83 emphasizes the potential advantage
of monoclonal antibodies against APM determinants, which would 
provide an unlimited supply of antibodies of a defined titre, 
specificity and cytotoxicity. Since the whole APM has a complex 
antigenic composition, attempts were made to identify adipocyte
specific antigens which were important in the fat-reducing properties 
of the polyclonal antisera, so that such antigens could be used for 
the production of monoclonal antibodies.
It was also hoped that polyclonal and monoclonal antisera, 
raised against adipocyte specific antigens, might be devoid of the 
undesirable side effects of antisera raised against the whole APM, 
such as the immediate effects on food intake and subsequent effects 
on the kidney and liver. In addition, the use of highly-purified, 
well-defined adipocyte specific immunogens for active immunisation 
might eliminate one potential cause of variability in the response 
induced by immunistion with whole APM.
Adsorption of an antiserum raised against the whole APM (A/S 
164) with liver rendered that antiserum more adipocyte specific, as
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indicated by ELISA. This antiserum retained its fat-reducing 
properties in vivo but no longer caused liver abnormalities. This 
was an important discovery because, while the adsorbed antiserum was 
not totally adipocyte specific, it did indicate that antibodies 
directed against adipocyte specific antigens could cause a reduction 
in adiposity and so provided impetus for the preparation of adipocyte 
specific antigens. The adsorbed antiserum still had anaesthetic-like 
effects immediately after treatment and caused a reduction in food 
intake on the first day of treatment. The effects on food intake may 
be an inevitable consequence of the release of fat from adipose 
tissue but this is unlikely to be the case since the anaesthetic-like 
effects were not evident in rats treated with A/S 83, an antiserum 
with potent fat-reducing properties. It is of great importance that 
the antigens recognised by antibodies responsible for the 
anaesthetic-like effects, or at least the tissues on which they are 
expressed, should be identified so that screening for adipocyte 
specificity and adsorption procedures can include these tissues. It 
is also important to determine whether the adsorbed antiserum, which 
showed very little in vitro reactivity against kidney membranes, 
caused transient nephritis, as seen in A/S 83-treated rats. This 
would indicate whether the nephritis results from anti-(kidney) 
antibodies or from the non-specific deposition of immune complexes in 
the glomerulus.
The methods used to prepare the ASA preparation provided a 
considerable degree of purification of the APM but the adipocyte 
specificity of at least the rat ASA must be questioned and this 
preparation was almost certainly contaminated with sheep IgG. 
Clearly, further characterisation of all the components of all the
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ASA preparations is necessary. The raising of polyclonal antisera
against individual polypeptide components of the ASA, excised or
eluted from polyacrylamide gels, or the raising of monoclonal 
antibodies against the ASA, and the determination of their adipocyte 
specificity and cytotoxicity would indicate the potential use of 
individual polypeptides as immunogens. It would also be of interest 
to determine whether any of the components of the ASA are 
glycoproteins, since rat APM have been reported to include 2 major 
glycoproteins with molecular weights of 94 and 78 kD which, when 
incorporated into liposomes, have been shown to exhibit glucose 
transport activity (Shanahan and Czech, 1977). By incorporation into 
liposomes, potential transport activity of any of the components of 
the ASA could be examined. Hormone binding to the ASA could also be 
studied. High performance liquid chromatography of the ASA would 
provide pure preparations of the different components for these types 
of characterisation.
The fact that an antiserum raised against rat ASA was cytotoxic
to adipocytes in vitro and had fat-reducing properties in vivo
suggests that one or more of the antigens in this preparation may be 
able to induce the formation of cytotoxic antibodies. However, it is 
possible that, using the method of antigen purification described in 
this thesis, other adipocyte specific antigens, capable of inducing a 
potent cytotoxic response, may have been lost. Since several 
antisera, raised in both sheep and rabbits, against rat APM are now 
available, a panel of antisera could be used for antigen purification 
to minimise the chances of missing potentially useful antigens. The 
method of antigen preparation may also require modification. The APM 
affinity column, used for the initial purification of anti-(APM)
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antibodies, consistently gave poorer yields than would be expected 
from high titre antisera, which may have resulted in the loss of 
antibodies capable of binding to potentially useful antigens. Better 
results might be obtained using insoluble APM coupled to the affinity 
support rather than their solubilized counterparts. The questionable 
adipocyte specificity of some of the antigens prepared suggests that 
either a different detergent, such as deoxycholate or 
n-octylglucoside, might be used in order to achieve a more effective 
solubilization of the APM, or that a more efficient method of 
adsorption should be devised. Perhaps an initial adsorption of the 
anti-(APM) antiserum with liver homogenate before affinity 
purification might yield antibodies showing a higher degree of 
adipocyte specificity than those used for the ASA preparation. Since 
an anti serum raised against rat ASA bound to kidney and hepatocyte 
plasma membranes in vitro and had anaesthetic-like effects in vivo, 
more rigorous demands in terms of adipocyte specificity should be 
made of antibodies before their use for antigen purification. If the 
adipocyte specificity of antigens prepared by affinity chromatography 
cannot be improved, it may be necessary to adopt the approach, used 
by Lee et al (1986), of immunoprecipitation of adipocyte specific 
antigens from solubilized APM using pre-adsorbed adipocyte specific 
antisera. Such an approach, however, would not yield the quantity of 
antigen that can potentially be achieved using affinity 
chromatography because of the ability to re-use affinity columns. It 
would, however, overcome the inherent problem of affinity 
chromatography - i.e. that only moderate affinity antibodies are of 
practical use, since irreversible binding may occur to high affinity 
antibodies.
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Despite doubts about the true adipocyte specificity of all the 
ASA preparations, an antiserum raised against the rat ASA was 
considerably more tissue specific than antisera raised against whole 
APM, as shown by both in vitro and in vivo experiments and had 
fat-reducing properties. Some components of the preparations 
described in this thesis may, therefore, be of use as immunogens for 
active immunisation or the raising of monoclonal or polyclonal 
antisera.
7.2.1.3 The requirement for in vitro assays able to predict the 
in vivo effects of antisera
ELISA and in vitro cytotoxicity assays, performed in the way 
described in this thesis, did not reliably predict the in vivo 
effects of an antiserum in terms of the effects on adipose tissue, 
the liver or the immediate anaesthetic-like effects. The use of 
polyclonal or monoclonal antisera for passive immunisation of animals 
or humans requires the development of in vitro assays able to predict 
the results of the in vivo administration of an antiserum.
It may be necessary to perform in vitro cytotoxicity assays in 
the presence of complement of the species to be immunised, for more 
than 24 h, in the presence of lower concentrations of antibody than 
have previously been used, in order to mimic the in vivo situation 
more closely. No cytotoxicity against adipocytes in the presence of 
rat complement could be measured using the assays described in 
Section 2.7.2. Therefore, the main role of complement in mediating 
the fat-reducing properties of antisera may be the attraction of 
phagocytic cells, rather than cytolysis through the formation of the 
membrane attack complex of complement. If this is the case, the 
critical properties determining the potency of an antiserum may be
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its ability to activate complement and the proportion of the antibody 
able to bind to adipose tissue. Assays of complement activation, 
rather than complement-mediated cytolysis of target cells, might, 
therefore, prove to be more appropriate and, at the very least, 
beneficial. Measurements of antibody binding to whole cells, rather 
than plasma membranes adsorbed to plastic, might also provide a 
better indication of the ability of an antiserum to bind to a tissue 
in vivo. Western blotting of antisera against a wide range of 
tissues, including muscle, the central nervous system, lungs etc., 
might help to identify critical antigens, the binding to which is 
responsible for in vivo side effects.
7.2.1.4 The requirement for further investigations of the effects 
of passive and active immunisation on non-adipose tissues
The precise fate of fat released from adipose tissue as a 
result of passive or active immunisation against the adipocyte must 
be determined, particularly when considering the treatment of obese 
humans, since the deposition of released fat into, for instance, the 
arteries may have long-term undesirable consequences.
Clearly, the effects of passive and active immunisation on 
non-adipose tissues must be investigated more thoroughly. Adverse 
effects on the liver and kidney were found in some passively 
immunised rats suggesting that more detailed studies of liver and 
kidney function in both passively and actively immunised rats should 
be made.
The effects of passive and active immunisation on muscle and 
meat quality have yet to be examined. 3-agonists have been 
successful in increasing the protein content and decreasing the fat 
content of the carcass (Dalrymple et al. 1984; Hanrahan et al.,
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1986). However, the muscles of treated animals have been shown to 
have a high pH, increasing the likelihood of early spoilage, a dark 
colour and reduced intra-muscular fat, resulting in the production of 
dry meat (Warriss and Kestin, 1988). The effects on these parameters 
of passive and active immunistion against the adipocyte should also 
be examined.
7.2.1.5 The relative merits of passive and active immunisation 
against the adipocyte and alternative methods of modifying 
body composition
When examining the relative merits of passive and active 
immunisation against the adipocyte and alternative methods of 
modifying body composition of meat species, it is necessary to
consider the effectiveness of the approach in inducing increased
protein deposition and reduced fat deposition, the cost effectiveness 
and flexibility of the approach, the effects of the approach on 
animal health and potential harm to the consumer.
While bovine and porcine growth hormones have been shown to
improve carcass protein:fat ratios in meat-producing species (Muir et 
al., 1983; Chung, Etherton and Wiggins, 1985), the use of this 
approach may be limited by its cost effectiveness. As with other 
hormones and synthetic ^-agonists, the effects of growth hormone on 
nutrient partitioning and hence body composition are reduced within a 
few days of cessation of treatment. The administration of an 
anti-(APM) antiserum on 4 consecutive days caused a reduction in body 
fat that lasted for at least 6 months in the rat. This approach to 
modifying body composition does not require frequent administration 
of antiserum because the effects are achieved, at least in part, by 
causing a long-term reduction in adipocyte numbers, rather than
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causing short-term alterations in metabolism. However, the amounts 
of antiserum required for even single treatments of large animals are 
likely to render this approach practical only for the treatment of 
poultry, unless highly cytotoxic, adipocyte specific monoclonal 
antibodies, possibly linked to a cytotoxin, can be developed. Active 
immunisation against the adipocyte may prove a more practical 
approach than passive immunisation for the treatment of large 
animals. Even for poultry, active immunisation is an attractive 
proposition because the immunisation of a single laying hen may 
result in the treatment of large numbers of progeny through passive 
transfer of maternal antibodies to the yolk. The active immunisation 
experiments using rats suggested that, while more effective methods 
of immunisation need to be devised to increase the intensity of the 
immune response induced, it is possible to induce an autoimmune 
response against adipose tissue, as shown by the decreased numbers of 
adipocytes in immunised animals. Clearly, chemically defined 
antigens must be used as immunogens for active immunisation of humans 
or meat-producing species. The use of anti-idiotypic antibodies, 
raised against anti-(adipocyte) antibodies, as antigen images, may 
prove useful for the large scale production of immunogens for this 
purpose. Attempts have been made to utilise such an approach for 
vaccine production. The administration of anti-idiotypic antibodies, 
raised against antibodies recognising parasitic (Grzyck, Capron, 
Lambert, Dissons, Torres and Capron, 1985), bacterial (Stein and 
Soderstrom, 1984) and viral (Kennedy, Dressman, Butel and Lanford, 
1985) antigens, have been shown to confer protective immunity against 
the corresponding infectious agents in experimental animals.
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Passive immunisation against the adipocyte has the advantage 
over all existing approaches towards the manipulation of body 
composition of allowing selection of which adipose depots to reduce, 
by varying the site of injection or the specificity of the antibodies 
towards individual depots. This would be useful in the meat industry 
as a certain amount of subcutaneous fat may be desirable for the 
maintenance of eating quality of meat (Moran, 1986).
The 3 active immunisation experiments described in Chapter 5 
were treated separately in order to illustrate the variation in the 
effects of the same treatment on body weight gain and adiposity in 
different groups of rats. Variation in the immune response between 
individuals of the same breed and between breeds is a potential 
limitation of the use of active immunisation, unless very effective 
immunostimulatory protocols can be devised.
One of the major limitations of the use of any method of 
manipulating carcass composition is the possibility of harmful 
effects on the treated animals. Information on such effects of 
existing approaches is limited but sex steroids can have adverse 
effects on reproductive function and behaviour, while 3-agonists may 
have harmful effects on the cardiovascular system (Heitzman, 1986). 
Whether reduction of carcass fat content would have potential harmful 
effects during nutritional stress, for example, is one important 
consideration. Immunological techniques, such as active immunisation 
against somatostatin (Spencer, Garssen and Hart, 1983) or against the 
adipocyte, require the development of non-toxic, metabolizable 
immunological adjuvants. While progress is being made in this field 
(Warren et al., 1986), a non-toxic synthetic adjuvant has yet to be 
found that can mimic all the potent stimulatory effects of Freunds 
adjuvant.
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With regard to the commercial use of passive immunisation 
against the adipocyte, it would be necessary to identify and 
eliminate the cause of the adverse effects on the liver and the 
anaesthetic-like effects of treatment. It may prove impossible to 
prevent the initial effects on food intake of passive immunisation, 
since all antisera with in vivo fat-reducing properties caused a 
dramatic reduction in food intake on the first day of treatment.
The current EEC ban on the use of steroid growth promoters in 
animal production arose from concern about possible harmful effects 
of residues on consumers. The only known harmful effects of such 
agents has been the result of the illegal injection of prohibited 
anabolic agents into the edible tissues of veal calves which 
subsequently contaminated batches of baby food (Heitzmann, 1986). 
|3-agonists are clearly orally active hormones and so are likely to be 
subject to similar attention to that received by steroid growth 
promoters, which is likely to limit their commercial use. Passive 
immunisation against the adipocyte would be unlikely to leave harmful 
residues in the edible tissues, since treatment could be timed to 
allow clearance of antibody before slaughter and such antibodies 
would not survive either cooking or digestion in the alimentary 
tract. However, considerations for the safety of consumers would 
almost certainly prevent the use of immunotoxins to increase the 
potency for anything other than their use in human obesity where the 
condition was life-threatening.
7.2.2 The examination of competition between adipose and mammary 
tissue during lactation
The discovery that A/S 83 temporarily reduced fat deposition in 
existing adipocytes, as well as reducing adipocyte numbers, suggests
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that the effects on milk production of inhibiting fat deposition in 
adipose tissue in late lactation could be examined using this 
approach. It would first, however, be essential to ensure that the 
antiserum had no effects on mammary tissue and to prevent the
inhibitory effects of the antiserum on food intake. Since the 
reduction in food intake may be an inevitable consequence of the 
reduction in adiposity, it may be necessary to treat rats before
mating, in which case a greater reduction in adiposity than that
achieved in the experiments described in this thesis may be required.
7.2.3 The investigation of the regulation of adiposity
In most mammals body fat mass is normally a stable proportion 
of total body mass, implying that changes in adiposity can be 
detected and are corrected by alterations in food intake or
metabolism. It is not clear whether adipose mass, adipocyte number 
or adipocyte volume is monitored. The likely response to passive or 
active immunisation against the adipocyte will depend upon which of 
these parameters is the 'lipostat'. If adipocyte number or adipose 
mass is monitored, the response to a reduction in adipocyte number 
would be the recovery of lost tissue through enlargement of existing 
adipocytes or proliferation and/or differentiation of pre-adipocytes. 
If adipocyte volume is monitored, assuming that the reduction in 
adipocyte number was not accompanied by any change in the mean cell 
volume of remaining adipocytes, no recovery of lost mass would be 
expected to occur.
In actively immunised rats 16 weeks after treatment, adipocyte 
size was increased to compensate for lost adipocyte numbers, so that 
total dissected adipose mass was similar to that of control rats,
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implying that adipose mass rather than adipocyte size is monitored. 
In contrast, 24 weeks after treatment parametrial adipocytes of 
passively immunised rats were the same size as those of controls, 
while the mass of the tissue was 50% of that of controls, suggesting 
that, at least in this tissue, adipocyte size, rather than adipocyte 
number or adipose mass is monitored and regulated. Studies of the 
effects of nutritional manipulations and lipectomy on rats by Faust 
et al. (1976, 1977, 1978) provide a possible explanation for these 
apparently contradictory results. Adult rats fed a palatable high fat 
diet for prolonged periods became obese, initially through an
increase in adipocyte size, and then also by increases in adipocyte
number (Faust et al., 1978). Upon re-introduction of a normal diet,
rats initially lost weight due to the return of adipocyte size to a 
normal level, but the elevated adipocyte number and, hence, an 
elevated body weight, was retained. These authors suggested that a 
given diet predisposes rats to a particular mean adipocyte size, 
regardless of adipocyte number or adipose mass. However, nutritional 
manipulations cause a number of metabolic changes, making the
results of such studies difficult to interpret. Consequently, the 
same authors performed a series of lipectomy experiments, whereby 
adipocyte numbers were reduced without affecting adipocyte size. 
Removal of the epididymal fat depots of Swiss mice and Sprague-Dawley 
rats did not result in regeneration of lost tissue or compensatory 
hypertrophy of remaining fat depots (Faust et al., 1976), again
suggesting that adipocyte size is regulated. However, lipectomy of 
the epididymal fat depot of the Osborne-Mendel rat resulted in
compensatory hypertrophy of remaining adipose depots such that total 
fat mass reached the level of controls, when the rats were fed a
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normal diet. When lipectomised rats were fed a high-fat diet, the 
rats initially showed hypertrophy of remaining depots until a 
'critical' adipocyte size was reached, when food intake was reduced 
and total body fat mass did not reach the level of control rats, fed 
the same diet (Faust et al., 1977). It would appear that, in this
strain of rat, when the animal is lean, adipose mass or adipocyte 
number is the major regulator. When the animal reaches a particular 
stage of maturity or "critical' adipocyte volume, a mechanism 
whereby adipocyte size is detected and regulated comes into 
operation. Therefore, while the experiments described above suggest 
a role for the regulation of adipocyte size in the regulation of 
adiposity, the time at which this mechanism comes into operation 
probably depends upon the species and strain of animal. A possible 
hypothesis to explain the results of passive and active immunization
would be that, in Wistar rats, at 19 weeks of age (when the actively
immunised rats were examined) adipose mass is the major regulating 
factor so that loss of adipocytes as a result of active immunisation
was compensated for by increases in adipocyte size. At 30 weeks of
age, when the passively immunised rats were examined, adipocyte size 
would have increased so that it may have become the major regulator, 
resulting in a permanent reduction in adipose mass in passively 
immunised rats since adipocyte numbers were still decreased. It is 
worthy of note that in neither form of treatment was there evidence 
for compensatory increases in cell number. The apparent differences 
in the response to a decreased adipocyte number in passively and 
actively immunised rats may have been the result, therefore, of the 
different stages of maturity at which the animals were killed, which 
coincided with differences in the way in which adiposity is 
regulated.
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Alternative explanations for the response to passive and active 
immunisation against the adipocyte, other than that given above, can 
be proposed. Prolonged exposure of actively immunised rats to low 
concentrations of anti-(APM) antibodies may have paradoxically 
stimulated lipid accumulation in adipocytes. A/S 83, at low 
concentrations, exhibited stimulatory effects on lipid deposition in 
isolated adipocytes (Flint et al., 1985) so that the elevated 
adipocyte size in actively immunised rats may have been a direct 
response to stimulatory antibodies, rather than regulation of body 
fat mass. However, since the mass of dissectable fat in actively 
immunised rats was very similar to that of controls, despite a 50% 
reduction in parametrial adipocyte numbers, this seems unlikely. In 
passively immunised rats, the surviving parametrial adipocytes took 
several weeks to recover from the effects of passive immunisation and 
so 24 weeks after treatment, when the rats were killed, adipocytes 
may still have been in the process of making compensatory increases 
in adipocyte size. Had these rats been examined at a later time 
point, parametrial adipocytes of treated rats may have been found to 
be larger than those of controls.
Although the response to active immunisation against the 
adipocyte was uniform in all of the adipose depots studied, passive 
immunisation by intraperitoneal injection of A/S 83 had a greater 
effect on parametrial than on other internal and subcutaneous adipose 
depots. Treatment with A/S 83 caused a significant reduction in 
subcutaneous and peri-renal adipocyte numbers 1 week after treatment 
but by 3 weeks after treatment adipocyte numbers in both depots were 
nearly recovered. The subcutaneous and peri-renal adipose depots may 
still be in a period of proliferation in female Wistar rats at 6
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weeks of age and so lost adipocytes could be replaced. The majority
of proliferation in parametrial adipose tissue may be over by 6 weeks
of age, reducing the capacity of the tissue for recovery of lost
adipocytes. Since most studies of adipocyte development have been 
performed in male rats, no firm conclusions can be drawn in this
regard. Alternatively, since the parametrial adipose depot was
initially the depot most affected by treatment with A/S 83, the 
recovery time for supporting tissues, such as blood vessels necessary 
for the provision of signals for proliferation or differentiation of
preadipocytes, may have been longer for this than for other depots.
It cannot be assumed that there was no proliferative response in 
parametrial adipose tissue in response to the effects of passive 
immunisation. Proliferation may have been balanced by a gradual loss 
of damaged adipocytes. Similarly it is not known whether there was 
any proliferation in adipose tissue of actively immunised rats to 
replace lost adipocytes. As these rats were examined at only one 
time point after the initiation of treatment, the time course of loss 
of adipocytes is unknown, so it is not possible to determine whether 
adipocyte loss occurred at a time when intense proliferation was 
still underway in adipose tissue.
In summary, therefore, the results of both active and passive 
immunisation against the adipocyte are consistent with the regulation 
of adiposity through the regulation of adipose mass rather than 
adipocyte size in the female Wistar rat, at least until 19 weeks of
age. By 24 weeks of age a mechanism whereby adipocyte size is
monitored and regulated may be in operation. This model requires 
that the animal is able to detect either adipose mass or adipocyte 
number early in life and adipocyte size later in life. The means
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whereby such detection might be achieved are not clear. Liebel 
(1977) proposed a biological radar system whereby the intensity of a 
humoral signal, such as insulin or the ratio of insulin to glucose, 
varied according to the adipose cell surface area. There were no 
consistent differences in serum insulin or glucose levels in 
passively immunised rats at any time point measured after treatment. 
It would be of interest to measure adipsin levels in both passive and 
actively immunised rats, since this serine protease homologue is 
synthesized and secreted by adipocytes and levels are decreased in 
genetically obese rodents where mechanisms regulating adiposity have 
broken down (Flier et al., 1987).
The model described above also requires that the animal 
responds early in life to a reduction in adipose mass or adipocyte 
number by increasing the size of existing adipocytes or increasing 
proliferation and/or differentiation of preadipocytes. While 
adipocyte size was clearly increased in actively immunised rats, it 
is not known whether compensatory increases in adipocyte number also 
occurred. Later in life, the animal must respond to the attainment 
of a 'critical' adipocyte size either by recruiting new adipocytes 
into the population, repartitioning nutrients away from fat 
deposition or reducing food intake. The rats in the experiments 
described in this thesis were not allowed to reach a sufficient stage 
of maturity to answer these questions but Faust (1977) found that 
lipectomised Osborne-Mendel rats reduced their food intake when a 
critical adipocyte size had been reached. Vasselli (1986) detected 
both a reduction in food intake and an increase in adipocyte numbers 
in Zucker rats upon reaching a 'critical' adipocyte size.
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Clearly, a systematic investigation of the effects of passive 
and active immunisation on adipose tissue at more time points .than 
examined in the experiments described above, including time points 
beyond 24 weeks after treatment, would clarify the response to these 
treatments, in terms of adipocyte hypertrophy and hyperplasia, and 
effects on food intake. However, before conclusions can be drawn 
from such experiments about the regulation of adiposity in the female 
Wistar rat, the effects of passive and active immunisation on 
preadipocytes must be determined in order to discover whether the 
ability of the rat to respond to lost adipocytes with a proliferative 
response has been affected. Cryer (1985) found that an antiserum 
raised against mature rat adipocytes showed little binding to 
preconfluent adipocyte precursors, but a marked increase in binding 
was observed after the reaching of confluence, suggesting that the 
majority of antibodies were directed against adipocyte 
differentiation antigens, not present or only present at very low 
frequency on preadipocytes.
The investigation of the very long-term effects of passive or 
active immunisation against the adipocyte might be aided by the 
feeding of treated rats with a high fat diet which would promote the 
reaching of a 'critical' adipocyte size at an early age. 
Alternatively, a greater reduction in adipocyte numbers might be 
achieved by repeat treatments with A/S 83, in which case it would 
first be necessary to tolerise the rats to sheep IgG in order to 
prevent immuno-neutralisation of antibodies administered subsequent 
to the primary injection. A combination of passive and active 
immunisation might also cause a greater reduction in adipocyte 
numbers than either treatment alone.
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It should be noted that any conclusions about the regulation of 
adiposity drawn from these experiments apply only to the sex and 
strain of the rat used. However, preliminary experiments showed that
A / S  83 bound to APM of rats of a different sex and strain and so this
technique might be used for comparisons of the regulation of 
adiposity of rats of different sex and strains.
7.4 PERSPECTIVE
In the experiments described in this thesis, a long-term 
reduction in adiposity, accompanied by increased protein deposition, 
was achieved by passive immunisation against the adipocyte, rendering 
this a potentially attractive approach towards the manipulation of 
body composition in meat-producing species. In common with other 
methods of improving carcass composition, considerations of animal 
welfare and safety of the consumer may prevent the use of this
approach commercially. In addition, lack of knowledge of the
long-term effects may prevent its use for the treatment of obese 
humans. However, both passive and active immunisation against the 
adipocyte provide a novel and potentially informative means of 
studying the regulation of adiposity which may provide a greater 
understanding of the causes of obesity.
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